article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,title_clean,bert_similarity_rank_vulvar_cancer,bert_similarity_rank_vulvar_cancer_percentile
Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review.,Annals of surgical oncology,Ann. Surg. Oncol.,2002-11-01,"Urogenital melanoma is a rare neoplasm with poor prognosis. Its management in the past involved radical vulvectomy and complete bilateral inguinofemoral lymphadenectomy. Sentinel lymph node biopsy is an accurate low-morbidity procedure when used in the context of cutaneous melanoma. However, prophylactic lymphadenectomy has not been shown to improve survival of melanoma patients. We wanted to determine the feasibility of sentinel lymph node biopsy in patients with female urogenital melanoma as a staging procedure. Six patients with vulvar or vaginal melanomas underwent preoperative lymphatic mapping with (99m)Tc-labeled sulfur colloid followed by sentinel lymphadenectomy. In addition, we reviewed the literature on the application of sentinel lymph node biopsy in urogenital tract melanomas. One or more sentinel nodes were identified in all six patients by lymphoscintigraphy. All patients underwent sentinel lymphadenectomy, except for one patient with a deep vaginal melanoma that drained to pelvic nodes. The five successful cases had unilateral drainage patterns. None of the sentinel lymph nodes excised had tumor invasion. Combined with five other patients from the published literature, the success rate of localizing sentinel lymph nodes in the patients with urogenital melanoma approaches 100%. This experience, plus reports of a small number of patients from three similar studies, supports the impression that sentinel lymph node biopsy is feasible for vulvar and vaginal melanoma.",Journal Article,6290.0,59.0,Urogenital melanoma rare neoplasm poor prognosis management past involved radical vulvectomy complete bilateral inguinofemoral lymphadenectomy Sentinel lymph node biopsy accurate low-morbidity procedure context cutaneous melanoma prophylactic lymphadenectomy shown improve survival melanoma patients wanted determine feasibility sentinel lymph node biopsy patients female urogenital melanoma staging procedure patients vulvar vaginal melanomas underwent preoperative lymphatic mapping 99m Tc-labeled sulfur colloid followed sentinel lymphadenectomy addition reviewed literature application sentinel lymph node biopsy urogenital tract melanomas sentinel nodes identified patients lymphoscintigraphy patients underwent sentinel lymphadenectomy patient deep vaginal melanoma drained pelvic nodes successful cases unilateral drainage patterns sentinel lymph nodes excised invasion Combined patients published literature success rate localizing sentinel lymph nodes patients urogenital melanoma approaches 100 experience plus reports small number patients similar studies supports impression sentinel lymph node biopsy feasible vulvar vaginal melanoma,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[15162, 16, 8, 622, 2131, 5, 334, 356, 211, 284, 4, 3, 1219, 646, 711, 22043, 2, 236, 1607, 30333, 2048, 1323, 263, 289, 411, 16, 35, 1481, 154, 787, 1299, 198, 95, 4, 3, 1533, 1, 1486, 137, 1862, 2048, 71, 44, 85, 443, 6, 401, 25, 1, 7, 21, 7931, 6, 223, 3, 1437, 1, 1323, 263, 289, 411, 4, 7, 5, 1061, 15162, 22, 8, 632, 1299, 437, 7, 5, 15, 1965, 208, 498, 2936, 2568, 5, 6314, 3072, 2841, 10266, 7245, 370, 20, 1323, 2048, 4, 352, 21, 446, 3, 789, 23, 3, 1581, 1, 1323, 263, 289, 411, 4, 15162, 1696, 1965, 104, 15, 80, 1323, 502, 11, 108, 4, 62, 437, 7, 20, 6849, 62, 7, 208, 1323, 2048, 2187, 9, 104, 69, 5, 8, 2369, 17, 24458, 6, 1110, 502, 3, 365, 1401, 140, 42, 3208, 3528, 764, 1292, 1, 3, 1323, 263, 502, 5076, 42, 30, 578, 397, 5, 365, 127, 7, 29, 3, 983, 789, 3, 1825, 116, 1, 14384, 1323, 263, 502, 4, 3, 7, 5, 15162, 611, 394, 26, 730, 349, 1198, 1, 8, 302, 207, 1, 7, 29, 169, 288, 94, 2304, 3, 8925, 17, 1323, 263, 289, 411, 16, 1313, 9, 2]",1380.0,12417504,Sentinel node biopsy vulvar vaginal melanoma presentation cases literature review,0,0.0
Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma.,Gynecologic oncology,Gynecol. Oncol.,2002-12-01,"Primaryadenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established. A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease. Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection. She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions. Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life. She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis. We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma. We observed that Doxil was a well-tolerated and effective agent for this gynecologic malignancy, and warrants further investigation.",Case Reports,6260.0,9.0,Primaryadenocarcinoma vulva rare entity widely metastatic vulvar adenocarcinoma effective treatment established 65-year-old woman diagnosed regionally advanced vulvar adenocarcinoma bulky involvement bilateral groin lymph nodes associated extramammary Paget 's disease Initial therapy consisted multiagent chemotherapy vulvar groin irradiation followed radical vulvectomy groin pelvic lymph node dissection subsequently developed widely metastatic disease including brain pulmonary hepatic osseus subcutaneous lesions Treatment liposomal doxorubicin Doxil resulted dramatic regression metastatic lesions marked improvement quality-of-life remains clinically greater 1 year initiating Doxil treatment widely metastatic vulvar adenocarcinoma surpassed 5 years survival initial diagnosis report case Doxil treatment metastatic chemorefractory vulvar adenocarcinoma observed Doxil well-tolerated effective agent gynecologic malignancy warrants investigation,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[53279, 1, 3, 9263, 16, 8, 622, 2983, 2, 9, 1792, 113, 449, 77, 323, 24, 71, 85, 635, 8, 556, 111, 1095, 2854, 10, 265, 5, 8183, 131, 449, 5, 4112, 799, 1, 1607, 9264, 263, 502, 2, 41, 14461, 7497, 292, 34, 388, 36, 1695, 1, 7148, 56, 2, 2, 9264, 1104, 370, 20, 711, 22043, 5, 9264, 2, 1110, 263, 289, 1161, 3109, 1611, 276, 1792, 113, 34, 141, 342, 1087, 939, 43103, 2, 2529, 406, 24, 5, 3275, 856, 11740, 627, 4, 3079, 320, 1, 113, 406, 2, 2003, 767, 4, 372, 1, 358, 3109, 469, 505, 149, 378, 76, 14, 111, 1192, 2637, 11740, 24, 9, 1792, 113, 449, 2, 71, 17697, 33, 60, 1, 25, 1192, 1084, 388, 147, 21, 414, 3, 157, 473, 1, 11740, 95, 9, 3, 24, 1, 113, 8923, 449, 21, 164, 17, 11740, 10, 8, 149, 421, 2, 323, 420, 9, 26, 1512, 710, 2, 2782, 195, 940]",1138.0,12468332,Liposomal doxorubicin treatment metastatic chemorefractory vulvar adenocarcinoma,1,0.017543859649122806
Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure.,"European journal of obstetrics, gynecology, and reproductive biology",Eur. J. Obstet. Gynecol. Reprod. Biol.,2003-01-01,"To evaluate the effectiveness of CO(2) laser ablation of vaginal intraepithelial neoplasia (VAIN) and to define prognostic factors. Medical records of 24 patients with VAIN II or III, treated by CO(2) laser ablation from 1990 to 1998 were reviewed. The grade, location, and focality of the lesions, the age, follow-up period and menopausal status of the patients, the power and duration of laser ablation, the presence of concurrent cervical or vulvar neoplasia or previous hysterectomy were evaluated as possible prognostic factors. Ablations of the VAIN were successfully accomplished in all of the patients with a mean period of 25.2+10.2 min, including additional simultaneous ablations of the cervix or vulva in eight (33.3%) patients. There was no early or late major complication. VAIN was completely eliminated in 17 (70.8%) patients after the first and in 19 (79.2%) patients after multiple episodes of ablation with a mean follow-up of 26.7+19.6 months. VAIN progressed to invasive vaginal carcinoma in one woman. None of the evaluated prognostic factors was found to be related to the persistence or recurrence. CO(2) laser ablation was a safe and effective method for the treatment of VAIN. However, since no prognostic factor was defined, all patients should be closely evaluated for persistence, recurrence or progression to invasion.",Clinical Trial,6229.0,36.0,evaluate effectiveness 2 laser ablation vaginal intraepithelial neoplasia VAIN define prognostic factors Medical records 24 patients VAIN II III treated 2 laser ablation 1990 1998 reviewed grade location focality lesions age follow-up period menopausal status patients power duration laser ablation presence concurrent cervical vulvar neoplasia previous hysterectomy evaluated possible prognostic factors Ablations VAIN successfully accomplished patients mean period 25.2+10.2 min including additional simultaneous ablations cervix vulva 33.3 patients early late major complication VAIN completely eliminated 17 70.8 patients 19 79.2 patients multiple episodes ablation mean follow-up 26.7+19.6 months VAIN progressed invasive vaginal carcinoma woman evaluated prognostic factors related persistence recurrence 2 laser ablation safe effective treatment VAIN prognostic factor defined patients closely evaluated persistence recurrence progression invasion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 1236, 1, 1269, 18, 3555, 1650, 1, 4153, 2298, 14802, 2, 6, 1107, 177, 130, 484, 1064, 1, 259, 7, 5, 14802, 215, 15, 316, 73, 20, 1269, 18, 3555, 1650, 29, 2289, 6, 1850, 11, 446, 3, 88, 1147, 2, 24553, 1, 3, 406, 3, 89, 166, 126, 727, 2, 3565, 156, 1, 3, 7, 3, 2349, 2, 654, 1, 3555, 1650, 3, 463, 1, 750, 15, 2298, 15, 698, 2622, 11, 194, 22, 899, 177, 130, 15894, 1, 3, 14802, 11, 1878, 5741, 4, 62, 1, 3, 7, 5, 8, 313, 727, 1, 243, 18, 79, 18, 1538, 141, 402, 2824, 15894, 1, 3, 3629, 15, 9263, 4, 659, 466, 27, 7, 125, 10, 77, 191, 15, 807, 458, 1447, 14802, 10, 2500, 6173, 4, 269, 431, 66, 7, 50, 3, 157, 2, 4, 326, 842, 18, 7, 50, 232, 3750, 1, 1650, 5, 8, 313, 166, 126, 1, 432, 67, 326, 49, 53, 14802, 1839, 6, 416, 134, 4, 104, 2854, 1292, 1, 3, 194, 177, 130, 10, 204, 6, 40, 139, 6, 3, 4108, 15, 146, 1269, 18, 3555, 1650, 10, 8, 1165, 2, 323, 596, 9, 3, 24, 1, 14802, 137, 1192, 77, 177, 161, 10, 395, 62, 7, 257, 40, 3210, 194, 9, 4108, 146, 15, 91, 6, 578]",1281.0,12475584,Vaginal intraepithelial neoplasia treatment carbon dioxide laser risk factors failure,0,0.0
Clinically inapparent invasive vulvar carcinoma in an area of persistent Paget's disease: a case report.,Gynecologic oncology,Gynecol. Oncol.,2003-03-01,"Invasive vulvar carcinoma is reported to occur in 5 to 20% of patients with vulvar Paget's disease. We report a case in which a clinically inapparent invasive lesion was discovered on reexcision of microscopically persistent vulvar Paget's disease. A 58-year-old woman presented with a diagnosis of vulvar Paget's disease. A wide local excision of the lesion was performed and pathologic analysis revealed microscopic Paget's disease at two of the margins. The patient returned for a follow-up 4 months later and a vulvar biopsy revealing persistent Paget's cells was obtained from the area of the prior microscopically positive surgical margin. A reexcision was performed from the normal-appearing vulva and invasive vulvar carcinoma was noted in this specimen. This case demonstrates several concerning aspects of this disease, most important of which is that the clinically apparent lesion did not contain the clinically significant invasive lesion. Invasive vulvar carcinoma may occur in association with microscopically persistent vulvar Paget's disease, a condition often encountered after primary treatment with wide local excision.",Case Reports,6170.0,5.0,Invasive vulvar carcinoma reported occur 5 20 patients vulvar Paget 's disease report case clinically inapparent invasive lesion discovered reexcision microscopically persistent vulvar Paget 's disease 58-year-old woman presented diagnosis vulvar Paget 's disease wide local excision lesion performed pathologic revealed microscopic Paget 's disease margins patient returned follow-up 4 months later vulvar biopsy revealing persistent Paget 's obtained area prior microscopically positive surgical margin reexcision performed normal-appearing vulva invasive vulvar carcinoma noted specimen case demonstrates concerning aspects disease important clinically apparent lesion contain clinically significant invasive lesion Invasive vulvar carcinoma occur association microscopically persistent vulvar Paget 's disease condition encountered primary treatment wide local excision,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[416, 134, 16, 210, 6, 1271, 4, 33, 6, 179, 1, 7, 5, 7497, 292, 34, 21, 414, 8, 473, 4, 92, 8, 505, 33395, 416, 1180, 10, 2747, 23, 8771, 1, 7187, 1882, 7497, 292, 34, 8, 717, 111, 1095, 2854, 917, 5, 8, 147, 1, 7497, 292, 34, 8, 1019, 293, 1366, 1, 3, 1180, 10, 173, 2, 510, 65, 553, 2984, 7497, 292, 34, 28, 100, 1, 3, 1012, 3, 69, 5157, 9, 8, 166, 126, 39, 53, 1559, 2, 8, 411, 6475, 1882, 7497, 292, 37, 10, 683, 29, 3, 965, 1, 3, 324, 7187, 109, 221, 959, 8, 8771, 10, 173, 29, 3, 295, 6536, 9263, 2, 416, 134, 10, 1051, 4, 26, 2360, 26, 473, 1902, 392, 4243, 2695, 1, 26, 34, 96, 305, 1, 92, 16, 17, 3, 505, 2235, 1180, 205, 44, 3725, 3, 505, 93, 416, 1180, 416, 134, 68, 1271, 4, 248, 5, 7187, 1882, 7497, 292, 34, 8, 2850, 629, 3903, 50, 86, 24, 5, 1019, 293, 1366]",1078.0,12648600,Clinically inapparent invasive vulvar carcinoma area persistent Paget 's disease case report,0,0.0
Long-term outcome of perianal Paget's disease.,Diseases of the colon and rectum,Dis. Colon Rectum,2003-05-01,"Extramammary Paget's disease of the perianal region is a rare finding that often results in delayed diagnosis and treatment. Although the natural history of the disease is not well characterized, it historically has been associated with other cancers. This study summarizes the history and treatment of all patients diagnosed with perianal Paget's disease at a single institution. Charts of all patients with a diagnosis of extramammary Paget's disease of the perianal region confirmed or treated at Memorial Sloan-Kettering Cancer Center between 1950 and 2000 were reviewed. Patients with vulvar Paget's disease or Bowen's disease were excluded except when Paget's disease of the perianal region was diagnosed first. Whenever possible, follow-up information was updated. Estimates of overall and disease-free survival were made by the method of Kaplan and Meier. Twenty-seven patients with a median age of 63 years were diagnosed with perianal Paget's disease. Most patients (74 percent) were treated with wide excision. Local recurrence occurred in 37 percent of all patients treated and in 30 percent of patients (6/20) undergoing a wide excision as part of their treatment. An invasive component was identified in 44 percent of patients (12/27) with perianal Paget's disease. Six patients (22 percent) required a colostomy as part of the treatment for their disease. Adjuvant chemoradiotherapy was used in 22 percent of patients (6/27) who had more aggressive disease. At a median follow-up of 67 months, 56 percent (15/27) had no evidence of disease, and two patients had died of metastatic disease. The overall and disease-free survival at five years was 59 and 64 percent, respectively, which decreased to 33 and 39 percent, respectively, by ten years. Perianal Paget's disease is a rare finding even at a large referral center. The disease process is generally a prolonged one marked by frequent recurrences, and the treatment of first choice is wide excision. Patients with invasive malignancies require more extensive surgery. The role of chemoradiotherapy remains undefined in this disease.",Journal Article,6109.0,85.0,Extramammary Paget 's disease perianal region rare finding delayed diagnosis treatment natural history disease characterized historically associated summarizes history treatment patients diagnosed perianal Paget 's disease single institution Charts patients diagnosis extramammary Paget 's disease perianal region confirmed treated Memorial Sloan-Kettering Center 1950 2000 reviewed Patients vulvar Paget 's disease Bowen 's disease excluded Paget 's disease perianal region diagnosed possible follow-up information updated Estimates overall disease-free survival Kaplan Meier Twenty-seven patients median age 63 years diagnosed perianal Paget 's disease patients 74 percent treated wide excision Local recurrence occurred 37 percent patients treated 30 percent patients 6/20 undergoing wide excision treatment invasive component identified 44 percent patients 12/27 perianal Paget 's disease patients 22 percent required colostomy treatment disease Adjuvant chemoradiotherapy 22 percent patients 6/27 aggressive disease median follow-up 67 months 56 percent 15/27 evidence disease patients died metastatic disease overall disease-free survival years 59 64 percent respectively decreased 33 39 percent respectively years Perianal Paget 's disease rare finding large referral center disease process generally prolonged marked frequent recurrences treatment choice wide excision Patients invasive malignancies require extensive surgery role chemoradiotherapy remains undefined disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[14461, 7497, 292, 34, 1, 3, 10855, 1053, 16, 8, 622, 1567, 17, 629, 99, 4, 1612, 147, 2, 24, 242, 3, 1504, 532, 1, 3, 34, 16, 44, 149, 765, 192, 3578, 71, 85, 41, 5, 127, 163, 26, 45, 2869, 3, 532, 2, 24, 1, 62, 7, 265, 5, 10855, 7497, 292, 34, 28, 8, 226, 731, 4413, 1, 62, 7, 5, 8, 147, 1, 14461, 7497, 292, 34, 1, 3, 10855, 1053, 557, 15, 73, 28, 2563, 2783, 2784, 12, 574, 59, 17730, 2, 1081, 11, 446, 7, 5, 7497, 292, 34, 15, 43264, 292, 34, 11, 1800, 2187, 198, 7497, 292, 34, 1, 3, 10855, 1053, 10, 265, 157, 8395, 899, 166, 126, 487, 10, 2939, 1423, 1, 63, 2, 34, 115, 25, 11, 1229, 20, 3, 596, 1, 876, 2, 882, 737, 648, 7, 5, 8, 52, 89, 1, 676, 60, 11, 265, 5, 10855, 7497, 292, 34, 96, 7, 794, 714, 11, 73, 5, 1019, 1366, 293, 146, 489, 4, 567, 714, 1, 62, 7, 73, 2, 4, 201, 714, 1, 7, 49, 179, 479, 8, 1019, 1366, 22, 760, 1, 136, 24, 35, 416, 1249, 10, 108, 4, 584, 714, 1, 7, 133, 428, 5, 10855, 7497, 292, 34, 437, 7, 350, 714, 616, 8, 7635, 22, 760, 1, 3, 24, 9, 136, 34, 249, 1464, 10, 95, 4, 350, 714, 1, 7, 49, 428, 54, 42, 80, 571, 34, 28, 8, 52, 166, 126, 1, 598, 53, 664, 714, 167, 428, 42, 77, 241, 1, 34, 2, 100, 7, 42, 1016, 1, 113, 34, 3, 63, 2, 34, 115, 25, 28, 365, 60, 10, 728, 2, 660, 714, 106, 92, 340, 6, 466, 2, 587, 714, 106, 20, 1618, 60, 10855, 7497, 292, 34, 16, 8, 622, 1567, 871, 28, 8, 375, 2096, 574, 3, 34, 1129, 16, 1228, 8, 1069, 104, 2003, 20, 908, 1593, 2, 3, 24, 1, 157, 1866, 16, 1019, 1366, 7, 5, 416, 441, 1353, 80, 1344, 152, 3, 200, 1, 1464, 469, 5425, 4, 26, 34]",2063.0,12792436,Long-term outcome perianal Paget 's disease,0,0.0
Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy.,Gynecologic oncology,Gynecol. Oncol.,2003-09-01,"The objective of this study was to investigate the cause of groin recurrence in patients with vulvar cancer who had negative nodes in their superficial inguinal lymphadenectomy (SIL) specimens. The records of patients with vulvar cancer treated at M. D. Anderson Cancer Center between 1986 and 1997 were reviewed to identify patients with squamous histology, clinical and surgical stage I or II, depth of invasion greater than 1 mm, and primary treatment consisting of radical wide excision and SIL. One hundred four patients met these criteria. Among these, nine experienced recurrent disease that involved one or both of the groins. All of the original hematoxylin and eosin (H&E)-stained slides were reviewed by one pathologist (AM). Then, each paraffin block containing nodal tissue was recut at 40 microm intervals to obtain five sections for H&E staining and two unstained sections to be used for cytokeratin immunostaining if necessary. The median age at diagnosis and primary surgery was 65 years and the median depth of invasion was 4 mm. Seven patients underwent bilateral, and two underwent unilateral, groin dissections. The median number of lymph nodes removed per groin was seven. The median time to recurrence was 22 months. A total of 785 additional H&E-stained slides were prepared and examined at 100x and 400x magnification. No micrometastases were identified, and there were no other suspicious findings. Therefore, immunohistochemical staining was not performed. At recurrence, one patient had a biopsy only, and eight had attempted surgical resection. In two patients, tumor was identified in fibroadipose tissue only; no lymph nodes were identified. Among the other six patients, the median number of lymph nodes resected at the time of the recurrence was five (range 1 to 10). At last report, six patients had died and three were alive and free of disease. Median follow-up for survivors was 63 months (range 42 to 71). These data strongly suggest that groin relapse in patients with negative nodes on SIL is caused by metastatic disease in unresected inguinal nodes. SIL as performed on the patients in this study did not eliminate all sites of nodal metastasis.",Journal Article,5986.0,63.0,objective investigate cause groin recurrence patients vulvar negative nodes superficial inguinal lymphadenectomy SIL specimens records patients vulvar treated M. D. Anderson Center 1986 1997 reviewed identify patients squamous histology clinical surgical stage II depth invasion greater 1 mm primary treatment consisting radical wide excision SIL patients met criteria experienced recurrent disease involved groins original hematoxylin eosin H E -stained slides reviewed pathologist paraffin block containing nodal tissue recut 40 microm intervals obtain sections H E staining unstained sections cytokeratin immunostaining necessary median age diagnosis primary surgery 65 years median depth invasion 4 mm Seven patients underwent bilateral underwent unilateral groin dissections median number lymph nodes removed groin seven median time recurrence 22 months total 785 additional H E-stained slides prepared examined 100x 400x magnification micrometastases identified suspicious findings immunohistochemical staining performed recurrence patient biopsy attempted surgical resection patients identified fibroadipose tissue lymph nodes identified patients median number lymph nodes resected time recurrence range 1 10 report patients died alive free disease Median follow-up survivors 63 months range 42 71 strongly suggest groin relapse patients negative nodes SIL caused metastatic disease unresected inguinal nodes SIL performed patients eliminate sites nodal metastasis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 963, 3, 708, 1, 9264, 146, 4, 7, 5, 12, 54, 42, 199, 502, 4, 136, 3562, 4907, 2048, 10858, 623, 3, 1064, 1, 7, 5, 12, 73, 28, 188, 427, 1929, 12, 574, 59, 3751, 2, 2341, 11, 446, 6, 255, 7, 5, 691, 784, 38, 2, 221, 82, 70, 15, 215, 2436, 1, 578, 378, 76, 14, 321, 2, 86, 24, 2273, 1, 711, 1019, 1366, 2, 10858, 104, 1128, 294, 7, 543, 46, 371, 107, 46, 762, 592, 387, 34, 17, 646, 104, 15, 110, 1, 3, 26214, 62, 1, 3, 2279, 6209, 2, 5975, 555, 563, 3386, 3830, 11, 446, 20, 104, 5093, 5886, 818, 296, 2487, 2381, 1101, 779, 246, 10, 53749, 28, 327, 3550, 1582, 6, 3140, 365, 3013, 9, 555, 563, 1029, 2, 100, 17677, 3013, 6, 40, 95, 9, 4292, 5027, 492, 1493, 3, 52, 89, 28, 147, 2, 86, 152, 10, 556, 60, 2, 3, 52, 2436, 1, 578, 10, 39, 321, 648, 7, 208, 1607, 2, 100, 208, 3208, 9264, 6894, 3, 52, 207, 1, 263, 502, 2264, 379, 9264, 10, 648, 3, 52, 98, 6, 146, 10, 350, 53, 8, 181, 1, 11467, 402, 555, 563, 3386, 3830, 11, 4421, 2, 409, 28, 37540, 2, 53750, 22145, 77, 5485, 11, 108, 2, 125, 11, 77, 127, 3230, 272, 673, 1382, 1029, 10, 44, 173, 28, 146, 104, 69, 42, 8, 411, 158, 2, 659, 42, 4098, 221, 170, 4, 100, 7, 30, 10, 108, 4, 30479, 246, 158, 77, 263, 502, 11, 108, 107, 3, 127, 437, 7, 3, 52, 207, 1, 263, 502, 1133, 28, 3, 98, 1, 3, 146, 10, 365, 184, 14, 6, 79, 28, 1060, 414, 437, 7, 42, 1016, 2, 169, 11, 1701, 2, 115, 1, 34, 52, 166, 126, 9, 332, 10, 676, 53, 184, 595, 6, 792, 46, 74, 1327, 309, 17, 9264, 429, 4, 7, 5, 199, 502, 23, 10858, 16, 1546, 20, 113, 34, 4, 8096, 4907, 502, 10858, 22, 173, 23, 3, 7, 4, 26, 45, 205, 44, 4964, 62, 633, 1, 779, 278]",2129.0,13678736,Groin recurrence patients vulvar negative nodes superficial inguinal lymphadenectomy,4,0.07017543859649122
p16 expression in squamous lesions of the female genital tract.,Journal of molecular histology,J. Mol. Histol.,2004-02-01,"The aim of this study was to examine the role of p16 in the pathogenesis of squamous carcinoma of the gynecologic tract. Squamous carcinoma and carcinoma in situ from the female genital tract were examined for the expression of p16 by paraffin immunohistochemistry. About 74% (40/54) of cases showed p16 expression. By primary site, 77% (23/30) of cervical, 67% (6/9) of vaginal and 85% (11/13) of vulvar primaries expressed p16, but two endometrial primary squamous carcinomas were negative (0/2). In addition, p16 was not identified in non-dysplastic tissue and low grade dysplasia. In cases where there were matched vaginal or vulvar and cervical primaries in a given patient, there was concordant positive p16 expression. It is concluded that p16 is frequently expressed in squamous carcinoma of the cervix, vagina and vulva, but not seen in cases of benign and low grade lesions. It may be a marker of transformation from a low to a high grade lesion. More cases of endometrial primaries need to be studied to see if these evolve by a p16-independent pathway.",Journal Article,5833.0,8.0,aim examine role p16 pathogenesis squamous carcinoma gynecologic tract Squamous carcinoma carcinoma situ female genital tract examined expression p16 paraffin immunohistochemistry 74 40/54 cases showed p16 expression primary site 77 23/30 cervical 67 6/9 vaginal 85 11/13 vulvar primaries expressed p16 endometrial primary squamous carcinomas negative 0/2 addition p16 identified non-dysplastic tissue low grade dysplasia cases matched vaginal vulvar cervical primaries given patient concordant positive p16 expression concluded p16 frequently expressed squamous carcinoma cervix vagina vulva seen cases benign low grade lesions marker transformation low high grade lesion cases endometrial primaries need studied evolve p16-independent pathway,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 1004, 3, 200, 1, 1932, 4, 3, 1384, 1, 691, 134, 1, 3, 1512, 1696, 691, 134, 2, 134, 4, 957, 29, 3, 1061, 8226, 1696, 11, 409, 9, 3, 55, 1, 1932, 20, 2487, 888, 545, 794, 327, 667, 1, 140, 224, 1932, 55, 20, 86, 606, 849, 382, 201, 1, 598, 49, 83, 1, 2, 772, 175, 233, 1, 6183, 570, 1932, 84, 100, 86, 691, 826, 11, 199, 13, 18, 4, 352, 1932, 10, 44, 108, 4, 220, 6461, 246, 2, 154, 88, 2253, 4, 140, 1257, 125, 11, 655, 15, 2, 6183, 4, 8, 447, 69, 125, 10, 3610, 109, 1932, 55, 192, 16, 4724, 17, 1932, 16, 746, 570, 4, 691, 134, 1, 3, 3629, 7553, 2, 9263, 84, 44, 527, 4, 140, 1, 1002, 2, 154, 88, 406, 192, 68, 40, 8, 952, 1, 1392, 29, 8, 154, 6, 8, 64, 88, 1180, 80, 140, 1, 6183, 594, 6, 40, 656, 6, 3764, 492, 46, 4800, 20, 8, 1932, 306, 308]",962.0,15328914,p16 expression squamous lesions female genital tract,0,0.0
Conservative clitoral preservation surgery in the treatment of vulvar squamous cell carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2004-10-01,"To determine the safety and efficacy of clitoral-sparing surgery in women with squamous cell carcinoma (SCCA) of the anterior vulva not involving the clitoris. Patients with vulvar SCCA diagnosed between 1984 and 2000 were identified and data collected. In this descriptive analysis, women treated with complete radical vulvectomy were compared to those treated with clitoral-sparing modified radical vulvectomy. All slides were re-reviewed. Of the 41 women with vulvar carcinoma, 13 had clitoral-sparing modified vulvectomies (group A) while the remaining 28 underwent complete radical vulvectomies (group B). The 13 patients in group A included, 8 with stage I, 2 stage II, 2 stage III, and 1 with stage IV disease. The two groups had similar demographic and pathologic prognostic factors. After a median follow-up of 59 months, no patients in group A had loco-regional failure. Clitoral-sparing vulvar cancer surgery does not compromise the rate of loco-regional control in patients and may be offered to selected women.",Journal Article,5590.0,13.0,determine safety efficacy clitoral-sparing surgery women squamous carcinoma SCCA anterior vulva involving clitoris Patients vulvar SCCA diagnosed 1984 2000 identified collected descriptive women treated complete radical vulvectomy compared treated clitoral-sparing modified radical vulvectomy slides re-reviewed 41 women vulvar carcinoma 13 clitoral-sparing modified vulvectomies group remaining 28 underwent complete radical vulvectomies group B 13 patients group included 8 stage 2 stage II 2 stage III 1 stage IV disease groups similar demographic pathologic prognostic factors median follow-up 59 months patients group loco-regional failure Clitoral-sparing vulvar surgery compromise rate loco-regional control patients offered selected women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 367, 2, 209, 1, 24751, 1851, 152, 4, 117, 5, 691, 31, 134, 6372, 1, 3, 2882, 9263, 44, 1267, 3, 43724, 7, 5, 6372, 265, 59, 6036, 2, 1081, 11, 108, 2, 74, 786, 4, 26, 3778, 65, 117, 73, 5, 236, 711, 22043, 11, 72, 6, 135, 73, 5, 24751, 1851, 1230, 711, 22043, 62, 3830, 11, 1491, 446, 1, 3, 605, 117, 5, 134, 233, 42, 24751, 1851, 1230, 43725, 87, 8, 369, 3, 1844, 339, 208, 236, 711, 43725, 87, 132, 3, 233, 7, 4, 87, 8, 159, 66, 5, 82, 70, 18, 82, 215, 18, 82, 316, 2, 14, 5, 82, 478, 34, 3, 100, 271, 42, 288, 1540, 2, 510, 177, 130, 50, 8, 52, 166, 126, 1, 728, 53, 77, 7, 4, 87, 8, 42, 7214, 951, 496, 24751, 1851, 12, 152, 1097, 44, 4665, 3, 116, 1, 7214, 951, 182, 4, 7, 2, 68, 40, 2216, 6, 715, 117]",980.0,15385125,Conservative clitoral preservation surgery treatment vulvar squamous carcinoma,0,0.0
Clinically identifying women with vulvar lichen sclerosus at increased risk of squamous cell carcinoma: a case-control study.,The Journal of reproductive medicine,J Reprod Med,2004-10-01,"To identify clinical factors that might identify women with vulvar lichen sclerosus who are at increased risk of developing squamous cell cacinoma. A retrospective, case-control study compared 46 women presenting between 1992 and 2000 with clinical and histologic evidence of squamous cell carcinoma of the vulva arising in a background of lichen sclerosus and 213 new referrals with vulvar lichen sclerosus during the same period. The ages of the patients and presence of clinical hyperplasia were the only differences between the 2 groups. Women presenting with vulvar cancer arising within a background of lichen sclerosus are significantly older than women presenting with lichen sclerosus. In addition, clinical evidence of squamous hyperplasia is independently associated with vulvar carcinoma. Neither the presence nor duration of symptoms nor the loss of vulvar architecture is a useful indicator of potential cancer risk.",Comparative Study,5590.0,55.0,identify clinical factors identify women vulvar lichen sclerosus increased risk developing squamous cacinoma retrospective case-control compared 46 women presenting 1992 2000 clinical histologic evidence squamous carcinoma vulva arising background lichen sclerosus 213 new referrals vulvar lichen sclerosus period ages patients presence clinical hyperplasia differences 2 groups Women presenting vulvar arising background lichen sclerosus significantly older women presenting lichen sclerosus addition clinical evidence squamous hyperplasia independently associated vulvar carcinoma presence duration symptoms loss vulvar architecture useful indicator potential risk,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 255, 38, 130, 17, 822, 255, 117, 5, 14899, 28318, 54, 32, 28, 101, 43, 1, 931, 691, 31, 54511, 8, 459, 473, 182, 45, 72, 641, 117, 1656, 59, 2846, 2, 1081, 5, 38, 2, 884, 241, 1, 691, 31, 134, 1, 3, 9263, 2635, 4, 8, 2426, 1, 14899, 28318, 2, 5833, 217, 6902, 5, 14899, 28318, 190, 3, 827, 727, 3, 2165, 1, 3, 7, 2, 463, 1, 38, 3176, 11, 3, 158, 362, 59, 3, 18, 271, 117, 1656, 5, 12, 2635, 262, 8, 2426, 1, 14899, 28318, 32, 97, 434, 76, 117, 1656, 5, 14899, 28318, 4, 352, 38, 241, 1, 691, 3176, 16, 1042, 41, 5, 134, 2174, 3, 463, 2110, 654, 1, 507, 2110, 3, 407, 1, 4447, 16, 8, 999, 3287, 1, 174, 12, 43]",887.0,15568404,Clinically identifying women vulvar lichen sclerosus increased risk squamous carcinoma case-control,0,0.0
Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2005-12-20,"To compare short- and long-term morbidity associated with saphenous vein sparing versus ligation during inguinal lymphadenectomy for vulvar carcinoma. A retrospective evaluation of patients with carcinoma of the vulva that underwent inguinal lymphadenectomy was performed. Operative reports were evaluated and patients were divided into those who had sparing of the saphenous vein versus ligation. Postoperative short- and long-term complications were compared between the two groups using Pearson chi squared analysis. There were a total of 49 inguinal lymphadenectomies performed on 29 patients. The saphenous vein was spared in 18 (37%) groin dissections compared to 31(63%) in which the saphenous vein was ligated. The two groups were similar in regards to clinical characteristics. All patients received closed suction drains and prophylactic antibiotics. Median number of nodes dissected was similar. Cellulitis was more common in the vein-ligated group compared to the vein-spared group (45% vs. 0%; P < 0.001). Wound breakdown occurred in 25% of dissections where the saphenous vein was ligated versus 0% in dissections where the vein was spared (P = or < 0.02). Short-term edema (< or = 6 months) was similar between vein-ligated and vein-spared groups (67% vs. 72%, P < 1.0). Subsequently, chronic lymphedema (> 6 months) persisted in 38% of the vein-ligated group compared to 11% in the vein-spared group (P < 0.05). The incidence of recurrent disease was similar in both groups (19.3 % vs. 22.2% P < 0.1). Routine preservation of the saphenous vein during inguinal lymphadenectomy for vulvar carcinoma may reduce the incidence of wound cellulitis, wound breakdown, and chronic lymphedema.",Journal Article,5145.0,52.0,compare short- long-term morbidity associated saphenous vein sparing versus ligation inguinal lymphadenectomy vulvar carcinoma retrospective evaluation patients carcinoma vulva underwent inguinal lymphadenectomy performed Operative reports evaluated patients divided sparing saphenous vein versus ligation Postoperative short- long-term complications compared groups Pearson chi squared total 49 inguinal lymphadenectomies performed 29 patients saphenous vein spared 18 37 groin dissections compared 31 63 saphenous vein ligated groups similar regards clinical characteristics patients received closed suction drains prophylactic antibiotics Median number nodes dissected similar Cellulitis common vein-ligated group compared vein-spared group 45 vs. 0 P 0.001 Wound breakdown occurred 25 dissections saphenous vein ligated versus 0 dissections vein spared P 0.02 Short-term edema 6 months similar vein-ligated vein-spared groups 67 vs. 72 P 1.0 Subsequently chronic lymphedema 6 months persisted 38 vein-ligated group compared 11 vein-spared group P 0.05 incidence recurrent disease similar groups 19.3 vs. 22.2 P 0.1 Routine preservation saphenous vein inguinal lymphadenectomy vulvar carcinoma reduce incidence wound cellulitis wound breakdown chronic lymphedema,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 932, 978, 2, 319, 337, 787, 41, 5, 24877, 2762, 1851, 185, 5307, 190, 4907, 2048, 9, 134, 8, 459, 451, 1, 7, 5, 134, 1, 3, 9263, 17, 208, 4907, 2048, 10, 173, 1208, 1198, 11, 194, 2, 7, 11, 2176, 237, 135, 54, 42, 1851, 1, 3, 24877, 2762, 185, 5307, 573, 978, 2, 319, 337, 521, 11, 72, 59, 3, 100, 271, 75, 4720, 3163, 8515, 65, 125, 11, 8, 181, 1, 739, 4907, 16322, 173, 23, 462, 7, 3, 24877, 2762, 10, 6830, 4, 203, 567, 9264, 6894, 72, 6, 456, 676, 4, 92, 3, 24877, 2762, 10, 18971, 3, 100, 271, 11, 288, 4, 8930, 6, 38, 374, 62, 7, 103, 3745, 20368, 14881, 2, 1862, 5214, 52, 207, 1, 502, 7973, 10, 288, 11168, 10, 80, 186, 4, 3, 2762, 18971, 87, 72, 6, 3, 2762, 6830, 87, 512, 105, 13, 19, 13, 144, 2689, 12498, 489, 4, 243, 1, 6894, 1257, 3, 24877, 2762, 10, 18971, 185, 13, 4, 6894, 1257, 3, 2762, 10, 6830, 19, 15, 13, 588, 978, 337, 3306, 15, 49, 53, 10, 288, 59, 2762, 18971, 2, 2762, 6830, 271, 598, 105, 720, 19, 14, 13, 1611, 442, 3063, 49, 53, 3760, 4, 519, 1, 3, 2762, 18971, 87, 72, 6, 175, 4, 3, 2762, 6830, 87, 19, 13, 474, 3, 287, 1, 387, 34, 10, 288, 4, 110, 271, 326, 27, 105, 350, 18, 19, 13, 14, 1311, 2224, 1, 3, 24877, 2762, 190, 4907, 2048, 9, 134, 68, 969, 3, 287, 1, 2689, 11168, 2689, 12498, 2, 442, 3063]",1618.0,16364412,Saphenous vein sparing inguinal lymphadenectomy reduce morbidity patients vulvar carcinoma,0,0.0
The outcomes of patients with positive margins after excision for intraepithelial Paget's disease of the vulva.,Gynecologic oncology,Gynecol. Oncol.,2006-10-24,"Vulvar Paget's disease is a rare neoplasm that usually occurs in postmenopausal women. Treatment with surgical excision can be complicated by extension of microscopic disease in an irregular manner well beyond the visible margins of the lesion. The objective or our study was to analyze the outcomes of patients with primary vulvar intraepithelial Paget's disease who had positive microscopic margins after primary excision. We reviewed the records of all patients with Paget's disease of the vulva treated at our institution from 1/80 to 9/02. Patients whose sample showed stromal invasion or an underlying carcinoma were excluded. Data were collected regarding patient demographics, disease location, treatment, surgical margin status, additional treatment, and clinical outcome. The medical records and histopathologic specimens of 28 women with intraepithelial Paget's disease of the vulva were evaluated. Surgical treatment consisted of radical vulvectomy in 3 patients (11%), simple vulvectomy in 18 patients (64%), and wide local excision in the other 7 patients (25%). Of the 20 patients with microscopically positive margins, 14 (70%) developed recurrent disease and the remaining 6 (30%) are disease free. Of the 8 patients with negative margins, 3 (38%) developed disease recurrence and the remaining 5 (63%) are disease free. With a median follow-up of 49 months (range, 3-186 months), there was no correlation between disease recurrence and margin status (P=0.20). Of the 17 patients who recurred, 14 (82%) underwent additional surgical excision and 1 patient was treated with Retin-A. The remaining 2 patients refused further treatment and were lost to follow-up. In those patients who underwent surgery for recurrence, between 1 and 3 re-excisions were performed. Of the 15 evaluable patients who were treated for recurrent disease, 12 (80%) had no evidence of persistent disease and 3 (20%) had persistent disease at a median follow-up of 63.7 months (range, 18.5-186 months). Microscopically positive margins following surgical excision of vulvar intraepithelial Paget's disease is a frequent finding, and disease recurrence is common regardless of surgical margin status. Long-term monitoring of patients is recommended, and repeat surgical excision is often necessary.",Journal Article,4837.0,84.0,Vulvar Paget 's disease rare neoplasm usually occurs postmenopausal women Treatment surgical excision complicated extension microscopic disease irregular manner visible margins lesion objective outcomes patients primary vulvar intraepithelial Paget 's disease positive microscopic margins primary excision reviewed records patients Paget 's disease vulva treated institution 1/80 9/02 Patients showed stromal invasion underlying carcinoma excluded collected patient demographics disease location treatment surgical margin status additional treatment clinical outcome medical records histopathologic specimens 28 women intraepithelial Paget 's disease vulva evaluated Surgical treatment consisted radical vulvectomy 3 patients 11 simple vulvectomy 18 patients 64 wide local excision 7 patients 25 20 patients microscopically positive margins 14 70 developed recurrent disease remaining 6 30 disease free 8 patients negative margins 3 38 developed disease recurrence remaining 5 63 disease free median follow-up 49 months range 3-186 months correlation disease recurrence margin status P=0.20 17 patients recurred 14 82 underwent additional surgical excision 1 patient treated Retin-A remaining 2 patients refused treatment lost follow-up patients underwent surgery recurrence 1 3 re-excisions performed 15 evaluable patients treated recurrent disease 12 80 evidence persistent disease 3 20 persistent disease median follow-up 63.7 months range 18.5-186 months Microscopically positive margins following surgical excision vulvar intraepithelial Paget 's disease frequent finding disease recurrence common regardless surgical margin status Long-term monitoring patients recommended repeat surgical excision necessary,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[7497, 292, 34, 16, 8, 622, 2131, 17, 2082, 1780, 4, 1679, 117, 24, 5, 221, 1366, 122, 40, 4286, 20, 2401, 1, 2984, 34, 4, 35, 8685, 1708, 149, 1654, 3, 4822, 1012, 1, 3, 1180, 3, 461, 15, 114, 45, 10, 6, 1992, 3, 123, 1, 7, 5, 86, 4153, 7497, 292, 34, 54, 42, 109, 2984, 1012, 50, 86, 1366, 21, 446, 3, 1064, 1, 62, 7, 5, 7497, 292, 34, 1, 3, 9263, 73, 28, 114, 731, 29, 14, 493, 6, 83, 588, 7, 1310, 1000, 224, 1126, 578, 15, 35, 1181, 134, 11, 1800, 74, 11, 786, 666, 69, 2221, 34, 1147, 24, 221, 959, 156, 402, 24, 2, 38, 228, 3, 484, 1064, 2, 2630, 623, 1, 339, 117, 5, 4153, 7497, 292, 34, 1, 3, 9263, 11, 194, 221, 24, 1695, 1, 711, 22043, 4, 27, 7, 175, 2763, 22043, 4, 203, 7, 660, 2, 1019, 293, 1366, 4, 3, 127, 67, 7, 243, 1, 3, 179, 7, 5, 7187, 109, 1012, 213, 431, 276, 387, 34, 2, 3, 1844, 49, 201, 32, 34, 115, 1, 3, 66, 7, 5, 199, 1012, 27, 519, 276, 34, 146, 2, 3, 1844, 33, 676, 32, 34, 115, 5, 8, 52, 166, 126, 1, 739, 53, 184, 27, 5869, 53, 125, 10, 77, 816, 59, 34, 146, 2, 959, 156, 19, 13, 179, 1, 3, 269, 7, 54, 3363, 213, 878, 208, 402, 221, 1366, 2, 14, 69, 10, 73, 5, 55844, 8, 3, 1844, 18, 7, 8237, 195, 24, 2, 11, 3009, 6, 166, 126, 4, 135, 7, 54, 208, 152, 9, 146, 59, 14, 2, 27, 1491, 10741, 11, 173, 1, 3, 167, 859, 7, 54, 11, 73, 9, 387, 34, 133, 493, 42, 77, 241, 1, 1882, 34, 2, 27, 179, 42, 1882, 34, 28, 8, 52, 166, 126, 1, 676, 67, 53, 184, 203, 33, 5869, 53, 7187, 109, 1012, 366, 221, 1366, 1, 4153, 7497, 292, 34, 16, 8, 908, 1567, 2, 34, 146, 16, 186, 1583, 1, 221, 959, 156, 319, 337, 1315, 1, 7, 16, 793, 2, 2334, 221, 1366, 16, 629, 1493]",2201.0,17067662,outcomes patients positive margins excision intraepithelial Paget 's disease vulva,0,0.0
Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era.,Gynecologic oncology,Gynecol. Oncol.,2007-05-31,"Patients with vulvar cancer were stratified into risk groups for survival based on surgicopathologic findings from a prospective study conducted by the Gynecologic Oncology Group from 1977-1984. The purpose of this study is to reassess these risk groups in patients treated in an era of contemporary management. Patients with vulvar carcinoma were identified from 1990-2005 for retrospective analysis. Charts were abstracted for clinical, histopathologic and surgical data, and patients stratified into four risk groups for survival based on the clinical size of tumor and extent of lymph node metastasis. Univariate and multivariate characteristics were evaluated and 5-year survival determined by Kaplan-Meier method. 175 patients were identified that underwent surgical management with a median age at diagnosis of 59.9 years. Stage distribution included: I (n=89, 51%), II (n=53, 30%), III (n=29, 17%), and IV (n=4, 2%). Stratification into risk groups included: minimal (n=89, 51%), low (n=69, 40%), intermediate (n=11, 6%), and high (n=6; 3%). The survival rate was 100%, 97%, 82% and 100%, respectively, at median follow-up of 54.5 months. Comparatively, the survival rates for historic groups were 97.9%, 87.4%, 74.8% and 29.0%. Using multivariate analysis, age (p=0.04) and lymph node metastasis (p=0.009) were predictive of survival. Survival among the minimal and low risk groups is preserved in spite of less radical surgery. 5-year survival rate for intermediate and high risk patients also appears to be improved. This is likely a result of advancement in adjuvant chemo-radiation and a younger patient population that presents with less advanced disease.",Journal Article,4618.0,23.0,Patients vulvar stratified risk groups survival based surgicopathologic findings prospective conducted Gynecologic Oncology Group 1977-1984 purpose reassess risk groups patients treated era contemporary management Patients vulvar carcinoma identified 1990-2005 retrospective Charts abstracted clinical histopathologic surgical patients stratified risk groups survival based clinical size extent lymph node metastasis Univariate multivariate characteristics evaluated 5-year survival determined Kaplan-Meier 175 patients identified underwent surgical management median age diagnosis 59.9 years Stage distribution included n=89 51 II n=53 30 III n=29 17 IV n=4 2 Stratification risk groups included minimal n=89 51 low n=69 40 intermediate n=11 6 high n=6 3 survival rate 100 97 82 100 respectively median follow-up 54.5 months Comparatively survival rates historic groups 97.9 87.4 74.8 29.0 multivariate age p=0.04 lymph node metastasis p=0.009 predictive survival Survival minimal low risk groups preserved spite radical surgery 5-year survival rate intermediate high risk patients appears improved likely advancement adjuvant chemo-radiation younger patient population presents advanced disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 12, 11, 1173, 237, 43, 271, 9, 25, 90, 23, 30888, 272, 29, 8, 482, 45, 426, 20, 3, 1512, 413, 87, 29, 11792, 6036, 3, 743, 1, 26, 45, 16, 6, 19046, 46, 43, 271, 4, 7, 73, 4, 35, 1713, 1, 2667, 284, 7, 5, 134, 11, 108, 29, 2289, 1242, 9, 459, 65, 4413, 11, 4106, 9, 38, 2630, 2, 221, 74, 2, 7, 1173, 237, 294, 43, 271, 9, 25, 90, 23, 3, 38, 444, 1, 30, 2, 1039, 1, 263, 289, 278, 880, 2, 331, 374, 11, 194, 2, 33, 111, 25, 509, 20, 876, 882, 596, 3300, 7, 11, 108, 17, 208, 221, 284, 5, 8, 52, 89, 28, 147, 1, 728, 83, 60, 82, 1395, 159, 70, 78, 887, 725, 215, 78, 699, 201, 316, 78, 462, 269, 2, 478, 78, 39, 18, 1541, 237, 43, 271, 159, 1048, 78, 887, 725, 154, 78, 790, 327, 919, 78, 175, 49, 2, 64, 78, 49, 27, 3, 25, 116, 10, 394, 1015, 878, 2, 394, 106, 28, 52, 166, 126, 1, 667, 33, 53, 11584, 3, 25, 151, 9, 6875, 271, 11, 1015, 83, 912, 39, 794, 66, 2, 462, 13, 75, 331, 65, 89, 19, 13, 755, 2, 263, 289, 278, 19, 13, 2376, 11, 464, 1, 25, 25, 107, 3, 1048, 2, 154, 43, 271, 16, 5797, 4, 9018, 1, 299, 711, 152, 33, 111, 25, 116, 9, 919, 2, 64, 43, 7, 120, 1233, 6, 40, 231, 26, 16, 322, 8, 757, 1, 7496, 4, 249, 3341, 121, 2, 8, 773, 69, 266, 17, 2740, 5, 299, 131, 34]",1579.0,17540438,Gynecologic Oncology Group risk groups vulvar carcinoma improvement survival modern era,0,0.0
Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation.,Gynecologic oncology,Gynecol. Oncol.,2007-12-26,"To review outcome measures including overall survival (OS), progression free survival (PFS), and patterns of recurrence in patients with advanced vulvar cancer managed by primary surgery (PS) or primary chemoradiation (PCRT) as well as population characteristics for the two groups. Patients diagnosed with stage III and IV squamous cell carcinoma of the vulva from 1990 to 2006 were identified for retrospective analysis at a single institution. Charts were abstracted for clinical and pathologic findings, treatment modalities, complications, recurrence, and follow-up. Kaplan-Meier method was used to determine PFS and OS. Sixty-three patients with stage III (n=47) and IV (n=16) carcinoma of the vulva were identified; 30 patients were treated with PS, and 33 patients had tumor that was unresectable by vulvectomy and underwent PCRT. Patients treated with PCRT were younger (61 vs. 72 years; p=0.09), had less metastasis to lymph nodes (54% vs. 83%, p=0.01), and larger tumors (6 vs. 3.5 cm, p=0.0001) compared to patients treated with PS. Despite these differences, OS for the PS and PCRT groups was 69% and 76% (NS), respectively, with median follow-up at 31 months. There were no differences in PFS or recurrence rates between the two groups. By multivariate analysis, age was the only significant predictor of OS or PFS. Patients with advanced vulvar cancer that are managed with PS tend to be older patients that have smaller lesions but positive lymph nodes, whereas patients requiring PCRT are younger and have larger volume disease but fewer lymph node metastases. Despite these differences, patients treated with PS and PCRT have no differences in OS, PFS, or recurrence rates. Age is the most powerful predictor of survival when size, lymph node status, stage and treatment are accounted for.",Comparative Study,4409.0,32.0,review outcome measures including overall survival OS progression free survival PFS patterns recurrence patients advanced vulvar managed primary surgery PS primary chemoradiation PCRT population characteristics groups Patients diagnosed stage III IV squamous carcinoma vulva 1990 2006 identified retrospective single institution Charts abstracted clinical pathologic findings treatment modalities complications recurrence follow-up Kaplan-Meier determine PFS OS Sixty-three patients stage III n=47 IV n=16 carcinoma vulva identified 30 patients treated PS 33 patients unresectable vulvectomy underwent PCRT Patients treated PCRT younger 61 vs. 72 years p=0.09 metastasis lymph nodes 54 vs. 83 p=0.01 larger 6 vs. 3.5 cm p=0.0001 compared patients treated PS Despite differences OS PS PCRT groups 69 76 NS respectively median follow-up 31 months differences PFS recurrence rates groups multivariate age significant predictor OS PFS Patients advanced vulvar managed PS tend older patients smaller lesions positive lymph nodes patients requiring PCRT younger larger volume disease fewer lymph node metastases Despite differences patients treated PS PCRT differences OS PFS recurrence rates Age powerful predictor survival size lymph node status stage treatment accounted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 206, 228, 1018, 141, 63, 25, 118, 91, 115, 25, 300, 2, 764, 1, 146, 4, 7, 5, 131, 12, 2231, 20, 86, 152, 1511, 15, 86, 975, 28750, 22, 149, 22, 266, 374, 9, 3, 100, 271, 7, 265, 5, 82, 316, 2, 478, 691, 31, 134, 1, 3, 9263, 29, 2289, 6, 1324, 11, 108, 9, 459, 65, 28, 8, 226, 731, 4413, 11, 4106, 9, 38, 2, 510, 272, 24, 1558, 521, 146, 2, 166, 126, 876, 882, 596, 10, 95, 6, 223, 300, 2, 118, 1746, 169, 7, 5, 82, 316, 78, 662, 2, 478, 78, 245, 134, 1, 3, 9263, 11, 108, 201, 7, 11, 73, 5, 1511, 2, 466, 7, 42, 30, 17, 10, 1468, 20, 22043, 2, 208, 28750, 7, 73, 5, 28750, 11, 773, 713, 105, 720, 60, 19, 13, 1730, 42, 299, 278, 6, 263, 502, 667, 105, 852, 19, 13, 355, 2, 1077, 57, 49, 105, 27, 33, 494, 19, 13, 488, 72, 6, 7, 73, 5, 1511, 550, 46, 362, 118, 9, 3, 1511, 2, 28750, 271, 10, 790, 2, 846, 4044, 106, 5, 52, 166, 126, 28, 456, 53, 125, 11, 77, 362, 4, 300, 15, 146, 151, 59, 3, 100, 271, 20, 331, 65, 89, 10, 3, 158, 93, 980, 1, 118, 15, 300, 7, 5, 131, 12, 17, 32, 2231, 5, 1511, 5406, 6, 40, 434, 7, 17, 47, 2170, 406, 84, 109, 263, 502, 547, 7, 1888, 28750, 32, 773, 2, 47, 1077, 433, 34, 84, 1497, 263, 289, 196, 550, 46, 362, 7, 73, 5, 1511, 2, 28750, 47, 77, 362, 4, 118, 300, 15, 146, 151, 89, 16, 3, 96, 3757, 980, 1, 25, 198, 444, 263, 289, 156, 82, 2, 24, 32, 3688, 9]",1734.0,18155755,Comparison outcome measures patients advanced squamous carcinoma vulva treated surgery primary chemoradiation,1,0.017543859649122806
A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2008-05-15,"To evaluate VH fibrin sealant's influence on lower extremity lymphedema after inguinal lymphadenectomy in vulvar cancer patients. Patients undergoing an inguinal lymphadenectomy during the management of vulvar malignancy were randomized to receive sutured closure (SC) vs VH fibrin sealant sprayed into the groin followed by sutured closure (FS). Leg measurements were taken preoperatively and during postoperative encounters when surgical outcomes were assessed. Grade 2 or 3 lymphedema was defined as circumferential measurement increases of 3-5 cm and >5 cm, respectively. 150 patients were enrolled. 137 patients were evaluable for lymphedema analysis with 67 and 70 patients in the SC arm and FS arm, respectively. The incidence of grade 2 and 3 lymphedema was 67%(45/67) in the SC arm, and 60% (42/70) FS arm (p=0.4779). The incidence of lymphedema was strongly associated with inguinal infection (p=0.0165). Lymphedema was not statistically increased in those who received adjuvant radiation. 139 patients remained evaluable for a descriptive analysis of their surgical complications. The overall incidence of complications was 61%(43/70) and 59% (41/69) for SC and FS arms, respectively. There was no statistically significant difference in duration of drains, drain output or incidence of inguinal infections, wound breakdowns or seromas. There was an increased incidence of vulvar infections in the FS arm (23/69) vs (10/70) (p=0.0098). The utilization of a Blake drain was associated with an increase in vulvar (p=0.0157) and inguinal wound breakdown (p=0.0456). VH fibrin sealant in inguinal lymphadenectomies does not reduce leg lymphedema and may increase the risk for complications in the vulvar wound.","Clinical Trial, Phase III",4268.0,84.0,evaluate VH fibrin sealant 's influence lower extremity lymphedema inguinal lymphadenectomy vulvar patients Patients undergoing inguinal lymphadenectomy management vulvar malignancy randomized receive sutured closure SC vs VH fibrin sealant sprayed groin followed sutured closure FS Leg measurements taken preoperatively postoperative encounters surgical outcomes assessed Grade 2 3 lymphedema defined circumferential measurement increases 3-5 cm 5 cm respectively 150 patients enrolled 137 patients evaluable lymphedema 67 70 patients SC arm FS arm respectively incidence grade 2 3 lymphedema 67 45/67 SC arm 60 42/70 FS arm p=0.4779 incidence lymphedema strongly associated inguinal infection p=0.0165 Lymphedema statistically increased received adjuvant radiation 139 patients remained evaluable descriptive surgical complications overall incidence complications 61 43/70 59 41/69 SC FS arms respectively statistically significant difference duration drains drain output incidence inguinal infections wound breakdowns seromas increased incidence vulvar infections FS arm 23/69 vs 10/70 p=0.0098 utilization Blake drain associated increase vulvar p=0.0157 inguinal wound breakdown p=0.0456 VH fibrin sealant inguinal lymphadenectomies reduce leg lymphedema increase risk complications vulvar wound,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 15608, 17412, 23680, 292, 1054, 23, 280, 2678, 3063, 50, 4907, 2048, 4, 12, 7, 7, 479, 35, 4907, 2048, 190, 3, 284, 1, 710, 11, 384, 6, 560, 25084, 4830, 2969, 105, 15608, 17412, 23680, 45132, 237, 3, 9264, 370, 20, 25084, 4830, 4110, 10873, 1685, 11, 1633, 3888, 2, 190, 573, 8525, 198, 221, 123, 11, 275, 88, 18, 15, 27, 3063, 10, 395, 22, 7937, 2204, 1106, 1, 27, 33, 494, 2, 33, 494, 106, 1577, 7, 11, 346, 4352, 7, 11, 859, 9, 3063, 65, 5, 598, 2, 431, 7, 4, 3, 2969, 475, 2, 4110, 475, 106, 3, 287, 1, 88, 18, 2, 27, 3063, 10, 598, 512, 598, 4, 3, 2969, 475, 2, 335, 595, 431, 4110, 475, 19, 13, 45133, 3, 287, 1, 3063, 10, 1327, 41, 5, 4907, 930, 19, 13, 38119, 3063, 10, 44, 712, 101, 4, 135, 54, 103, 249, 121, 4929, 7, 958, 859, 9, 8, 3778, 65, 1, 136, 221, 521, 3, 63, 287, 1, 521, 10, 713, 601, 431, 2, 728, 605, 790, 9, 2969, 2, 4110, 1335, 106, 125, 10, 77, 712, 93, 523, 4, 654, 1, 14881, 9203, 6911, 15, 287, 1, 4907, 1875, 2689, 31075, 15, 38723, 125, 10, 35, 101, 287, 1, 1875, 4, 3, 4110, 475, 382, 790, 105, 79, 431, 19, 13, 21126, 3, 1961, 1, 8, 57061, 9203, 10, 41, 5, 35, 344, 4, 19, 13, 57062, 2, 4907, 2689, 12498, 19, 13, 34466, 15608, 17412, 23680, 4, 4907, 16322, 1097, 44, 969, 10873, 3063, 2, 68, 344, 3, 43, 9, 521, 4, 3, 2689]",1633.0,18482765,randomized phase III trial VH fibrin sealant reduce lymphedema inguinal lymph node dissection Gynecologic Oncology Group,0,0.0
The spectrum and clinical sequelae of human papillomavirus infection.,Gynecologic oncology,Gynecol. Oncol.,2007-11-01,"Infection with the human papillomavirus (HPV) is the most common sexually transmitted disease afflicting approximately 80% of the population. HPV infection is an essential factor in cervical carcinogenesis and cervical carcinoma is the second most common cause of cancer among women worldwide. In addition to cervical cancer, other malignancies in both men and women such as esophageal, oropharyngeal, and anal cancer have been causally associated with this virus. Other gender-specific HPV-related cancers include penile, vulvar and vaginal cancer. HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin. HPV-16 together with HPV-18 accounts for approximately 70% of cervical cancers. Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis.",Journal Article,4464.0,62.0,Infection human papillomavirus HPV common sexually transmitted disease afflicting approximately 80 population HPV infection essential factor cervical carcinogenesis cervical carcinoma second common cause women worldwide addition cervical malignancies men women esophageal oropharyngeal anal causally associated virus gender-specific HPV-related include penile vulvar vaginal HPV-16 common HPV type associated malignant phenotype regardless organ origin HPV-16 HPV-18 accounts approximately 70 cervical non-oncogenic HPV types including HPV types 6 11 associated 90 benign HPV-related lesions genital warts juvenile respiratory papillomatosis,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[930, 5, 3, 171, 3242, 933, 16, 3, 96, 186, 13588, 12959, 34, 45139, 705, 493, 1, 3, 266, 933, 930, 16, 35, 1452, 161, 4, 1719, 2, 134, 16, 3, 419, 96, 186, 708, 1, 12, 107, 117, 2358, 4, 352, 6, 12, 127, 441, 4, 110, 325, 2, 117, 225, 22, 2, 12, 47, 85, 12511, 41, 5, 26, 1450, 127, 1632, 112, 933, 139, 163, 643, 2, 12, 933, 245, 16, 3, 96, 186, 933, 267, 41, 5, 8, 393, 1005, 1583, 1, 1259, 1, 1938, 933, 245, 1162, 5, 933, 203, 4162, 9, 705, 431, 1, 163, 127, 220, 1302, 933, 630, 141, 933, 630, 49, 2, 175, 32, 41, 5, 252, 424, 1, 1002, 933, 139, 406, 225, 22, 8226, 19515, 2, 7857, 2718, 22118]",810.0,18499914,spectrum clinical sequelae human papillomavirus infection,2,0.03508771929824561
"Lymphatic mapping and sentinel node biopsy in vulvar, vaginal, and cervical cancers.","Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2008-04-01,"Over the past 15 years, lymphatic mapping and sentinel lymph node biopsy in vulvar, vaginal, and cervical cancers have been explored by gynecologic oncologists around the world. Based on the results of multiple single-institution studies, most in our field are optimistic that these techniques will increase the rates of detection of lymph node metastasis while decreasing the morbidity associated with lymphadenectomy. Large validation studies are currently underway in both the United States and Europe. In this review article, we present the published data on mapping techniques and discuss future considerations for these technologies.",Journal Article,4312.0,9.0,past 15 years lymphatic mapping sentinel lymph node biopsy vulvar vaginal cervical explored gynecologic oncologists world Based multiple single-institution studies field optimistic techniques increase rates detection lymph node metastasis decreasing morbidity associated lymphadenectomy Large validation studies currently underway United States Europe review article present published mapping techniques discuss future considerations technologies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[252, 3, 1219, 167, 60, 2936, 2568, 2, 1323, 263, 289, 411, 4, 2, 163, 47, 85, 1443, 20, 1512, 1339, 3337, 3, 1956, 90, 23, 3, 99, 1, 232, 226, 731, 94, 96, 4, 114, 1067, 32, 9566, 17, 46, 1092, 303, 344, 3, 151, 1, 638, 1, 263, 289, 278, 369, 2777, 3, 787, 41, 5, 2048, 375, 929, 94, 32, 694, 3948, 4, 110, 3, 1088, 907, 2, 3934, 4, 26, 206, 946, 21, 364, 3, 983, 74, 23, 2568, 1092, 2, 1139, 508, 3891, 9, 46, 2590]",606.0,18533402,Lymphatic mapping sentinel node biopsy vulvar vaginal cervical,2,0.03508771929824561
Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer research.,Comparative medicine,Comp. Med.,2008-06-01,"Mice in a colony used for pancreatic cancer research and maintained in a barrier animal facility presented with vulvar masses. A census and examination of all colony animals was conducted on 17 February 2006; line, gender, and mass location were recorded; a slide caliper was used to measure the width, length, and height of each mass; and the volume of each mass was calculated. Progeny female mice from crossbreeding of the B6.FVB-Tg(Ipf1-cre)1Tuv and B6;129-Kras2tm4Tyj (KRAS(G12D/+)) strains presented with external vulvar and periauricular papillomas. The papillomas were present in 41.2% of all female crossbred mice and ranged in size from 8 to 36 mm3. Age of mice and tumor size were not correlated. Compared with the B6.FVB-Tg(Ipf1-cre)1Tuv line, the crossbred female mice were more likely to have a vulvar mass, with an odds ratio of 29.3, 95% confidence interval (1.5, 563.9) and a positive predictive value of 42.9%. Diagnostic evaluation, including electron microscopy, light microscopy, serology, and bacteriology, did not reveal a viral or other infectious etiology. Therefore, we speculate that interaction between the genetic background of the mice and the introduced Kras oncogene may be responsible for these papillomas.",Journal Article,4251.0,7.0,Mice colony pancreatic research maintained barrier animal facility presented vulvar masses census examination colony animals conducted 17 February 2006 line gender mass location recorded slide caliper measure width length height mass volume mass calculated Progeny female mice crossbreeding B6.FVB-Tg Ipf1-cre 1Tuv B6 129-Kras2tm4Tyj KRAS G12D/+ strains presented external vulvar periauricular papillomas papillomas present 41.2 female crossbred mice ranged size 8 36 mm3 Age mice size correlated Compared B6.FVB-Tg Ipf1-cre 1Tuv line crossbred female mice likely vulvar mass odds ratio 29.3 95 confidence interval 1.5 563.9 positive predictive value 42.9 Diagnostic evaluation including electron microscopy light microscopy serology bacteriology reveal viral infectious etiology speculate interaction genetic background mice introduced Kras oncogene responsible papillomas,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[399, 4, 8, 1975, 95, 9, 12, 389, 2, 1955, 4, 8, 3318, 2026, 3483, 917, 5, 2692, 8, 7319, 2, 1385, 1, 62, 1975, 2258, 10, 426, 23, 269, 3010, 1324, 328, 1632, 2, 782, 1147, 11, 1872, 8, 7911, 45182, 10, 95, 6, 1463, 3, 5195, 1318, 2, 4594, 1, 296, 782, 2, 3, 433, 1, 296, 782, 10, 981, 13525, 1061, 399, 29, 57212, 1, 3, 10169, 11953, 5107, 45183, 7102, 45184, 2, 10169, 4649, 57213, 723, 5727, 5175, 917, 5, 1455, 2, 57214, 14816, 3, 14816, 11, 364, 4, 605, 18, 1, 62, 1061, 38760, 399, 2, 1869, 4, 444, 29, 66, 6, 511, 8434, 89, 1, 399, 2, 30, 444, 11, 44, 438, 72, 5, 3, 10169, 11953, 5107, 45183, 7102, 45184, 328, 3, 38760, 1061, 399, 11, 80, 322, 6, 47, 8, 782, 5, 35, 610, 197, 1, 462, 27, 48, 307, 268, 14, 33, 13140, 83, 2, 8, 109, 464, 549, 1, 595, 83, 752, 451, 141, 4560, 3804, 1691, 3804, 10654, 2, 57215, 205, 44, 2396, 8, 1667, 15, 127, 3398, 2855, 673, 21, 11778, 17, 915, 59, 3, 336, 2426, 1, 3, 399, 2, 3, 3955, 723, 1836, 68, 40, 2327, 9, 46, 14816]",1174.0,18589869,Spontaneous vulvar papillomas colony mice pancreatic research,0,0.0
Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases.,Gynecologic and obstetric investigation,Gynecol. Obstet. Invest.,2009-10-10,"Rectovaginal fistula in long-standing Crohn's disease is possibly associated with malignant transformation to mucinous adenocarcinoma of the vagina. However, there have been no previously reported cases documenting vulvar cancer in association with rectovaginal fistula in Crohn's disease. We report 2 cases of vulvar mucinous adenocarcinoma associated with Crohn's disease. Both showed vulvar symptoms after the development of rectovaginal fistula. CASE 1: A 48-year-old woman, with a 30-year history of Crohn's disease including a rectovaginal fistula, developed persistent pyoderma gangrenosum. Further workup revealed metastatic vulvar mucinous adenocarcinoma. CASE 2: A 37-year-old woman with long-standing Crohn's disease including numerous episodes of perianal or rectovaginal fistulas complained of a vulvar mass suspicious for an abscess. Biopsy showed mucinous adenocarcinoma. Vulvar lesions or symptoms in the setting of rectovaginal fistula in Crohn's disease are an important clinical feature and the possible development of vulvar cancer should be considered.",Case Reports,3755.0,6.0,Rectovaginal fistula long-standing Crohn 's disease possibly associated malignant transformation mucinous adenocarcinoma vagina previously reported cases documenting vulvar association rectovaginal fistula Crohn 's disease report 2 cases vulvar mucinous adenocarcinoma associated Crohn 's disease showed vulvar symptoms development rectovaginal fistula CASE 1 48-year-old woman 30-year history Crohn 's disease including rectovaginal fistula developed persistent pyoderma gangrenosum workup revealed metastatic vulvar mucinous adenocarcinoma CASE 2 37-year-old woman long-standing Crohn 's disease including numerous episodes perianal rectovaginal fistulas complained vulvar mass suspicious abscess Biopsy showed mucinous adenocarcinoma Vulvar lesions symptoms setting rectovaginal fistula Crohn 's disease important clinical feature possible development vulvar considered,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[22569, 4920, 4, 319, 10909, 11612, 292, 34, 16, 2150, 41, 5, 393, 1392, 6, 2391, 449, 1, 3, 7553, 137, 125, 47, 85, 77, 373, 210, 140, 9255, 12, 4, 248, 5, 22569, 4920, 4, 11612, 292, 34, 21, 414, 18, 140, 1, 2391, 449, 41, 5, 11612, 292, 34, 110, 224, 507, 50, 3, 193, 1, 22569, 4920, 473, 14, 8, 576, 111, 1095, 2854, 5, 8, 201, 111, 532, 1, 11612, 292, 34, 141, 8, 22569, 4920, 276, 1882, 43141, 43142, 195, 4755, 553, 113, 2391, 449, 473, 18, 8, 567, 111, 1095, 2854, 5, 319, 10909, 11612, 292, 34, 141, 2331, 3750, 1, 10855, 15, 22569, 13244, 22520, 1, 8, 782, 3230, 9, 35, 7979, 411, 224, 2391, 449, 406, 15, 507, 4, 3, 546, 1, 22569, 4920, 4, 11612, 292, 34, 32, 35, 305, 38, 2705, 2, 3, 899, 193, 1, 12, 257, 40, 515]",1016.0,19828998,Vulvar mucinous adenocarcinoma associated Crohn 's disease report cases,0,0.0
The risk of squamous cell carcinoma in persistent vulvar ulcers.,"Menopause (New York, N.Y.)",Menopause,2011-10-01,"The standard evaluation for vulvar ulcers includes an office biopsy. There are limited data regarding the false-negative rate of a punch biopsy in detecting squamous cell carcinoma of the vulva. This study reports on pathologic discrepancies between office biopsy and subsequent wide local excision for nonhealing vulvar ulcers. A retrospective review of the surgical records of 118 consecutive vulvar procedures was performed. Eleven women with persistent vulvar ulcers in the absence of a mass or pigmented lesion were identified. Patient demographics, physical examination, office evaluation, and surgical and pathology reports for these 11 women were reviewed. A persistent vulvar ulcer was the presenting complaint in 11 (13.8%) of 80 women with squamous cell disease. Most women were postmenopausal, with a median age of 72 years. Nine of the 11 women had an office biopsy performed before consultation with a gynecologic oncologist. Five (55%) of these specimens had benign findings on office biopsy but revealed invasive squamous cell carcinoma after subsequent excision. Three of four women with prior diagnosis of lichen sclerosis had ulcers harboring invasive carcinoma. Vulvar ulceration may be the only presenting symptom in women with vulvar squamous cell carcinoma especially in postmenopausal women. Prompt office biopsy should remain part of the standard diagnostic evaluation; however, cancer should be suspected even with a negative biopsy result if ulcerations persist. More extensive tissue sampling in the operating room should be considered for these women.",Journal Article,3034.0,10.0,standard evaluation vulvar ulcers includes office biopsy limited false-negative rate punch biopsy detecting squamous carcinoma vulva reports pathologic discrepancies office biopsy subsequent wide local excision nonhealing vulvar ulcers retrospective review surgical records 118 consecutive vulvar procedures performed women persistent vulvar ulcers absence mass pigmented lesion identified Patient demographics physical examination office evaluation surgical pathology reports 11 women reviewed persistent vulvar ulcer presenting complaint 11 13.8 80 women squamous disease women postmenopausal median age 72 years 11 women office biopsy performed consultation gynecologic oncologist 55 specimens benign findings office biopsy revealed invasive squamous carcinoma subsequent excision women prior diagnosis lichen sclerosis ulcers harboring invasive carcinoma Vulvar ulceration presenting symptom women vulvar squamous carcinoma especially postmenopausal women Prompt office biopsy remain standard diagnostic evaluation suspected negative biopsy ulcerations persist extensive tissue sampling operating room considered women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 260, 451, 9, 14879, 1920, 35, 6489, 411, 125, 32, 383, 74, 666, 3, 2133, 199, 116, 1, 8, 12769, 411, 4, 2502, 691, 31, 134, 1, 3, 9263, 26, 45, 1198, 23, 510, 7631, 59, 6489, 411, 2, 706, 1019, 293, 1366, 9, 38763, 14879, 8, 459, 206, 1, 3, 221, 1064, 1, 4002, 935, 1369, 10, 173, 2627, 117, 5, 1882, 14879, 4, 3, 1127, 1, 8, 782, 15, 11646, 1180, 11, 108, 69, 2221, 900, 1385, 6489, 451, 2, 221, 2, 1117, 1198, 9, 46, 175, 117, 11, 446, 8, 1882, 8792, 10, 3, 1656, 13332, 4, 175, 233, 66, 1, 493, 117, 5, 691, 31, 34, 96, 117, 11, 1679, 5, 8, 52, 89, 1, 720, 60, 762, 1, 3, 175, 117, 42, 35, 6489, 411, 173, 348, 2981, 5, 8, 1512, 2709, 365, 614, 1, 46, 623, 42, 1002, 272, 23, 6489, 411, 84, 553, 416, 691, 31, 134, 50, 706, 1366, 169, 1, 294, 117, 5, 324, 147, 1, 14899, 7426, 42, 14879, 2105, 416, 134, 5158, 68, 40, 3, 158, 1656, 934, 4, 117, 5, 691, 31, 134, 1093, 4, 1679, 117, 4776, 6489, 411, 257, 918, 760, 1, 3, 260, 752, 451, 137, 12, 257, 40, 2768, 871, 5, 8, 199, 411, 757, 492, 28313, 5589, 80, 1344, 246, 2874, 4, 3, 2584, 4698, 257, 40, 515, 9, 46, 117]",1505.0,21670713,risk squamous carcinoma persistent vulvar ulcers,2,0.03508771929824561
A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.,Gynecologic oncology,Gynecol. Oncol.,2011-11-09,"To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma. Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily  32 fractions=57.6 Gy) plus weekly cisplatin (40 mg/m(2)) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor. A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69%) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N=4), toxicity (N=9), death (N=2), other (N=3). There were 37 patients with a complete clinical response (37/58; 64%). Among these women there were 34 who underwent surgical biopsy and 29 (78%) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes. This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.","Clinical Trial, Phase II",2995.0,83.0,determine efficacy toxicity radiation therapy concurrent weekly cisplatin chemotherapy achieving complete clinical pathologic response primary treatment locally-advanced vulvar carcinoma Patients locally-advanced T3 T4 amenable surgical resection radical vulvectomy previously untreated squamous carcinoma vulva treated radiation 1.8 Gy daily 32 fractions=57.6 Gy plus weekly cisplatin 40 mg/m 2 followed surgical resection residual biopsy confirm complete clinical response Management groin lymph nodes standardized statistical endpoint Primary endpoints complete clinical pathologic response rates primary vulvar planned interim indicated sufficient activity reopen second stage accrual 58 evaluable patients 40 69 completed treatment Reasons prematurely discontinuing treatment included patient refusal N=4 toxicity N=9 death N=2 N=3 37 patients complete clinical response 37/58 64 women 34 underwent surgical biopsy 29 78 complete pathological response Common adverse effects included leukopenia pain radiation dermatitis pain metabolic changes combination radiation therapy plus weekly cisplatin successfully yielded high complete clinical pathologic response rates acceptable toxicity,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 209, 2, 155, 1, 121, 36, 2, 750, 709, 540, 56, 4, 1785, 8, 236, 38, 2, 510, 51, 198, 95, 9, 3, 86, 24, 1, 795, 131, 134, 7, 5, 795, 131, 2065, 15, 2463, 57, 44, 4070, 6, 221, 170, 847, 711, 22043, 373, 1278, 691, 31, 134, 1, 3, 9263, 11, 73, 5, 121, 14, 66, 381, 391, 531, 1550, 696, 49, 381, 349, 709, 540, 327, 81, 188, 18, 370, 20, 221, 170, 1, 753, 30, 15, 411, 6, 1843, 236, 38, 51, 284, 1, 3, 9264, 263, 502, 10, 1670, 2, 10, 44, 8, 1050, 1138, 86, 1387, 11, 236, 38, 2, 510, 51, 151, 1, 3, 86, 30, 8, 1465, 2914, 65, 1103, 1952, 128, 6, 60780, 3, 45, 6, 8, 419, 82, 1, 2262, 107, 717, 859, 7, 125, 11, 327, 790, 54, 781, 45, 24, 2325, 9, 9771, 7971, 24, 159, 69, 8104, 78, 39, 155, 78, 83, 273, 78, 18, 127, 78, 27, 125, 11, 567, 7, 5, 8, 236, 38, 51, 567, 717, 660, 107, 46, 117, 125, 11, 562, 54, 208, 221, 411, 2, 462, 833, 54, 120, 42, 8, 236, 1301, 51, 186, 290, 176, 159, 3904, 559, 121, 5236, 559, 15, 1436, 400, 26, 150, 1, 121, 36, 349, 709, 540, 1878, 2178, 64, 236, 38, 2, 510, 51, 151, 5, 1595, 155]",1490.0,22079361,phase II trial radiation therapy weekly cisplatin chemotherapy treatment locally-advanced squamous carcinoma vulva gynecologic oncology group,0,0.0
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-07-02,"To determine the safety of sentinel lymph node biopsy as a replacement for inguinal femoral lymphadenectomy in selected women with vulvar cancer. Eligible women had squamous cell carcinoma, at least 1-mm invasion, and tumor size  2 cm and  6 cm. The primary tumor was limited to the vulva, and there were no groin lymph nodes that were clinically suggestive of cancer. All women underwent intraoperative lymphatic mapping, sentinel lymph node biopsy, and inguinal femoral lymphadenectomy. Histologic ultra staging of the sentinel lymph node was prescribed. In all, 452 women underwent the planned procedures, and 418 had at least one sentinel lymph node identified. There were 132 node-positive women, including 11 (8.3%) with false-negative nodes. Twenty-three percent of the true-positive patients were detected by immunohistochemical analysis of the sentinel lymph node. The sensitivity was 91.7% (90% lower confidence bound, 86.7%) and the false-negative predictive value (1-negative predictive value) was 3.7% (90% upper confidence bound, 6.1%). In women with tumor less than 4 cm, the false-negative predictive value was 2.0% (90% upper confidence bound, 4.5%). Sentinel lymph node biopsy is a reasonable alternative to inguinal femoral lymphadenectomy in selected women with squamous cell carcinoma of the vulva.","Clinical Trial, Phase III",2759.0,169.0,determine safety sentinel lymph node biopsy replacement inguinal femoral lymphadenectomy selected women vulvar Eligible women squamous carcinoma 1-mm invasion size  2 cm  6 cm primary limited vulva groin lymph nodes clinically suggestive women underwent intraoperative lymphatic mapping sentinel lymph node biopsy inguinal femoral lymphadenectomy Histologic ultra staging sentinel lymph node prescribed 452 women underwent planned procedures 418 sentinel lymph node identified 132 node-positive women including 11 8.3 false-negative nodes Twenty-three percent true-positive patients detected immunohistochemical sentinel lymph node sensitivity 91.7 90 lower confidence bound 86.7 false-negative predictive value 1-negative predictive value 3.7 90 upper confidence bound 6.1 women 4 cm false-negative predictive value 2.0 90 upper confidence bound 4.5 Sentinel lymph node biopsy reasonable alternative inguinal femoral lymphadenectomy selected women squamous carcinoma vulva,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 367, 1, 1323, 263, 289, 411, 22, 8, 3892, 9, 4907, 7649, 2048, 4, 715, 117, 5, 12, 625, 117, 42, 691, 31, 134, 28, 506, 14, 321, 578, 2, 30, 444, 749, 18, 494, 2, 1552, 49, 494, 3, 86, 30, 10, 383, 6, 3, 9263, 2, 125, 11, 77, 9264, 263, 502, 17, 11, 505, 3832, 1, 12, 62, 117, 208, 1720, 2936, 2568, 1323, 263, 289, 411, 2, 4907, 7649, 2048, 884, 12223, 632, 1, 3, 1323, 263, 289, 10, 2746, 4, 62, 12638, 117, 208, 3, 1465, 1369, 2, 10387, 42, 28, 506, 104, 1323, 263, 289, 108, 125, 11, 4255, 289, 109, 117, 141, 175, 66, 27, 5, 2133, 199, 502, 737, 169, 714, 1, 3, 2501, 109, 7, 11, 530, 20, 1382, 65, 1, 3, 1323, 263, 289, 3, 485, 10, 970, 67, 424, 280, 307, 2951, 868, 67, 2, 3, 2133, 199, 464, 549, 14, 199, 464, 549, 10, 27, 67, 424, 1726, 307, 2951, 49, 14, 4, 117, 5, 30, 299, 76, 39, 494, 3, 2133, 199, 464, 549, 10, 18, 13, 424, 1726, 307, 2951, 39, 33, 1323, 263, 289, 411, 16, 8, 3203, 1091, 6, 4907, 7649, 2048, 4, 715, 117, 5, 691, 31, 134, 1, 3, 9263]",1271.0,22753905,Lymphatic mapping sentinel lymph node biopsy women squamous carcinoma vulva gynecologic oncology group,0,0.0
Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2013-07-24,"The purpose of this study was to examine changes over time in survival for African-American (AA) and white women diagnosed with squamous cell carcinoma of the vulva. The Surveillance, Epidemiology, and End Results (SEER) Program for 1973-2009 was used for this analysis. We evaluated racial differences in survival between AA and white women. Kaplan-Meier and Cox proportional hazards survival methods were used to assess differences in survival by race by decade of diagnosis. The study sample included 5867 women, including 5379 whites (91.6%) and 488 AA (8.3%). AA women were younger (57 vs 67 years; P < .001) and had a higher rate of distant metastasis (6.1% vs 3.7%; P < .001). AA women had surgery less frequently (84.2% vs 87.6%; P = .03) and more frequently radiotherapy (24.2% vs 20.6%; P < .001). AA women had a hazard ratio (HR) of 0.84 (95% confidence interval [CI], 0.74-0.95) of all-cause mortality and 0.66 (95% CI, 0.53-0.82) of vulvar cancer mortality compared with whites. Adjusting for SEER Registry, marital status, stage, age, surgery, radiotherapy, grade, lymph node status, and decade, AA women had an HR of 0.67 (95% CI, 0.53-0.84) of vulvar cancer-related mortality compared with whites. After adjusting for the same variables, there was a significant difference in survival between AA and whites in the periods of 1990-1999 (HR, 0.62; 95% CI, 0.41-0.95) and 2000-2009 (HR, 0.46; 95% CI, 0.30-0.72) but not earlier. AA presented at a significantly younger age compared with white women and had better survival compared with whites.",Journal Article,2372.0,9.0,purpose examine changes time survival African-American AA white women diagnosed squamous carcinoma vulva Surveillance Epidemiology End SEER Program 1973-2009 evaluated racial differences survival AA white women Kaplan-Meier Cox proportional hazards survival methods assess differences survival race decade diagnosis included 5867 women including 5379 whites 91.6 488 AA 8.3 AA women younger 57 vs 67 years P .001 higher rate distant metastasis 6.1 vs 3.7 P .001 AA women surgery frequently 84.2 vs 87.6 P .03 frequently radiotherapy 24.2 vs 20.6 P .001 AA women hazard ratio HR 0.84 95 confidence interval CI 0.74-0.95 all-cause mortality 0.66 95 CI 0.53-0.82 vulvar mortality compared whites Adjusting SEER Registry marital status stage age surgery radiotherapy grade lymph node status decade AA women HR 0.67 95 CI 0.53-0.84 vulvar cancer-related mortality compared whites adjusting variables significant difference survival AA whites periods 1990-1999 HR 0.62 95 CI 0.41-0.95 2000-2009 HR 0.46 95 CI 0.30-0.72 earlier AA presented significantly younger age compared white women better survival compared whites,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 1004, 400, 252, 98, 4, 25, 9, 1410, 597, 1519, 2, 886, 117, 265, 5, 691, 31, 134, 1, 3, 9263, 3, 617, 1284, 2, 396, 99, 1605, 1243, 9, 4756, 1238, 10, 95, 9, 26, 65, 21, 194, 2257, 362, 4, 25, 59, 1519, 2, 886, 117, 876, 882, 2, 418, 831, 1017, 25, 636, 11, 95, 6, 423, 362, 4, 25, 20, 1047, 20, 2025, 1, 147, 3, 45, 1000, 159, 63136, 117, 141, 63137, 2556, 970, 49, 2, 9620, 1519, 66, 27, 1519, 117, 11, 773, 696, 105, 598, 60, 19, 144, 2, 42, 8, 142, 116, 1, 626, 278, 49, 14, 105, 27, 67, 19, 144, 1519, 117, 42, 152, 299, 746, 874, 18, 105, 912, 49, 19, 680, 2, 80, 746, 310, 259, 18, 105, 179, 49, 19, 144, 1519, 117, 42, 8, 360, 197, 168, 1, 13, 874, 48, 307, 268, 58, 13, 794, 13, 48, 1, 62, 708, 282, 2, 13, 700, 48, 58, 13, 699, 13, 878, 1, 12, 282, 72, 5, 2556, 1358, 9, 1605, 1608, 5345, 156, 82, 89, 152, 310, 88, 263, 289, 156, 2, 2025, 1519, 117, 42, 35, 168, 1, 13, 598, 48, 58, 13, 699, 13, 874, 1, 12, 139, 282, 72, 5, 2556, 50, 1358, 9, 3, 827, 682, 125, 10, 8, 93, 523, 4, 25, 59, 1519, 2, 2556, 4, 3, 3338, 1, 2289, 2043, 168, 13, 744, 48, 58, 13, 605, 13, 48, 2, 1081, 1238, 168, 13, 641, 48, 58, 13, 201, 13, 720, 84, 44, 1677, 1519, 917, 28, 8, 97, 773, 89, 72, 5, 886, 117, 2, 42, 380, 25, 72, 5, 2556]",1455.0,23891626,Racial disparities changes clinical characteristics survival vulvar time,0,0.0
Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease.,International journal of surgical pathology,Int. J. Surg. Pathol.,2013-08-05,"Paget's disease of the vulva is a rare malignancy primarily affecting Caucasian women in their seventh to eighth decades. Most patients experience an indolent disease course and undergo surgical excision for disease control. Although progression to invasive adenocarcinoma is rare, recurrence is common because of the difficulty of achieving negative surgical margins. We report a case of a 73-year-old woman with a long-standing history of recurrent vulvar Paget's disease who presented with postmenopausal bleeding. Workup revealed extensive endocervical involvement by Paget's disease, resulting in Paget cells on endocervical curettage, as well as endometrial curettage (because of cervical contamination). Extensive endocervical involvement by vulvar Paget's disease can occur despite multiple reexcisions and topical therapy. The presence of Paget cells on endometrial and endocervical curettings, particularly in patients without visible vulvar or cervical lesions, should raise suspicion of endocervical involvement and prompt further evaluation of disease extension.",Case Reports,2360.0,1.0,Paget 's disease vulva rare malignancy primarily affecting Caucasian women seventh eighth decades patients experience indolent disease course undergo surgical excision disease control progression invasive adenocarcinoma rare recurrence common difficulty achieving negative surgical margins report case 73-year-old woman long-standing history recurrent vulvar Paget 's disease presented postmenopausal bleeding Workup revealed extensive endocervical involvement Paget 's disease resulting Paget endocervical curettage endometrial curettage cervical contamination Extensive endocervical involvement vulvar Paget 's disease occur despite multiple reexcisions topical therapy presence Paget endometrial endocervical curettings particularly patients visible vulvar cervical lesions raise suspicion endocervical involvement prompt evaluation disease extension,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[7497, 292, 34, 1, 3, 9263, 16, 8, 622, 710, 1561, 2319, 3229, 117, 4, 136, 8114, 6, 7732, 1968, 96, 7, 730, 35, 2316, 34, 906, 2, 1251, 221, 1366, 9, 34, 182, 242, 91, 6, 416, 449, 16, 622, 146, 16, 186, 408, 1, 3, 4035, 1, 1785, 199, 221, 1012, 21, 414, 8, 473, 1, 8, 803, 111, 1095, 2854, 5, 8, 319, 10909, 532, 1, 387, 7497, 292, 34, 54, 917, 5, 1679, 2294, 4755, 553, 1344, 10174, 799, 20, 7497, 292, 34, 1113, 4, 7497, 37, 23, 10174, 12529, 22, 149, 22, 12529, 408, 1, 9866, 1344, 10174, 799, 20, 7497, 292, 34, 122, 1271, 550, 232, 34594, 2, 5879, 36, 3, 463, 1, 7497, 37, 23, 2, 10174, 63187, 823, 4, 7, 187, 4822, 15, 406, 257, 5008, 5782, 1, 10174, 799, 2, 4776, 195, 451, 1, 34, 2401]",1002.0,23918905,Paget Endometrial Endocervical Curettings Patient Recurrent Vulvar Paget 's Disease,4,0.07017543859649122
Outcomes in patients with mucosal melanomas.,Journal of surgical oncology,J Surg Oncol,2013-10-16,"Our goal was to evaluate the different subtypes of mucosal melanoma and describe specific variables that predict outcomes. Prospective review of two tertiary care center databases identified 76 mucosal melanoma patients; 73 with complete records were included. Demographic and clinical data were analyzed. Cox regression determined variables impacting recurrence and survival. In the 73 patients, the mean age was 64 years, and 74% were female. Sixty-seven percent presented with lymph node involvement, and 73% had ulcerated tumors. Major sites affected were nasal/palate/oral (36%), vulvar/vaginal/cervical (48%), and anorectal (15%). Mean overall and disease-free survival were 56.9 and 27.2 months. Variables associated with decreased survival included: lymphovascular invasion (HR17.70, P=0.0093), Caucasian race (HR3.02, P=0.0362), nasal/palate/oral sub-group (HR1.85, P=0.026), Breslow thickness (HR1.23, P=0.00004), T stage (HR1.34, P=0.0075), M stage (HR3.03, P=0.0039), and chemotherapy (HR3.13, P=0.0002). The worst prognosis was seen in the nasal/palate/oral sub-group, with a median overall survival of 9.7 months and recurrence-free time of 4.5 months. This subtype also demonstrated high lymph node positivity, ulceration, and larger tumor size. The nasal, palate, oral subtype has the worst prognosis compared to other mucosal melanoma locations. Studies are ongoing to evaluate pathologic and genomic variables that may predict outcomes.",Journal Article,2288.0,23.0,goal evaluate different subtypes mucosal melanoma specific variables predict outcomes Prospective review tertiary care center databases identified 76 mucosal melanoma patients 73 complete records included Demographic clinical Cox regression determined variables impacting recurrence survival 73 patients mean age 64 years 74 female Sixty-seven percent presented lymph node involvement 73 ulcerated Major sites affected nasal/palate/oral 36 vulvar/vaginal/cervical 48 anorectal 15 Mean overall disease-free survival 56.9 27.2 months Variables associated decreased survival included lymphovascular invasion HR17.70 P 0.0093 Caucasian race HR3.02 P 0.0362 nasal/palate/oral sub-group HR1.85 P 0.026 Breslow thickness HR1.23 P 0.00004 stage HR1.34 P 0.0075 stage HR3.03 P 0.0039 chemotherapy HR3.13 P 0.0002 worst prognosis seen nasal/palate/oral sub-group median overall survival 9.7 months recurrence-free time 4.5 months subtype demonstrated high lymph node positivity ulceration larger size nasal palate oral subtype worst prognosis compared mucosal melanoma locations Studies ongoing evaluate pathologic genomic variables predict outcomes,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[114, 1326, 10, 6, 376, 3, 338, 814, 1, 3068, 2, 897, 112, 682, 17, 678, 123, 482, 206, 1, 100, 2557, 165, 574, 2348, 108, 846, 3068, 7, 803, 5, 236, 1064, 11, 159, 1540, 2, 38, 74, 11, 311, 418, 320, 509, 682, 8661, 146, 2, 25, 4, 3, 803, 7, 3, 313, 89, 10, 660, 60, 2, 794, 11, 1061, 1746, 648, 714, 917, 5, 263, 289, 799, 2, 803, 42, 13571, 57, 458, 633, 1424, 11, 6743, 10988, 518, 511, 48010, 18982, 18237, 576, 2, 9778, 167, 313, 63, 2, 34, 115, 25, 11, 664, 83, 2, 428, 18, 53, 682, 41, 5, 340, 25, 159, 2933, 578, 63528, 431, 19, 13, 26813, 3229, 1047, 40512, 588, 19, 13, 40227, 6743, 10988, 518, 551, 87, 25099, 772, 19, 13, 4554, 6931, 2903, 25099, 382, 19, 13, 30815, 102, 82, 25099, 562, 19, 13, 23345, 188, 82, 40512, 680, 19, 13, 20518, 2, 56, 40512, 233, 19, 13, 3531, 3, 4066, 356, 10, 527, 4, 3, 6743, 10988, 518, 551, 87, 5, 8, 52, 63, 25, 1, 83, 67, 53, 2, 146, 115, 98, 1, 39, 33, 53, 26, 875, 120, 264, 64, 263, 289, 1887, 5158, 2, 1077, 30, 444, 3, 6743, 10988, 518, 875, 71, 3, 4066, 356, 72, 6, 127, 3068, 4069, 94, 32, 942, 6, 376, 510, 2, 572, 682, 17, 68, 678, 123]",1364.0,24132665,Outcomes patients mucosal melanomas,2,0.03508771929824561
Pelvic exenteration: impact of age on surgical and oncologic outcomes.,Gynecologic oncology,Gynecol. Oncol.,2013-11-18,"To evaluate whether preoperative age impacts surgical outcomes, complication rates, and/or recurrence in women undergoing pelvic exenteration. All women who underwent a pelvic exenteration for any gynecologic indication at our institution from 1993 to 2010 were included. Women were stratified into groups based on age in years (young:  50, middle: 51-64, and senior:  65). Baseline characteristics, surgical outcomes, early (<60 days) and late ( 60 days) postoperative complications, and recurrence/survival outcomes were ascertained. Fisher's exact test or Kruskal-Wallis test was performed. Kaplan-Meier survival curves were compared. 161 patients were included (58 young, 62 in the middle, and 41 senior). Women in the young group predominately had a diagnosis of cervical cancer (82.8%) while women in the senior group primarily had a diagnosis of vulvar or vaginal cancer (70.7%). Senior women were also more likely to have hypertension (p < 0.0001) and pulmonary disease (p = 0.040). Operative time was significantly shorter for women in the senior group (8.5h) compared with the middle (9.5h) and young group (10.1h) (p = 0.0089). There were no significant differences in early or late complications when stratified by age. The overall survival did not differ between age groups (p = 0.3760). Although hypertension and pulmonary disease were more frequent in the senior age group, duration of surgery, blood loss, length of hospital stay and complication rates did not increase with age. Advanced chronological age should not be considered a contraindication to a potentially curative surgical procedure.",Journal Article,2255.0,16.0,evaluate preoperative age impacts surgical outcomes complication rates and/or recurrence women undergoing pelvic exenteration women underwent pelvic exenteration gynecologic indication institution 1993 2010 included Women stratified groups based age years young  50 middle 51-64 senior  65 Baseline characteristics surgical outcomes early 60 days late  60 days postoperative complications recurrence/survival outcomes ascertained Fisher 's exact test Kruskal-Wallis test performed Kaplan-Meier survival curves compared 161 patients included 58 young 62 middle 41 senior Women young group predominately diagnosis cervical 82.8 women senior group primarily diagnosis vulvar vaginal 70.7 Senior women likely hypertension p 0.0001 pulmonary disease p 0.040 Operative time significantly shorter women senior group 8.5h compared middle 9.5h young group 10.1h p 0.0089 significant differences early late complications stratified age overall survival differ age groups p 0.3760 hypertension pulmonary disease frequent senior age group duration surgery blood loss length hospital stay complication rates increase age Advanced chronological age considered contraindication potentially curative surgical procedure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 317, 498, 89, 4719, 221, 123, 1447, 151, 2, 15, 146, 4, 117, 479, 1110, 5668, 62, 117, 54, 208, 8, 1110, 5668, 9, 500, 1512, 3607, 28, 114, 731, 29, 3343, 6, 1120, 11, 159, 117, 11, 1173, 237, 271, 90, 23, 89, 4, 60, 1169, 1552, 212, 3897, 725, 660, 2, 10898, 749, 556, 330, 374, 221, 123, 191, 335, 162, 2, 807, 749, 335, 162, 573, 521, 2, 146, 25, 123, 11, 5240, 3135, 292, 2472, 412, 15, 8800, 8875, 412, 10, 173, 876, 882, 25, 2400, 11, 72, 5377, 7, 11, 159, 717, 1169, 744, 4, 3, 3897, 2, 605, 10898, 117, 4, 3, 1169, 87, 11583, 42, 8, 147, 1, 12, 878, 66, 369, 117, 4, 3, 10898, 87, 1561, 42, 8, 147, 1, 15, 12, 431, 67, 10898, 117, 11, 120, 80, 322, 6, 47, 1824, 19, 13, 488, 2, 1087, 34, 19, 13, 6824, 1208, 98, 10, 97, 985, 9, 117, 4, 3, 10898, 87, 66, 38494, 72, 5, 3, 3897, 83, 38494, 2, 1169, 87, 79, 10147, 19, 13, 21191, 125, 11, 77, 93, 362, 4, 191, 15, 807, 521, 198, 1173, 20, 89, 3, 63, 25, 205, 44, 1505, 59, 89, 271, 19, 13, 40545, 242, 1824, 2, 1087, 34, 11, 80, 908, 4, 3, 10898, 89, 87, 654, 1, 152, 315, 407, 1318, 1, 702, 2020, 2, 1447, 151, 205, 44, 344, 5, 89, 131, 14921, 89, 257, 44, 40, 515, 8, 8363, 6, 8, 751, 1075, 221, 1299]",1526.0,24262877,Pelvic exenteration impact age surgical oncologic outcomes,0,0.0
Management of vulvar and vaginal melanomas: current and future strategies.,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,Am Soc Clin Oncol Educ Book,2014-01-01,"Melanomas arising in the vulva and vagina are rare and therefore there is minimal data specific to these malignancies. Data are often extrapolated from other cutaneous melanomas, which may or may not be appropriate. Surgery remains the primary treatment modality at initial diagnosis and in select recurrent cases. Wide local excision of the primary lesion not requiring an exenteration, along with sentinel lymph node (SLN) mapping, should be routinely considered in vulvar melanomas. Local excision and SLN mapping is difficult and often not considered for vaginal melanomas. Primary exenterative procedures should not be routinely offered. In locally advanced cases potentially requiring an exenterative procedure, radiation therapy with or without concurrent immunotherapy is a consideration. The role of adjuvant therapy remains unclear. Surgery or radiation therapy can be considered in recurrent cases. Systemic chemotherapy agents have a modest response rate with associated poor survival outcomes. Novel immunotherapeutic and targeted agents have been reported to improve survival in melanoma and should be considered in cases of vulvovaginal melanoma. All cases should be tested for at least c-KIT and BRAF V600E mutations. Patients with vulvovaginal melanomas should be strongly encouraged to participate in clinical trials. ",Journal Article,2211.0,20.0,Melanomas arising vulva vagina rare minimal specific malignancies extrapolated cutaneous melanomas appropriate Surgery remains primary treatment modality initial diagnosis select recurrent cases Wide local excision primary lesion requiring exenteration sentinel lymph node SLN mapping routinely considered vulvar melanomas Local excision SLN mapping difficult considered vaginal melanomas Primary exenterative procedures routinely offered locally advanced cases potentially requiring exenterative procedure radiation therapy concurrent immunotherapy consideration role adjuvant therapy remains unclear Surgery radiation therapy considered recurrent cases Systemic chemotherapy agents modest response rate associated poor survival outcomes Novel immunotherapeutic targeted agents reported improve survival melanoma considered cases vulvovaginal melanoma cases tested c-KIT BRAF V600E Patients vulvovaginal melanomas strongly encouraged participate clinical trials,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1965, 2635, 4, 3, 9263, 2, 7553, 32, 622, 2, 673, 125, 16, 1048, 74, 112, 6, 46, 441, 74, 32, 629, 10727, 29, 127, 1486, 1965, 92, 68, 15, 68, 44, 40, 870, 152, 469, 3, 86, 24, 1396, 28, 388, 147, 2, 4, 1717, 387, 140, 1019, 293, 1366, 1, 3, 86, 1180, 44, 1888, 35, 5668, 1510, 5, 1323, 263, 289, 1099, 2568, 257, 40, 3066, 515, 4, 1965, 293, 1366, 2, 1099, 2568, 16, 1740, 2, 629, 44, 515, 9, 1965, 86, 23501, 1369, 257, 44, 40, 3066, 2216, 4, 795, 131, 140, 751, 1888, 35, 23501, 1299, 121, 36, 5, 15, 187, 750, 726, 16, 8, 2415, 3, 200, 1, 249, 36, 469, 1200, 152, 15, 121, 36, 122, 40, 515, 4, 387, 140, 403, 56, 183, 47, 8, 1721, 51, 116, 5, 41, 334, 25, 123, 229, 3222, 2, 238, 183, 47, 85, 210, 6, 401, 25, 4, 2, 257, 40, 515, 4, 140, 1, 18998, 62, 140, 257, 40, 650, 9, 28, 506, 256, 1164, 2, 566, 2047, 138, 7, 5, 18998, 1965, 257, 40, 1327, 5865, 6, 3506, 4, 38, 143]",1283.0,24857113,Management vulvar vaginal melanomas current future strategies,0,0.0
Overall survival after pelvic exenteration for gynecologic malignancy.,Gynecologic oncology,Gynecol. Oncol.,2014-07-09,"Five-Year survival after pelvic exenteration for gynecologic malignancies has been reported as high as 60%. The objective of this study was to determine overall survival (OS) after pelvic exenteration and evaluate factors impacting outcome. A retrospective review of all women who underwent pelvic exenteration at our institution between February 1993 and December 2010 was performed. OS was defined as time from exenteration to date of death or last contact. Survival analysis was performed using the Kaplan Meyer method. Multivariate analysis was performed to determine the impact of clinical and pathologic factors on survival outcomes. One hundred sixty patients with gynecologic malignancy underwent pelvic exenteration. Five-year recurrence free survival (RFS) was 33% (95%CI 0.25-0.40). Factors which negatively impacted RFS included shorter treatment-free interval (p=.050), vulvar primary (p=.032), positive margins (p<.001), lymphovascular space invasion (LVSI, p<.001), positive lymph nodes (p<.001) and perineural invasion (p=0.030). In multivariate analysis, positive margins (p=.040), positive nodes (p<.001) and lymphovascular space invasion (LVSI, p=.003) retained a significant impact on RFS. Five-year OS was 40% (95% CI 0.32-0.48). Factors which negatively impacted OS included vulvar primary (p=.04), positive margins (p<.001), LVSI (p<.001), positive lymph nodes (p<.001) and perineural invasion (p=.008). In multivariate analysis, positive nodes (p=.001) and LVSI (p=.001) retained a significant impact on OS. Five-year OS after pelvic exenteration was 40%. Survival outcomes have not significantly improved despite improvements in technique and patient selection. Multiple non-modifiable factors at the time of exenteration are associated with poor survival.",Journal Article,2022.0,42.0,Five-Year survival pelvic exenteration gynecologic malignancies reported high 60 objective determine overall survival OS pelvic exenteration evaluate factors impacting outcome retrospective review women underwent pelvic exenteration institution February 1993 December 2010 performed OS defined time exenteration date death contact Survival performed Kaplan Meyer Multivariate performed determine impact clinical pathologic factors survival outcomes patients gynecologic malignancy underwent pelvic exenteration Five-year recurrence free survival RFS 33 95 CI 0.25-0.40 Factors negatively impacted RFS included shorter treatment-free interval p=.050 vulvar primary p=.032 positive margins p .001 lymphovascular space invasion LVSI p .001 positive lymph nodes p .001 perineural invasion p=0.030 multivariate positive margins p=.040 positive nodes p .001 lymphovascular space invasion LVSI p=.003 retained significant impact RFS Five-year OS 40 95 CI 0.32-0.48 Factors negatively impacted OS included vulvar primary p=.04 positive margins p .001 LVSI p .001 positive lymph nodes p .001 perineural invasion p=.008 multivariate positive nodes p=.001 LVSI p=.001 retained significant impact OS Five-year OS pelvic exenteration 40 Survival outcomes significantly improved despite improvements technique patient selection Multiple non-modifiable factors time exenteration associated poor survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[365, 111, 25, 50, 1110, 5668, 9, 1512, 441, 71, 85, 210, 22, 64, 22, 335, 3, 461, 1, 26, 45, 10, 6, 223, 63, 25, 118, 50, 1110, 5668, 2, 376, 130, 8661, 228, 8, 459, 206, 1, 62, 117, 54, 208, 1110, 5668, 28, 114, 731, 59, 3010, 3343, 2, 1397, 1120, 10, 173, 118, 10, 395, 22, 98, 29, 5668, 6, 1244, 1, 273, 15, 1060, 4393, 25, 65, 10, 173, 75, 3, 876, 64606, 596, 331, 65, 10, 173, 6, 223, 3, 345, 1, 38, 2, 510, 130, 23, 25, 123, 104, 1128, 1746, 7, 5, 1512, 710, 208, 1110, 5668, 365, 111, 146, 115, 25, 1272, 10, 466, 48, 58, 13, 243, 13, 327, 130, 92, 2723, 4619, 1272, 159, 985, 24, 115, 268, 19, 10801, 86, 19, 4708, 109, 1012, 19, 144, 2933, 3865, 578, 8004, 19, 144, 109, 263, 502, 19, 144, 2, 4917, 578, 19, 13, 6542, 4, 331, 65, 109, 1012, 19, 6824, 109, 502, 19, 144, 2, 2933, 3865, 578, 8004, 19, 1421, 3532, 8, 93, 345, 23, 1272, 365, 111, 118, 10, 327, 48, 58, 13, 531, 13, 576, 130, 92, 2723, 4619, 118, 159, 86, 19, 755, 109, 1012, 19, 144, 8004, 19, 144, 109, 263, 502, 19, 144, 2, 4917, 578, 19, 2155, 4, 331, 65, 109, 502, 19, 144, 2, 8004, 19, 144, 3532, 8, 93, 345, 23, 118, 365, 111, 118, 50, 1110, 5668, 10, 327, 25, 123, 47, 44, 97, 231, 550, 1474, 4, 1312, 2, 69, 881, 232, 220, 5222, 130, 28, 3, 98, 1, 5668, 32, 41, 5, 334, 25]",1694.0,25014540,Overall survival pelvic exenteration gynecologic malignancy,2,0.03508771929824561
"Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?",Gynecologic oncology,Gynecol. Oncol.,2014-07-30,"To determine whether intra-operative radiation therapy (IORT) at the time of pelvic exenteration (PE) or laterally extended endopelvic resection (LEER) improves progression-free survival (PFS) in patients with recurrent, previously irradiated gynecologic cancers. We conducted a single institution retrospective review of patients who had undergone a complete PE for locally recurrent gynecologic cancer. Demographic and clinicopathologic data were collected. 32 patients were identified (2000-2012); 21 (66%) cervical cancer, 8 (25%) vaginal, and 3 (9%) vulvar cancer. All patients were previously irradiated. Twenty-one (66%) received IORT. Mean age was 51. Eight patients had a LEER, all with IORT. Median PFS and OS, respectively, for those with PE alone was 33 and 41 vs. 10 and 10 months for PE+IORT compared to 9 and 17 months for LEER+IORT (P=.04). Increasing tumor size negatively impacted PFS (hazard ratio 1.3; 95%CI 1.12-1.52). Margin status was not associated with survival. No patients undergoing LEER+IORT recurred only locally whereas 62% recurred with a distant component (+/- local). Patients with PE alone had mainly local (36%) and few (9%) distant recurrences compared to 31% local and 38% distant (+/- local) recurrences for those with PE+IORT. We failed to demonstrate that IORT changes survival and recurrence outcomes. However, patients with clinical indications for IORT at the time of PE have worse prognosis compared to those who do not require IORT. If the need for IORT is anticipated, the surgeon may consider performing a LEER to decrease local recurrence if cure is the goal or consider palliative treatment options.",Journal Article,2001.0,15.0,determine intra-operative radiation therapy IORT time pelvic exenteration PE laterally extended endopelvic resection LEER improves progression-free survival PFS patients recurrent previously irradiated gynecologic conducted single institution retrospective review patients undergone complete PE locally recurrent gynecologic Demographic clinicopathologic collected 32 patients identified 2000-2012 21 66 cervical 8 25 vaginal 3 9 vulvar patients previously irradiated Twenty-one 66 received IORT Mean age 51 patients LEER IORT Median PFS OS respectively PE 33 41 vs. 10 10 months PE+IORT compared 9 17 months LEER+IORT P=.04 Increasing size negatively impacted PFS hazard ratio 1.3 95 CI 1.12-1.52 Margin status associated survival patients undergoing LEER+IORT recurred locally 62 recurred distant component +/- local Patients PE mainly local 36 9 distant recurrences compared 31 local 38 distant +/- local recurrences PE+IORT failed demonstrate IORT changes survival recurrence outcomes patients clinical indications IORT time PE worse prognosis compared require IORT need IORT anticipated surgeon consider performing LEER decrease local recurrence cure goal consider palliative treatment options,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 317, 2392, 1208, 121, 36, 4158, 28, 3, 98, 1, 1110, 5668, 4878, 15, 17800, 1747, 64703, 170, 32313, 1804, 91, 115, 25, 300, 4, 7, 5, 387, 373, 2398, 1512, 163, 21, 426, 8, 226, 731, 459, 206, 1, 7, 54, 42, 1989, 8, 236, 4878, 9, 795, 387, 1512, 12, 1540, 2, 1399, 74, 11, 786, 531, 7, 11, 108, 1081, 1195, 239, 700, 12, 66, 243, 2, 27, 83, 12, 62, 7, 11, 373, 2398, 737, 104, 700, 103, 4158, 313, 89, 10, 725, 659, 7, 42, 8, 32313, 62, 5, 4158, 52, 300, 2, 118, 106, 9, 135, 5, 4878, 279, 10, 466, 2, 605, 105, 79, 2, 79, 53, 9, 4878, 4158, 72, 6, 83, 2, 269, 53, 9, 32313, 4158, 19, 755, 602, 30, 444, 2723, 4619, 300, 360, 197, 14, 27, 48, 58, 14, 133, 14, 653, 959, 156, 10, 44, 41, 5, 25, 77, 7, 479, 32313, 4158, 3363, 158, 795, 547, 744, 3363, 5, 8, 626, 1249, 293, 7, 5, 4878, 279, 42, 2615, 293, 511, 2, 1021, 83, 626, 1593, 72, 6, 456, 293, 2, 519, 626, 293, 1593, 9, 135, 5, 4878, 4158, 21, 1551, 6, 608, 17, 4158, 400, 25, 2, 146, 123, 137, 7, 5, 38, 2406, 9, 4158, 28, 3, 98, 1, 4878, 47, 639, 356, 72, 6, 135, 54, 1022, 44, 1353, 4158, 492, 3, 594, 9, 4158, 16, 4078, 3, 1897, 68, 2419, 3620, 8, 32313, 6, 775, 293, 146, 492, 1722, 16, 3, 1326, 15, 2419, 994, 24, 838]",1560.0,25084510,intra-operative radiation time pelvic exenteration improve survival patients recurrent previously irradiated cervical vaginal vulvar,1,0.017543859649122806
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.,Leukemia & lymphoma,Leuk. Lymphoma,2014-11-03,"The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure. ",Journal Article,1905.0,13.0,incidence pattern secondary neoplasms patients acute promyelocytic leukemia APL treated all-trans retinoic acid ATRA -containing regimens described compared 160 patients APL treated ATRA plus idarubicin n 54 ATRA plus arsenic trioxide ATO n 106 incidence secondary unit time follow-up Median follow-up times cohorts 136 29 months respectively patients developed secondary chemotherapy group included breast myelodysplastic syndromes/acute myeloid leukemia vulvar prostate colon soft tissue sarcoma melanoma pancreatic developed ATO group conclude treatment patients APL non-chemotherapy regimen ATRA plus ATO associated higher incidence secondary p 0.29 adjusted unit time exposure,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 287, 2, 1177, 1, 568, 1179, 4, 7, 5, 286, 4300, 2578, 73, 5, 62, 3437, 3887, 971, 2822, 1101, 472, 16, 44, 149, 1027, 21, 72, 3457, 7, 5, 2578, 73, 5, 2822, 349, 5684, 78, 667, 15, 2822, 349, 3217, 4574, 4021, 78, 3251, 9, 3, 287, 1, 568, 163, 379, 2712, 98, 1, 166, 126, 52, 166, 126, 1072, 9, 3, 100, 736, 11, 4829, 2, 462, 53, 106, 762, 7, 276, 568, 163, 4, 3, 56, 87, 46, 159, 100, 163, 169, 2040, 286, 533, 104, 12, 104, 12, 104, 12, 2, 104, 1214, 246, 8, 2, 104, 12, 276, 4, 3, 4021, 87, 21, 2060, 17, 24, 1, 7, 5, 2578, 75, 3, 220, 56, 477, 1, 2822, 349, 4021, 16, 44, 41, 5, 8, 142, 287, 1, 568, 163, 19, 13, 462, 586, 9, 2712, 98, 1, 645]",859.0,25120050,Incidence secondary neoplasms patients acute promyelocytic leukemia treated all-trans retinoic acid plus chemotherapy all-trans retinoic acid plus arsenic trioxide,0,0.0
The effect of groin treatment modality and sequence on clinically significant chronic lymphedema in patients with vulvar carcinoma.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2015-01-01,"Chronic lymphedema (CL) after inguinal lymph node dissection (ILND) or radiotherapy (RT) is a significant problem for vulvar cancer survivors. The treatment modality or combination of therapies that poses the greatest risk is not known. The objective of this study was to describe rates of clinically significant CL conferred by different groin treatment modalities. Medical records of vulvar cancer patients who had groin treatment with ILND, RT, or both were retrospectively reviewed. Each treated groin was considered individually, and divided into 4 treatment groups: ILND alone, ILND with adjuvant RT, neoadjuvant chemoradiation therapy (NCRT), or NCRT followed by ILND. Clinically significant CL was defined as that which required treatment and was recorded by laterality. Differences among groups were evaluated with (2) and Fisher exact test. Between 2000 and 2010, 146 patients with vulvar cancer who underwent therapy to 1 or both groins were identified for a total of 266 treated groins. The rates of CL for single-modality treatment, ILND or NCRT, were 10.9% and 6.7%, respectively. Multimodal treatment resulted in higher rates of CL, 13.5% for ILND followed by RT and 17.2% for NCRT followed by ILND, although differences were not significant (P = 0.37). Clinically significant CL was not different between treatment modalities in this study, but is underpowered. The results provide valuable information about treatment complications that will be useful for patient-centered counseling. Prospective evaluation of CL and its impact on quality of life is warranted.",Journal Article,1846.0,6.0,Chronic lymphedema CL inguinal lymph node dissection ILND radiotherapy RT significant problem vulvar survivors treatment modality combination therapies poses greatest risk known objective rates clinically significant CL conferred different groin treatment modalities Medical records vulvar patients groin treatment ILND RT retrospectively reviewed treated groin considered individually divided 4 treatment groups ILND ILND adjuvant RT neoadjuvant chemoradiation therapy NCRT NCRT followed ILND Clinically significant CL defined required treatment recorded laterality Differences groups evaluated  2 Fisher exact test 2000 2010 146 patients vulvar underwent therapy 1 groins identified total 266 treated groins rates CL single-modality treatment ILND NCRT 10.9 6.7 respectively Multimodal treatment resulted higher rates CL 13.5 ILND followed RT 17.2 NCRT followed ILND differences significant P 0.37 Clinically significant CL different treatment modalities underpowered provide valuable information treatment complications useful patient-centered counseling Prospective evaluation CL impact quality life warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 3063, 5192, 50, 4907, 263, 289, 1161, 17454, 15, 310, 240, 16, 8, 93, 2497, 9, 12, 332, 3, 24, 1396, 15, 150, 1, 235, 17, 7056, 3, 2199, 43, 16, 44, 440, 3, 461, 1, 26, 45, 10, 6, 897, 151, 1, 505, 93, 5192, 3851, 20, 338, 9264, 24, 1558, 484, 1064, 1, 12, 7, 54, 42, 9264, 24, 5, 17454, 240, 15, 110, 11, 894, 446, 296, 73, 9264, 10, 515, 4257, 2, 2176, 237, 39, 24, 271, 17454, 279, 17454, 5, 249, 240, 536, 975, 36, 8353, 15, 8353, 370, 20, 17454, 505, 93, 5192, 10, 395, 22, 17, 92, 616, 24, 2, 10, 1872, 20, 9915, 362, 107, 271, 11, 194, 5, 5112, 18, 2, 3135, 2472, 412, 59, 1081, 2, 1120, 4909, 7, 5, 12, 54, 208, 36, 6, 14, 15, 110, 26214, 11, 108, 9, 8, 181, 1, 8786, 73, 26214, 3, 151, 1, 5192, 9, 226, 1396, 24, 17454, 15, 8353, 11, 79, 83, 2, 49, 67, 106, 4122, 24, 627, 4, 142, 151, 1, 5192, 233, 33, 9, 17454, 370, 20, 240, 2, 269, 18, 9, 8353, 370, 20, 17454, 242, 362, 11, 44, 93, 19, 13, 567, 505, 93, 5192, 10, 44, 338, 59, 24, 1558, 4, 26, 45, 84, 16, 11689, 3, 99, 377, 2926, 487, 545, 24, 521, 17, 303, 40, 999, 9, 69, 4846, 2011, 482, 451, 1, 5192, 2, 211, 345, 23, 372, 1, 358, 16, 1197]",1514.0,25415076,effect groin treatment modality sequence clinically significant chronic lymphedema patients vulvar carcinoma,1,0.017543859649122806
Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system?,Gynecologic oncology,Gynecol. Oncol.,2014-12-16,"To evaluate treatment outcomes for patients with vulvar cancer with grossly positive pelvic lymph nodes (PLNs). From a database of 516 patients with vulvar cancer, we identified patients with grossly positive PLNs without distant metastasis at initial diagnosis. We identified 20 patients with grossly positive PLNs; inclusion criteria included PLN 1.5cm or larger in short axis dimension on CT/MRI (n=11), FDG-avid PLN on PET/CT (n=3), or biopsy-proven PLN disease (n=6). Ten patients were treated with chemoradiation therapy (CRT), 4 with RT alone, and 6 with various combinations of surgery, RT or CRT. Median follow-up time for patients who had not died of cancer was 47months (range, 4-228months). Mean primary vulvar tumor size was 6.4cm; 12 patients presented with 2009 AJCC T2 and 8 with T3 disease. All patients had grossly positive inguinal nodes, and the mean inguinal nodal diameter was 2.8cm. The 5-year overall survival and disease specific survival rates were 43% and 48%, respectively. Eleven patients had recurrences, some at multiple sites. There were 9 recurrences in the vulva, but no isolated nodal recurrences. Four patients developed distant metastasis within 6months of starting radiation therapy. Aggressive locoregional treatment can lead to favorable outcomes for many patients with grossly involved PLNs that is comparable to that of grossly involved inguinal nodes only. We recommend modification of the FIGO stage IVB classification to more accurately reflect the relatively favorable prognosis of patients with PLN involvement.",Journal Article,1862.0,11.0,evaluate treatment outcomes patients vulvar grossly positive pelvic lymph nodes PLNs database 516 patients vulvar identified patients grossly positive PLNs distant metastasis initial diagnosis identified 20 patients grossly positive PLNs inclusion criteria included PLN 1.5cm larger short axis dimension CT/MRI n=11 FDG-avid PLN PET/CT n=3 biopsy-proven PLN disease n=6 patients treated chemoradiation therapy CRT 4 RT 6 combinations surgery RT CRT Median follow-up time patients died 47months range 4-228months Mean primary vulvar size 6.4cm 12 patients presented 2009 AJCC T2 8 T3 disease patients grossly positive inguinal nodes mean inguinal nodal diameter 2.8cm 5-year overall survival disease specific survival rates 43 48 respectively patients recurrences multiple sites 9 recurrences vulva isolated nodal recurrences patients developed distant metastasis 6months starting radiation therapy Aggressive locoregional treatment lead favorable outcomes patients grossly involved PLNs comparable grossly involved inguinal nodes recommend modification FIGO stage IVB classification accurately reflect relatively favorable prognosis patients PLN involvement,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 24, 123, 9, 7, 5, 12, 5, 7185, 109, 1110, 263, 502, 16753, 29, 8, 609, 1, 11780, 7, 5, 12, 21, 108, 7, 5, 7185, 109, 16753, 187, 626, 278, 28, 388, 147, 21, 108, 179, 7, 5, 7185, 109, 16753, 1680, 371, 159, 15584, 14, 18615, 15, 1077, 4, 978, 2310, 6384, 23, 425, 704, 78, 175, 1285, 5189, 15584, 23, 495, 425, 78, 27, 15, 411, 1930, 15584, 34, 78, 49, 1618, 7, 11, 73, 5, 975, 36, 1089, 39, 5, 240, 279, 2, 49, 5, 747, 1247, 1, 152, 240, 15, 1089, 52, 166, 126, 98, 9, 7, 54, 42, 44, 1016, 1, 12, 10, 65355, 184, 39, 65356, 313, 86, 30, 444, 10, 49, 22690, 133, 7, 917, 5, 1238, 2271, 1786, 2, 66, 5, 2065, 34, 62, 7, 42, 7185, 109, 4907, 502, 2, 3, 313, 4907, 779, 2549, 10, 18, 48752, 3, 33, 111, 63, 25, 2, 34, 112, 25, 151, 11, 601, 2, 576, 106, 2627, 7, 42, 1593, 476, 28, 232, 633, 125, 11, 83, 1593, 4, 3, 9263, 84, 77, 1355, 779, 1593, 294, 7, 276, 626, 278, 262, 14695, 1, 1723, 121, 36, 571, 1325, 24, 122, 1122, 6, 913, 123, 9, 445, 7, 5, 7185, 646, 16753, 17, 16, 1279, 6, 17, 1, 7185, 646, 4907, 502, 158, 21, 2237, 2437, 1, 3, 3837, 82, 7042, 947, 6, 80, 2141, 2694, 3, 1352, 913, 356, 1, 7, 5, 15584, 799]",1497.0,25524458,Survival outcomes patients stage IVB vulvar grossly positive pelvic lymph nodes time reconsider FIGO staging,1,0.017543859649122806
Update on sentinel lymph node biopsy for early-stage vulvar cancer.,Gynecologic oncology,Gynecol. Oncol.,2015-05-27,"Two prospective, multicenter clinical trials have demonstrated the feasibility and reproducibility of sentinel lymph node (SLN) biopsy as part of the standard management of early-stage vulvar carcinoma. On the basis of the results of these trials, many gynecologic oncologists have incorporated SLN biopsy for vulvar cancer into their practice. Studies have further shown that SLN biopsy is associated with better quality of life than full lymphadenectomy, is more cost-effective than full lymphadenectomy, and improved pathologic evaluation. A large observational study is currently evaluating the outcomes of patients with early-stage vulvar cancer according to the results of their SLN biopsy and the approach to their care; this study may confirm that full inguinofemoral lymphadenectomy is no longer necessary in most patients with this disease. Here, we review the published data supporting SLN biopsy as part of the standard of care for women with early-stage vulvar cancer and discuss future considerations for the management of this disease. ",Journal Article,1700.0,18.0,prospective multicenter clinical trials demonstrated feasibility reproducibility sentinel lymph node SLN biopsy standard management early-stage vulvar carcinoma basis trials gynecologic oncologists incorporated SLN biopsy vulvar practice Studies shown SLN biopsy associated better quality life lymphadenectomy cost-effective lymphadenectomy improved pathologic evaluation large observational currently evaluating outcomes patients early-stage vulvar according SLN biopsy approach care confirm inguinofemoral lymphadenectomy longer necessary patients disease review published supporting SLN biopsy standard care women early-stage vulvar discuss future considerations management disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[100, 482, 1570, 38, 143, 47, 264, 3, 1437, 2, 4688, 1, 1323, 263, 289, 1099, 411, 22, 760, 1, 3, 260, 284, 1, 191, 82, 134, 23, 3, 877, 1, 3, 99, 1, 46, 143, 445, 1512, 1339, 47, 2449, 1099, 411, 9, 12, 237, 136, 758, 94, 47, 195, 443, 17, 1099, 411, 16, 41, 5, 380, 372, 1, 358, 76, 1647, 2048, 16, 80, 835, 323, 76, 1647, 2048, 2, 231, 510, 451, 8, 375, 2495, 45, 16, 694, 1435, 3, 123, 1, 7, 5, 191, 82, 12, 768, 6, 3, 99, 1, 136, 1099, 411, 2, 3, 353, 6, 136, 165, 26, 45, 68, 1843, 17, 1647, 30333, 2048, 16, 77, 589, 1493, 4, 96, 7, 5, 26, 34, 467, 21, 206, 3, 983, 74, 1912, 1099, 411, 22, 760, 1, 3, 260, 1, 165, 9, 117, 5, 191, 82, 12, 2, 1139, 508, 3891, 9, 3, 284, 1, 26, 34]",1009.0,26022527,Update sentinel lymph node biopsy early-stage vulvar,2,0.03508771929824561
Survivors of gynecologic malignancies: impact of treatment on health and well-being.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2015-08-06,"While overall survival from gynecologic malignancies has greatly improved over the last three decades, required treatments can lead to multiple health issues for survivors. Our objective was to identify health concerns that gynecologic cancer survivors face. A systematic, stratified sample of women with gynecologic malignancies was surveyed for 18 health issues occurring before, during, or after treatment. The impact of clinical features and treatment modality on health issues was assessed through multivariate logistic regression models. Of 2,546 surveys mailed, 622 were not received by eligible subjects secondary to invalid address, incorrect diagnosis, or death. Thus, 1924 survivors potentially received surveys. Of the 1,029 surveys (53.5%) completed, median age was 59 years; diagnoses included 29% cervical, 26% endometrial, 26% ovarian/primary peritoneal/fallopian tube, 12.1% vulvar, and 5.4% vaginal cancers. The most frequently reported health issues included fatigue (60.6%), sleep disturbance (54.9%), urinary difficulties (50.9%), sexual dysfunction (48.4%), neurologic issues (45.4%), bowel complaints (42.0%), depression (41.3%), and memory problems (41.2%). These rankings were consistent with patients' self-reported rankings of ""highest impact"" personal issues. After controlling for demographic and clinical variables, multivariate analyses revealed that treatment modality impacted the odds of experiencing a given health issue. Our study demonstrates that gynecologic cancer survivors experience a high frequency of health conditions and highlights the association between treatment modality and specific health concerns. The study findings highlight the multiple health concerns experienced by gynecologic cancer survivors and suggest the potential for developing interventions to mitigate these concerns in survivorship.",Journal Article,1629.0,17.0,"overall survival gynecologic malignancies greatly improved decades required treatments lead multiple health issues survivors objective identify health concerns gynecologic survivors face systematic stratified women gynecologic malignancies surveyed 18 health issues occurring treatment impact clinical features treatment modality health issues assessed multivariate logistic regression models 2,546 surveys mailed 622 received eligible subjects secondary invalid address incorrect diagnosis death 1924 survivors potentially received surveys 1,029 surveys 53.5 completed median age 59 years diagnoses included 29 cervical 26 endometrial 26 ovarian/primary peritoneal/fallopian tube 12.1 vulvar 5.4 vaginal frequently reported health issues included fatigue 60.6 sleep disturbance 54.9 urinary difficulties 50.9 sexual dysfunction 48.4 neurologic issues 45.4 bowel complaints 42.0 depression 41.3 memory problems 41.2 rankings consistent patients self-reported rankings `` highest impact '' personal issues controlling demographic clinical variables multivariate revealed treatment modality impacted odds experiencing given health issue demonstrates gynecologic survivors experience high frequency health conditions highlights association treatment modality specific health concerns findings highlight multiple health concerns experienced gynecologic survivors suggest potential developing interventions mitigate concerns survivorship",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[369, 63, 25, 29, 1512, 441, 71, 3510, 231, 252, 3, 1060, 169, 1968, 616, 640, 122, 1122, 6, 232, 341, 1553, 9, 332, 114, 461, 10, 6, 255, 341, 2061, 17, 1512, 12, 332, 3376, 8, 1556, 1173, 1000, 1, 117, 5, 1512, 441, 10, 3696, 9, 203, 341, 1553, 1821, 348, 190, 15, 50, 24, 3, 345, 1, 38, 404, 2, 24, 1396, 23, 341, 1553, 10, 275, 298, 331, 812, 320, 274, 1, 18, 11912, 3666, 6703, 11011, 11, 44, 103, 20, 625, 976, 568, 6, 25008, 1539, 11774, 147, 15, 273, 631, 36079, 332, 751, 103, 3666, 1, 3, 14, 4770, 3666, 699, 33, 781, 52, 89, 10, 728, 60, 2403, 159, 462, 432, 432, 6301, 86, 1639, 25234, 2330, 133, 14, 2, 33, 39, 163, 3, 96, 746, 210, 341, 1553, 159, 613, 335, 49, 2494, 6663, 667, 83, 1660, 4679, 212, 83, 2232, 1527, 576, 39, 2543, 1553, 512, 39, 1659, 6938, 595, 13, 1774, 605, 27, 2, 2407, 2408, 605, 18, 46, 17820, 11, 925, 5, 7, 1074, 210, 17820, 1, 1076, 345, 522, 3008, 1553, 50, 1893, 9, 1540, 2, 38, 682, 331, 318, 553, 17, 24, 1396, 4619, 3, 610, 1, 2985, 8, 447, 341, 2537, 114, 45, 1902, 17, 1512, 12, 332, 730, 8, 64, 675, 1, 341, 1298, 2, 2527, 3, 248, 59, 24, 1396, 2, 112, 341, 2061, 3, 45, 272, 1817, 3, 232, 341, 2061, 592, 20, 1512, 12, 332, 2, 309, 3, 174, 9, 931, 1151, 6, 5626, 46, 2061, 4, 2560]",1752.0,26245979,Survivors gynecologic malignancies impact treatment health well-being,0,0.0
Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors.,Obstetrics and gynecology,Obstet Gynecol,2015-10-01,"To assess whether there is an association of patient sociodemographic factors with stage at diagnosis, treatment, and overall survival in patients with vulvar cancer in the National Cancer Database. This was a retrospective cohort study of patients with primary squamous vulvar carcinoma identified from the National Cancer Database (1998-2004). Multivariate logistic regression was conducted to examine risk factors associated with advanced-stage (stage III or IV) disease at diagnosis. Multivariable Cox regression models were performed to explore risk factors associated with 5-year all-cause mortality. Of 11,153 patients, 42.3% (n=4,713) were diagnosed with stage I disease, 24.6% (n=2,745) stage II, 22.9% (n=2,556) stage III, and 10.2% (n=1,139) stage IV. Advanced stage was significantly associated with older age, nonprivate insurance, and treatment at a lower case volume center (P<.01). Of note, roughly 30% of patients with advanced-stage disease did not receive radiation therapy. Within the advanced stages, age 60 years or older and insurance type were associated with decreased survival (P<.01). In stage III disease, only black race and treatment at a community hospital were associated with a lower risk of death (P<.01). Patient sociodemographic and clinical characteristics are significantly associated with vulvar cancer stage presentation, treatment, and survival. Unfortunately, within this disease, surgical approaches and adjuvant radiation do not appear consistent. II.",Journal Article,1573.0,5.0,"assess association patient sociodemographic factors stage diagnosis treatment overall survival patients vulvar National Database retrospective cohort patients primary squamous vulvar carcinoma identified National Database 1998-2004 Multivariate logistic regression conducted examine risk factors associated advanced-stage stage III IV disease diagnosis Multivariable Cox regression models performed explore risk factors associated 5-year all-cause mortality 11,153 patients 42.3 n=4,713 diagnosed stage disease 24.6 n=2,745 stage II 22.9 n=2,556 stage III 10.2 n=1,139 stage IV Advanced stage significantly associated older age nonprivate insurance treatment lower case volume center P .01 note roughly 30 patients advanced-stage disease receive radiation therapy advanced stages age 60 years older insurance type associated decreased survival P .01 stage III disease black race treatment community hospital associated lower risk death P .01 Patient sociodemographic clinical characteristics significantly associated vulvar stage presentation treatment survival Unfortunately disease surgical approaches adjuvant radiation appear consistent II",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 423, 317, 125, 16, 35, 248, 1, 69, 4221, 130, 5, 82, 28, 147, 24, 2, 63, 25, 4, 7, 5, 12, 4, 3, 657, 12, 609, 26, 10, 8, 459, 180, 45, 1, 7, 5, 86, 691, 134, 108, 29, 3, 657, 12, 609, 1850, 1131, 331, 812, 320, 10, 426, 6, 1004, 43, 130, 41, 5, 131, 82, 82, 316, 15, 478, 34, 28, 147, 658, 418, 320, 274, 11, 173, 6, 1645, 43, 130, 41, 5, 33, 111, 62, 708, 282, 1, 175, 4251, 7, 595, 27, 78, 39, 14870, 11, 265, 5, 82, 70, 34, 259, 49, 78, 18, 14509, 82, 215, 350, 83, 78, 18, 12341, 82, 316, 2, 79, 18, 78, 14, 4929, 82, 478, 131, 82, 10, 97, 41, 5, 434, 89, 27273, 1935, 2, 24, 28, 8, 280, 473, 433, 574, 19, 355, 1, 5739, 7954, 201, 1, 7, 5, 131, 82, 34, 205, 44, 560, 121, 36, 262, 3, 131, 1153, 89, 335, 60, 15, 434, 2, 1935, 267, 11, 41, 5, 340, 25, 19, 355, 4, 82, 316, 34, 158, 1445, 1047, 2, 24, 28, 8, 1714, 702, 11, 41, 5, 8, 280, 43, 1, 273, 19, 355, 69, 4221, 2, 38, 374, 32, 97, 41, 5, 12, 82, 1031, 24, 2, 25, 3869, 262, 26, 34, 221, 611, 2, 249, 121, 1022, 44, 1322, 925, 215]",1424.0,26348176,Disparities Vulvar Reported National Database Influence Sociodemographic Factors,0,0.0
Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?,Journal of minimally invasive gynecology,J Minim Invasive Gynecol,2015-10-28,"Sentinel lymph node biopsy has proven safe and feasible in a number of gynecologic cancers such as vulvar cancer, cervical cancer, and endometrial cancer. The proposed aim of lymphatic mapping and sentinel node identification is to decrease the associated morbidity of a complete lymphadenectomy, particularly the rate of lymphedema, while also increasing the detection of small tumor deposits in the node. Different tracers have been shown to be useful, including technetium-99 and blue dye, with a detection reported in 66% to 86%. Recently, there has been increasing interest in the use of fluorescent dies such as indocyanine green (ICG). In this report we provide a review of the existing literature regarding the use of ICG in cervical or endometrial cancer with the goal to provide details on its utility and compare it with other tracers. ",Journal Article,1546.0,28.0,Sentinel lymph node biopsy proven safe feasible number gynecologic vulvar cervical endometrial proposed aim lymphatic mapping sentinel node identification decrease associated morbidity complete lymphadenectomy particularly rate lymphedema increasing detection small deposits node Different tracers shown useful including technetium-99 blue dye detection reported 66 86 Recently increasing use fluorescent dies indocyanine green ICG report provide review existing literature use ICG cervical endometrial goal provide details utility compare tracers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1323, 263, 289, 411, 71, 1930, 1165, 2, 1313, 4, 8, 207, 1, 1512, 163, 225, 22, 12, 12, 2, 12, 3, 1587, 1130, 1, 2936, 2568, 2, 1323, 289, 911, 16, 6, 775, 3, 41, 787, 1, 8, 236, 2048, 823, 3, 116, 1, 3063, 369, 120, 602, 3, 638, 1, 302, 30, 7626, 4, 3, 289, 338, 10089, 47, 85, 443, 6, 40, 999, 141, 11237, 1058, 2, 3352, 3796, 5, 8, 638, 210, 4, 700, 6, 868, 761, 125, 71, 85, 602, 1333, 4, 3, 119, 1, 2910, 67058, 225, 22, 18903, 4658, 9118, 4, 26, 414, 21, 377, 8, 206, 1, 3, 1692, 789, 666, 3, 119, 1, 9118, 4, 15, 12, 5, 3, 1326, 6, 377, 3791, 23, 211, 1207, 2, 932, 192, 5, 127, 10089]",781.0,26518716,Role Indocyanine Green Sentinel Node Mapping Gynecologic Fluorescence Imaging New Standard,0,0.0
Dying well: How equal is end of life care among gynecologic oncology patients?,Gynecologic oncology,Gynecol. Oncol.,2015-12-17,"To identify disparities in utilization of end of life (EoL) resources by gynecologic oncology (GO) patients. This retrospective analysis of the medical records of GO patients treated 1/2007-12/2011 and deceased 1/2012-8/2014 evaluated patient demographics, disease characteristics, and utilization of EoL resources. Chi-square, Fisher's exact test, Mann Whitney and Kruskal-Wallis tests were used for statistical analysis. Of 189 patients analyzed, 113 (60%) were white, 38 (20%) Hispanic, 31 (16%) black, and seven (4%) Asian. Ninety-five (48%) had ovarian cancer, 51 (26%) uterine, 47 (23%) cervical, seven (3%) vulvar/vaginal. In the last 30days of life (DoL), 18 (10%) had multiple hospital admissions, 10 (5%) admitted to the Intensive Care Unit (ICU), 30 (16%) multiple Emergency Room (ER) visits, 45 (24%) received aggressive medical care and eight (4%) received chemotherapy in the final 14 DoL. Furthermore, 54 (29%) had no Supportive Care referral and 29 (15%) no hospice referral. Only 46 (24%) had a Medical Power of Attorney (PoA) or Living Will (LW) on file. Non-white race was associated with increased odds of dying without hospice (OR 3.07; 95%CI [1.27, 2.46], p=0.013). However, non-white patients who enrolled in hospice did so earlier than white patients (42 v. 27days before death, p=0.054). Non-white patients were also significantly less likely to have PoA/LW documentation (24% v. 76%, p=0.009) even if enrolled in hospice (12% v. 31%, p=0.007). Significant racial disparities in hospice enrollment and PoA/LW documentation were seen in GO patients. This warrants further study to identify barriers to use of EoL resources.",Journal Article,1496.0,9.0,identify disparities utilization end life EoL resources gynecologic oncology patients retrospective medical records patients treated 1/2007-12/2011 deceased 1/2012-8/2014 evaluated patient demographics disease characteristics utilization EoL resources Chi-square Fisher 's exact test Mann Whitney Kruskal-Wallis tests statistical 189 patients 113 60 white 38 20 Hispanic 31 16 black seven 4 Asian Ninety-five 48 ovarian 51 26 uterine 47 23 cervical seven 3 vulvar/vaginal 30days life DoL 18 10 multiple hospital admissions 10 5 admitted Intensive Care Unit ICU 30 16 multiple Emergency Room ER visits 45 24 received aggressive medical care 4 received chemotherapy final 14 DoL Furthermore 54 29 Supportive Care referral 29 15 hospice referral 46 24 Medical Power Attorney PoA Living LW file Non-white race associated increased odds dying hospice 3.07 95 CI 1.27 2.46 p=0.013 non-white patients enrolled hospice earlier white patients 42 v. 27days death p=0.054 Non-white patients significantly likely PoA/LW documentation 24 v. 76 p=0.009 enrolled hospice 12 v. 31 p=0.007 Significant racial disparities hospice enrollment PoA/LW documentation seen patients warrants identify barriers use EoL resources,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 255, 2227, 4, 1961, 1, 396, 1, 358, 3946, 2892, 20, 1512, 413, 3537, 7, 26, 459, 65, 1, 3, 484, 1064, 1, 3537, 7, 73, 14, 1307, 133, 1132, 2, 11956, 14, 1195, 66, 1409, 194, 69, 2221, 34, 374, 2, 1961, 1, 3946, 2892, 3163, 3219, 3135, 292, 2472, 412, 7470, 7471, 2, 8800, 8875, 895, 11, 95, 9, 1050, 65, 1, 5899, 7, 311, 4259, 335, 11, 886, 519, 179, 1776, 456, 245, 1445, 2, 648, 39, 2399, 2493, 365, 576, 42, 12, 725, 432, 662, 382, 648, 27, 48010, 18982, 4, 3, 1060, 20849, 1, 358, 49483, 203, 79, 42, 232, 702, 5565, 79, 33, 4319, 6, 3, 1686, 165, 2712, 6195, 201, 245, 232, 4605, 4698, 516, 2690, 512, 259, 103, 571, 484, 165, 2, 659, 39, 103, 56, 4, 3, 1457, 213, 49483, 798, 667, 462, 42, 77, 1877, 165, 2096, 2, 462, 167, 77, 2490, 2096, 158, 641, 259, 42, 8, 484, 2349, 1, 21034, 20078, 15, 2798, 303, 36164, 23, 12339, 220, 886, 1047, 10, 41, 5, 101, 610, 1, 4536, 187, 2490, 15, 27, 1615, 48, 58, 14, 428, 18, 641, 19, 13, 3612, 137, 220, 886, 7, 54, 346, 4, 2490, 205, 1743, 1677, 76, 886, 7, 595, 603, 49085, 348, 273, 19, 13, 9546, 220, 886, 7, 11, 120, 97, 299, 322, 6, 47, 20078, 36164, 4965, 259, 603, 846, 19, 13, 2376, 871, 492, 346, 4, 2490, 133, 603, 456, 19, 13, 1999, 93, 2257, 2227, 4, 2490, 1798, 2, 20078, 36164, 4965, 11, 527, 4, 3537, 7, 26, 2782, 195, 45, 6, 255, 2160, 6, 119, 1, 3946, 2892]",1511.0,26706661,Dying equal end life care gynecologic oncology patients,12,0.21052631578947367
Carcinoma of the Bartholin Gland: A Review of 33 Cases.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2016-05-01,"Primary carcinoma of the Bartholin gland is a rare malignancy that accounts for approximately 5% of vulvar carcinomas. The aim of the study was to compare the outcomes of women with primary Bartholin gland carcinoma (BGC) with those with non-Bartholin gland-related vulvar carcinoma. A retrospective chart review of 429 patients with invasive vulvar carcinoma evaluated at a single institution between 1993 and 2011 was performed. Medical records were reviewed for demographic data, pathologic information, treatment type, and recurrence/outcome information. These variables were compared between patients with primary BGC and patients with non-Bartholin gland-related vulvar carcinoma. Thirty-three (7.7%) of the 429 patients with invasive vulvar carcinoma had primary carcinoma of the Bartholin gland. Twenty-nine patients (87.9%) had squamous cell histology and 4 patients (12.1%) had adenocarcinoma. When compared with non-Bartholin gland-related vulvar carcinoma, patients with primary BGC had a younger age at diagnosis (median, 57 vs 63 years; P = 0.045), had a higher rate of stage III/IV disease (60.6% vs 35.8%; P = 0.008), and were more likely to receive radiation therapy (78.8% vs 43.9%; P < 0.001). However, there were no significant differences between the 2 groups with regard to histologic subtype, lymphovascular space involvement, perineural invasion, positive margins, recurrence-free survival, or overall survival. Despite being diagnosed at a more advanced stage, patients with primary carcinoma of the Bartholin gland seem to have similar oncologic outcomes and survival rates to patients with non-Bartholin gland-related vulvar carcinoma.",Journal Article,1360.0,12.0,Primary carcinoma Bartholin gland rare malignancy accounts approximately 5 vulvar carcinomas aim compare outcomes women primary Bartholin gland carcinoma BGC non-Bartholin gland-related vulvar carcinoma retrospective chart review 429 patients invasive vulvar carcinoma evaluated single institution 1993 2011 performed Medical records reviewed demographic pathologic information treatment type recurrence/outcome information variables compared patients primary BGC patients non-Bartholin gland-related vulvar carcinoma Thirty-three 7.7 429 patients invasive vulvar carcinoma primary carcinoma Bartholin gland Twenty-nine patients 87.9 squamous histology 4 patients 12.1 adenocarcinoma compared non-Bartholin gland-related vulvar carcinoma patients primary BGC younger age diagnosis median 57 vs 63 years P 0.045 higher rate stage III/IV disease 60.6 vs 35.8 P 0.008 likely receive radiation therapy 78.8 vs 43.9 P 0.001 significant differences 2 groups regard histologic subtype lymphovascular space involvement perineural invasion positive margins recurrence-free survival overall survival Despite diagnosed advanced stage patients primary carcinoma Bartholin gland similar oncologic outcomes survival rates patients non-Bartholin gland-related vulvar carcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[86, 134, 1, 3, 25742, 2326, 16, 8, 622, 710, 17, 4162, 9, 705, 33, 1, 826, 3, 1130, 1, 3, 45, 10, 6, 932, 3, 123, 1, 117, 5, 86, 25742, 2326, 134, 27371, 5, 135, 5, 220, 25742, 2326, 139, 134, 8, 459, 2937, 206, 1, 8406, 7, 5, 416, 134, 194, 28, 8, 226, 731, 59, 3343, 2, 1132, 10, 173, 484, 1064, 11, 446, 9, 1540, 74, 510, 487, 24, 267, 2, 146, 228, 487, 46, 682, 11, 72, 59, 7, 5, 86, 27371, 2, 7, 5, 220, 25742, 2326, 139, 134, 977, 169, 67, 67, 1, 3, 8406, 7, 5, 416, 134, 42, 86, 134, 1, 3, 25742, 2326, 737, 762, 7, 912, 83, 42, 691, 31, 784, 2, 39, 7, 133, 14, 42, 449, 198, 72, 5, 220, 25742, 2326, 139, 134, 7, 5, 86, 27371, 42, 8, 773, 89, 28, 147, 52, 696, 105, 676, 60, 19, 13, 4918, 42, 8, 142, 116, 1, 82, 316, 478, 34, 335, 49, 105, 465, 66, 19, 13, 2155, 2, 11, 80, 322, 6, 560, 121, 36, 833, 66, 105, 601, 83, 19, 13, 144, 137, 125, 11, 77, 93, 362, 59, 3, 18, 271, 5, 2539, 6, 884, 875, 2933, 3865, 799, 4917, 578, 109, 1012, 146, 115, 25, 15, 63, 25, 550, 486, 265, 28, 8, 80, 131, 82, 7, 5, 86, 134, 1, 3, 25742, 2326, 3233, 6, 47, 288, 1998, 123, 2, 25, 151, 6, 7, 5, 220, 25742, 2326, 139, 134]",1558.0,26844611,Carcinoma Bartholin Gland Review 33 Cases,0,0.0
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.,JAMA oncology,JAMA Oncol,2016-04-01,"Patients with squamous cell carcinoma (SCC) of the cervix or vulva have limited therapeutic options, and the potential for immunotherapy for this population has not been evaluated. Recent trials suggest that tumors with a genetic basis for PD-1 (programmed cell death protein 1) ligand expression are highly sensitive to therapeutic antibodies targeting PD-1. To determine the genetic status of CD274 (encoding PD-L1 [programmed cell death 1 ligand 1]) and PDCD1LG2 (encoding PD-L2 [programmed cell death 1 ligand 2]) in SCCs of the cervix and vulva and to correlate the findings with PD-L1 protein expression. We performed fluorescence in situ hybridization (FISH) using probes targeting CD274, PDCD1LG2, and the centromeric portion of chromosome 9, and immunohistochemistry (IHC) using an antibody recognizing PD-L1 on formalin-fixed, paraffin-embedded (FFPE) biopsy specimens from 48 cervical SCCs and 23 vulvar SCCs. Tumors were categorized according to the genetic abnormality in CD274 and PDCD1LG2 (coamplification>cogain>polysomy>disomy) as detected by FISH, and evaluated on a semiquantitative scale (modified H score, the product of the percentage of tumor cells with positive staining and the maximum intensity of positive staining) for PD-L1 protein expression as detected by IHC. Overall, 71 samples of FFPE tissue from cases of cervical SCCs (n=48) and vulvar SCCs (n=23) were retrieved from the archives of Brigham and Women's Hospital and included in this study. We observed cogain or coamplification of CD274 and PDCD1LG2 in 32 of 48 cervical SCCs (67%) and 10 of 23 vulvar SCCs (43%). Median PD-L1 protein expression was highest among tumors with CD274 and PDCD1LG2 coamplification and lowest among tumors with disomy. Recurrent copy number gain of the genes encoding the PD-1 ligands provides a genetic basis for PD-L1 expression in a subset of cervical and vulvar SCCs and identifies a class of patients that are rational candidates for therapies targeting PD-1.",Journal Article,1390.0,59.0,Patients squamous carcinoma SCC cervix vulva limited therapeutic options potential immunotherapy population evaluated Recent trials suggest genetic basis PD-1 programmed death 1 ligand expression highly sensitive therapeutic antibodies targeting PD-1 determine genetic status CD274 encoding PD-L1 programmed death 1 ligand 1 PDCD1LG2 encoding PD-L2 programmed death 1 ligand 2 SCCs cervix vulva correlate findings PD-L1 expression performed fluorescence situ hybridization FISH probes targeting CD274 PDCD1LG2 centromeric portion chromosome 9 immunohistochemistry IHC antibody recognizing PD-L1 formalin-fixed paraffin-embedded FFPE biopsy specimens 48 cervical SCCs 23 vulvar SCCs categorized according genetic abnormality CD274 PDCD1LG2 coamplification cogain polysomy disomy detected FISH evaluated semiquantitative scale modified H score product percentage positive staining maximum intensity positive staining PD-L1 expression detected IHC Overall 71 FFPE tissue cases cervical SCCs n 48 vulvar SCCs n 23 retrieved archives Brigham Women 's Hospital included observed cogain coamplification CD274 PDCD1LG2 32 48 cervical SCCs 67 10 23 vulvar SCCs 43 Median PD-L1 expression highest CD274 PDCD1LG2 coamplification lowest disomy Recurrent copy number gain encoding PD-1 ligands provides genetic basis PD-L1 expression subset cervical vulvar SCCs identifies class patients rational candidates therapies targeting PD-1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[7, 5, 691, 31, 134, 1791, 1, 3, 3629, 15, 9263, 47, 383, 189, 838, 2, 3, 174, 9, 726, 9, 26, 266, 71, 44, 85, 194, 435, 143, 309, 17, 57, 5, 8, 336, 877, 9, 333, 14, 1846, 31, 273, 178, 14, 1232, 55, 32, 561, 745, 6, 189, 890, 529, 333, 14, 6, 223, 3, 336, 156, 1, 10511, 2362, 333, 729, 1846, 31, 273, 14, 1232, 14, 2, 14047, 2362, 333, 5111, 1846, 31, 273, 14, 1232, 18, 4, 6334, 1, 3, 3629, 2, 9263, 2, 6, 1513, 3, 272, 5, 333, 729, 178, 55, 21, 173, 1591, 4, 957, 1554, 1277, 75, 3701, 529, 10511, 14047, 2, 3, 15531, 3206, 1, 1170, 83, 2, 888, 1289, 75, 35, 548, 5842, 333, 729, 23, 3265, 1959, 2487, 2505, 4412, 411, 623, 29, 576, 6334, 2, 382, 6334, 57, 11, 2320, 768, 6, 3, 336, 3698, 4, 10511, 2, 14047, 17912, 49585, 5882, 13983, 22, 530, 20, 1277, 2, 194, 23, 8, 8942, 1124, 1230, 555, 368, 3, 2821, 1, 3, 1150, 1, 30, 37, 5, 109, 1029, 2, 3, 689, 837, 1, 109, 1029, 9, 333, 729, 178, 55, 22, 530, 20, 1289, 63, 792, 347, 1, 4412, 246, 29, 140, 1, 6334, 78, 576, 2, 6334, 78, 382, 11, 4539, 29, 3, 12810, 1, 10543, 2, 117, 292, 702, 2, 159, 4, 26, 45, 21, 164, 49585, 15, 17912, 1, 10511, 2, 14047, 4, 531, 1, 576, 6334, 598, 2, 79, 1, 382, 6334, 601, 52, 333, 729, 178, 55, 10, 1076, 107, 57, 5, 10511, 2, 14047, 17912, 2, 2101, 107, 57, 5, 13983, 387, 1337, 207, 1803, 1, 3, 214, 2362, 3, 333, 14, 3123, 777, 8, 336, 877, 9, 333, 729, 55, 4, 8, 697, 1, 2, 6334, 2, 2953, 8, 1040, 1, 7, 17, 32, 2696, 1931, 9, 235, 529, 333, 14]",1869.0,26913631,Genetic Basis PD-L1 Expression Squamous Carcinomas Cervix Vulva,1,0.017543859649122806
Consensus Recommendations for Radiation Therapy Contouring and Treatment ofVulvarCarcinoma.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2016-02-21,"The purpose of this study was to develop a radiation therapy (RT) contouring atlas and recommendations for women with postoperative and locally advanced vulvar carcinoma. An international committee of 35 expert gynecologic radiation oncologists completed a survey of the treatment of vulvar carcinoma. An initial set of recommendations for contouring was discussed and generated by consensus. Two cases, 1 locally advanced and 1 postoperative, were contoured by 14 physicians. Contours were compared and analyzed using an expectation-maximization algorithm for simultaneous truth and performance level estimation (STAPLE), and a 95% confidence interval contour was developed. The level of agreement among contours was assessed using a kappa statistic. STAPLE contours underwent full committee editing to generate the final atlas consensus contours. Analysis of the 14 contours showed substantial agreement, with kappa statistics of 0.69 and 0.64 for cases 1 and 2, respectively. There was high specificity for both cases (99%) and only moderate sensitivity of 71.3% and 64.9% for cases 1 and 2, respectively. Expert review and discussion generated consensus recommendations for contouring target volumes and treatment for postoperative and locally advanced vulvar cancer. These consensus recommendations for contouring and treatment of vulvar cancer identified areas of complexity and controversy. Given the lack of clinical research evidence in vulvar cancer radiation therapy, the committee advocates a conservative and consistent approach using standardized recommendations.",Journal Article,1430.0,21.0,purpose develop radiation therapy RT contouring atlas recommendations women postoperative locally advanced vulvar carcinoma international committee 35 expert gynecologic radiation oncologists completed survey treatment vulvar carcinoma initial set recommendations contouring discussed generated consensus cases 1 locally advanced 1 postoperative contoured 14 physicians Contours compared expectation-maximization algorithm simultaneous truth performance level estimation STAPLE 95 confidence interval contour developed level agreement contours assessed kappa statistic STAPLE contours underwent committee editing generate final atlas consensus contours 14 contours showed substantial agreement kappa statistics 0.69 0.64 cases 1 2 respectively high specificity cases 99 moderate sensitivity 71.3 64.9 cases 1 2 respectively Expert review discussion generated consensus recommendations contouring target volumes treatment postoperative locally advanced vulvar consensus recommendations contouring treatment vulvar identified areas complexity controversy Given lack clinical research evidence vulvar radiation therapy committee advocates conservative consistent approach standardized recommendations,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 690, 8, 121, 36, 240, 7997, 2643, 2, 883, 9, 117, 5, 573, 2, 795, 131, 134, 35, 944, 2002, 1, 465, 2005, 1512, 121, 1339, 781, 8, 1407, 1, 3, 24, 1, 134, 35, 388, 916, 1, 883, 9, 7997, 10, 1588, 2, 1419, 20, 1391, 100, 140, 14, 795, 131, 2, 14, 573, 11, 6476, 20, 213, 1261, 6137, 11, 72, 2, 311, 75, 35, 9988, 16318, 2124, 9, 2824, 14660, 2, 528, 301, 4470, 14259, 2, 8, 48, 307, 268, 7523, 10, 276, 3, 301, 1, 2024, 107, 6137, 10, 275, 75, 8, 3096, 4502, 14259, 6137, 208, 1647, 2002, 6120, 6, 2562, 3, 1457, 2643, 1391, 6137, 65, 1, 3, 213, 6137, 224, 1281, 2024, 5, 3096, 3065, 1, 13, 790, 2, 13, 660, 9, 140, 14, 2, 18, 106, 125, 10, 64, 1121, 9, 110, 140, 48495, 2, 158, 1163, 485, 1, 792, 27, 2, 660, 83, 9, 140, 14, 2, 18, 106, 2005, 206, 2, 2488, 1419, 1391, 883, 9, 7997, 283, 2225, 2, 24, 9, 573, 2, 795, 131, 12, 46, 1391, 883, 9, 7997, 2, 24, 1, 12, 108, 1361, 1, 3082, 2, 4089, 447, 3, 926, 1, 38, 389, 241, 4, 12, 121, 36, 3, 2002, 7781, 8, 4476, 2, 925, 353, 75, 1670, 883]",1514.0,27130794,Consensus Recommendations Radiation Therapy Contouring Treatment Vulvar Carcinoma,0,0.0
Menopausal hormone therapy in cancer survivors: A narrative review of the literature.,Maturitas,Maturitas,2016-07-27,"Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex, and includes assessment of its impact on disease-free or overall survival. Estrogen receptors are present in several cancer types, but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes. Estrogen may even be protective against certain cancers. Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types, but not others. We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of breast, gynecologic, lung, colorectal, hematologic cancers, and melanoma. Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types (e.g., colorectal and hematologic cancer, localized melanoma, and most cervical, vulvar and vaginal cancers), while nonhormonal treatment options may be preferred for others (e.g., breast cancer). In women with other cancer types, recommendations are less straightforward, and the use of MHT must be individualized. ",Journal Article,1273.0,12.0,Decision making use menopausal hormone therapy MHT treatment bothersome menopausal symptoms survivor complex includes assessment impact disease-free overall survival Estrogen receptors present types estrogen-mediated proliferation adverse cancer-related outcomes Estrogen protective certain Menopausal hormone therapy associated increased risk recurrence mortality diagnosis types provide narrative review medical literature risk recurrence associated mortality initiation MHT diagnosis breast gynecologic lung colorectal hematologic melanoma Menopausal hormone therapy considered management bothersome menopausal symptoms women types e.g. colorectal hematologic localized melanoma cervical vulvar vaginal nonhormonal treatment options preferred e.g. breast women types recommendations straightforward use MHT individualized,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[948, 1079, 666, 3, 119, 1, 3565, 785, 36, 10381, 9, 3, 24, 1, 14768, 3565, 507, 4, 8, 12, 2628, 122, 40, 840, 2, 1920, 455, 1, 211, 345, 23, 34, 115, 15, 63, 25, 808, 1186, 32, 364, 4, 392, 12, 630, 84, 26, 1097, 44, 3763, 757, 4, 808, 517, 30, 457, 2, 290, 12, 139, 123, 808, 68, 871, 40, 2864, 480, 1840, 163, 3565, 785, 36, 16, 41, 5, 35, 101, 43, 1, 146, 2, 282, 50, 147, 1, 476, 12, 630, 84, 44, 1749, 21, 377, 8, 8963, 206, 1, 3, 484, 789, 666, 3, 43, 1, 12, 146, 2, 41, 282, 5, 1118, 1, 10381, 50, 3, 147, 1, 1512, 813, 163, 2, 3565, 785, 36, 68, 40, 515, 9, 284, 1, 14768, 3565, 507, 4, 117, 5, 476, 12, 630, 563, 499, 2, 813, 12, 909, 2, 96, 2, 163, 369, 16196, 24, 838, 68, 40, 2514, 9, 1749, 563, 499, 12, 4, 117, 5, 127, 12, 630, 883, 32, 299, 12753, 2, 3, 119, 1, 10381, 1642, 40, 2596]",1173.0,27621244,Menopausal hormone therapy survivors narrative review literature,0,0.0
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-11-18,"<b>Purpose:</b> Primary vulvar melanoma (PVM) is the second most common vulvar malignancy. Despite their distinct anatomic site and unique molecular-genetic alterations, PVMs are staged according to the American Joint Committee on Cancer (AJCC) guidelines for primary cutaneous melanomas (PCM). However, whether parameters derived for PCM also apply to PVM remain a critical yet largely unexplored clinical question. The objective of this study was to determine the parameters predictive of survival in PVM.<b>Experimental Design:</b> We retrospectively reviewed 100 patients with PVM and determined associations between clinical and histopathologic parameters and disease-specific survival (DSS) and overall survival (OS).<b>Results:</b> Univariate Cox regression analysis demonstrated older age (>56 years), greater tumor thickness, higher dermal mitotic rate, ulceration, lymphovascular invasion, perineural invasion, microscopic satellitosis, and absence of precursor nevus associated with decreased OS. Furthermore, age, midline, and/or multifocal involvement, greater tumor thickness, higher dermal mitotic rate, ulceration, lack of regression, lymphovascular invasion, perineural invasion, and microscopic satellitosis associated with decreased DSS. Multivariate analysis demonstrated tumor thickness, dermal mitotic rate, lymphovascular invasion, microscopic satellitosis, and absence of precursor nevus independently predicted shorter OS. Only tumor thickness and increased dermal mitotic rate (2/mm<sup>2</sup>) independently predicted reduced DSS. In comparison with the AJCC T-category, a novel, bivariate T-category based only on tumor thickness and dermal mitotic rate robustly predicted OS and DSS in our patient cohort.<b>Conclusions:</b> In the largest single institutional study of PVM, we demonstrate a combination of tumor thickness and mitotic rate comprise a simple but robust T-category to direct staging and prognosis. <i>Clin Cancer Res; 23(8); 2093-104. 2016 AACR</i>.",Journal Article,1159.0,11.0,b Purpose /b Primary vulvar melanoma PVM second common vulvar malignancy Despite distinct anatomic site unique molecular-genetic alterations PVMs staged according American Joint Committee AJCC guidelines primary cutaneous melanomas PCM parameters derived PCM apply PVM remain critical largely unexplored clinical question objective determine parameters predictive survival PVM. b Experimental Design /b retrospectively reviewed 100 patients PVM determined associations clinical histopathologic parameters disease-specific survival DSS overall survival OS b /b Univariate Cox regression demonstrated older age 56 years greater thickness higher dermal mitotic rate ulceration lymphovascular invasion perineural invasion microscopic satellitosis absence precursor nevus associated decreased OS Furthermore age midline and/or multifocal involvement greater thickness higher dermal mitotic rate ulceration lack regression lymphovascular invasion perineural invasion microscopic satellitosis associated decreased DSS Multivariate demonstrated thickness dermal mitotic rate lymphovascular invasion microscopic satellitosis absence precursor nevus independently predicted shorter OS thickness increased dermal mitotic rate 2/mm sup 2 /sup independently predicted reduced DSS comparison AJCC T-category novel bivariate T-category based thickness dermal mitotic rate robustly predicted OS DSS patient cohort. b Conclusions /b largest single institutional PVM demonstrate combination thickness mitotic rate comprise simple robust T-category direct staging prognosis Clin Res 23 8 2093-104 2016 AACR /i,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[132, 743, 132, 86, 32675, 16, 3, 419, 96, 186, 710, 550, 136, 834, 2745, 606, 2, 991, 219, 336, 593, 69372, 32, 2930, 768, 6, 3, 597, 2093, 2002, 23, 12, 2271, 677, 9, 86, 1486, 1965, 12450, 137, 317, 1038, 526, 9, 12450, 120, 4930, 6, 32675, 918, 8, 740, 1145, 1733, 8398, 38, 2840, 3, 461, 1, 26, 45, 10, 6, 223, 3, 1038, 464, 1, 25, 4, 32675, 132, 1560, 771, 132, 21, 894, 446, 394, 7, 5, 32675, 2, 509, 685, 59, 38, 2, 2630, 1038, 2, 34, 112, 25, 1788, 2, 63, 25, 118, 132, 99, 132, 880, 418, 320, 65, 264, 434, 89, 664, 60, 378, 30, 2903, 142, 6132, 2346, 116, 5158, 2933, 578, 4917, 578, 2984, 23564, 2, 1127, 1, 2765, 8932, 41, 5, 340, 118, 798, 89, 8677, 2, 15, 3492, 799, 378, 30, 2903, 142, 6132, 2346, 116, 5158, 926, 1, 320, 2933, 578, 4917, 578, 2, 2984, 23564, 41, 5, 340, 1788, 331, 65, 264, 30, 2903, 6132, 2346, 116, 2933, 578, 2984, 23564, 2, 1127, 1, 2765, 8932, 1042, 783, 985, 118, 158, 30, 2903, 2, 101, 6132, 2346, 116, 3107, 321, 172, 18, 172, 1042, 783, 405, 1788, 4, 1155, 5, 3, 2271, 102, 2169, 8, 229, 7686, 102, 2169, 90, 158, 23, 30, 2903, 2, 6132, 2346, 116, 8547, 783, 118, 2, 1788, 4, 114, 69, 180, 132, 2130, 132, 4, 3, 2166, 226, 1115, 45, 1, 32675, 21, 608, 8, 150, 1, 30, 2903, 2, 2346, 116, 5238, 8, 2763, 84, 1922, 102, 2169, 6, 1196, 632, 2, 356, 70, 2459, 12, 1936, 382, 66, 41607, 3407, 3456, 1630, 70]",1906.0,27864417,Thickness Mitotic Rate Robustly Predict Melanoma-Specific Survival Patients Primary Vulvar Melanoma Retrospective Review 100 Cases,16,0.2807017543859649
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2016-11-22,"Advanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition. A dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48-96mg/m<sup>2</sup>) and i.v. cisplatin (20-75mg/m<sup>2</sup>) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine-cisplatin combination. Secondary endpoints included the rate of triapine-cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323). The MTD was 96mg/m<sup>2</sup> triapine daily days 1-4 and 75mg/m<sup>2</sup> cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%. The triapine-cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.","Clinical Trial, Phase I",1155.0,13.0,Advanced-stage malignancies increased deoxyribonucleotide demands DNA replication repair making deoxyribonucleotide supply potential exploitable target therapy based ribonucleotide reductase RNR inhibition dose-finding phase trial conducted intravenous i.v triapine small-molecule RNR inhibitor cisplatin chemotherapy patients advanced-stage solid malignancies Patients received dose-finding levels i.v triapine 48-96 mg/m sup 2 /sup i.v cisplatin 20-75 mg/m sup 2 /sup 1 3 different schedules primary endpoint identify maximum tolerated dose triapine-cisplatin combination Secondary endpoints included rate triapine-cisplatin objective response pharmacokinetics bioavailability single oral triapine dose Clinicaltrials.gov number NCT00024323 MTD 96 mg/m sup 2 /sup triapine daily days 1-4 75 mg/m sup 2 /sup cisplatin split day 2 day 3 Frequent grade 3 4 adverse events included fatigue dyspnea leukopenia thrombocytopenia electrolyte abnormalities objective responses observed 5 50 10 patients treated MTD stable disease Pharmacokinetics indicated oral triapine bioavailability 88 triapine-cisplatin combination given safely patients advanced-stage solid malignancies basis phase trial adequately powered evaluate oral triapine bioavailability women advanced-stage uterine cervix vulvar underway,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[131, 82, 441, 47, 101, 31046, 8988, 4, 261, 2079, 2, 972, 1079, 31046, 6296, 8, 174, 23773, 283, 9, 36, 90, 23, 7050, 4027, 18376, 297, 8, 61, 1567, 124, 70, 160, 10, 426, 1, 1262, 70, 603, 8604, 8, 302, 1354, 18376, 230, 2, 540, 56, 4, 7, 5, 131, 82, 537, 30, 441, 7, 103, 61, 1567, 148, 1, 70, 603, 8604, 576, 921, 81, 188, 172, 18, 172, 2, 70, 603, 540, 179, 481, 81, 188, 172, 18, 172, 23, 14, 1, 27, 338, 2314, 3, 86, 1138, 10, 6, 255, 3, 689, 421, 61, 1, 8, 8604, 540, 150, 568, 1387, 159, 3, 116, 1, 8604, 540, 461, 51, 2, 3, 1159, 2, 5499, 1, 8, 226, 518, 8604, 61, 1252, 1239, 207, 69382, 3, 961, 10, 921, 81, 188, 172, 18, 172, 8604, 391, 162, 14, 39, 2, 481, 81, 188, 172, 18, 172, 540, 6240, 252, 218, 18, 2, 218, 27, 908, 88, 27, 15, 39, 290, 281, 159, 613, 2923, 3904, 1340, 2, 10834, 1171, 77, 461, 253, 11, 164, 33, 212, 1, 79, 7, 73, 28, 3, 961, 42, 585, 34, 1159, 1103, 35, 518, 8604, 5499, 1, 889, 3, 8604, 540, 150, 68, 40, 447, 2268, 4, 7, 5, 131, 82, 537, 30, 441, 23, 3, 877, 1, 46, 99, 8, 124, 70, 160, 4215, 6855, 6, 376, 518, 8604, 5499, 4, 117, 5, 131, 82, 3629, 15, 163, 16, 3948]",1525.0,27878356,Phase trial daily triapine combination cisplatin chemotherapy advanced-stage malignancies,1,0.017543859649122806
"Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2017-01-01,"Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC. This manuscript discusses the recommendations outlined in the NCCN Guidelines for diagnosis, staging, treatment, and follow-up.",Journal Article,1115.0,30.0,Vulvar rare gynecologic malignancy Ninety percent vulvar predominantly squamous carcinomas SCCs arise human papilloma virus HPV -dependent HPV-independent pathways NCCN Vulvar panel interdisciplinary group representatives NCCN Member Institutions consisting specialists gynecological oncology medical oncology radiation oncology pathology NCCN Clinical Practice Guidelines Oncology NCCN Guidelines Vulvar provide evidence- consensus-based approach management patients vulvar SCC manuscript discusses recommendations outlined NCCN Guidelines diagnosis staging treatment follow-up,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 16, 8, 622, 1512, 710, 2493, 714, 1, 163, 32, 2117, 691, 31, 826, 6334, 92, 122, 3043, 298, 171, 7017, 1450, 933, 470, 2, 933, 306, 460, 3, 1944, 12, 993, 16, 35, 5911, 87, 1, 10204, 29, 1944, 2693, 1764, 2273, 1, 4409, 4, 6324, 413, 484, 413, 121, 413, 2, 1117, 3, 1944, 38, 758, 677, 4, 413, 1944, 677, 9, 12, 377, 35, 241, 2, 1391, 90, 353, 9, 3, 284, 1, 7, 5, 1791, 26, 5825, 2759, 3, 883, 6394, 4, 3, 1944, 677, 9, 147, 632, 24, 2, 166, 126]",697.0,28040721,Vulvar Version 1.2017 NCCN Clinical Practice Guidelines Oncology,0,0.0
Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer.,Gynecologic oncology,Gynecol. Oncol.,2017-05-12,"To examine adjuvant radiation therapy (RT) use, patterns of RT delivery, and clinical outcomes in older patients with node-positive vulvar cancer. Using SEER-Medicare linked data, we identified 444 patients (age66years) with node-positive squamous cell vulvar carcinoma, without distant metastases, and treated with primary surgery between 1991 and 2009. We used claims to examine RT use and the following delivery metrics: 1) completion of 20 fractions, 2) treatment duration <8weeks, 3) <1week of intra-treatment break, and 4) treatment interval from surgery to start of RT <8weeks. We tested associations between RT use and metrics with overall (OS) and cause-specific survival (CSS) using multivariate proportional hazards regression. Median age was 78years (interquartile range [IQR]=74-83). Median follow-up was 17months (IQR=9-40). Three hundred six patients (69%) received RT. Three delivery metrics were associated with improved outcomes: completion of 20 fractions, treatment duration <8weeks, and <1week of intra-treatment break. Patients who achieved these 3 metrics demonstrated better disease outcomes compared with surgery alone (OS hazard ratio [HR] for death=0.62, 95% confidence interval [CI]=0.46-0.82, P=0.001; CSS HR=0.58, 95% CI=0.40-0.85,P=0.005). Patients not achieving RT metrics demonstrated marginal improvements in disease outcomes over surgery alone (OS HR=0.73, 95% CI=0.55-0.99,P=0.04; CSS HR=0.76, 95% CI=0.52-1.11, P=0.16). Notably, only 51% of patients who received RT achieved all benchmarks. In this cohort of older women with node-positive vulvar cancer, achieving metrics for RT delivery was an important factor for optimizing disease benefits from treatment.",Journal Article,984.0,3.0,examine adjuvant radiation therapy RT use patterns RT delivery clinical outcomes older patients node-positive vulvar SEER-Medicare linked identified 444 patients age66years node-positive squamous vulvar carcinoma distant metastases treated primary surgery 1991 2009 claims examine RT use following delivery metrics 1 completion 20 fractions 2 treatment duration 8weeks 3 1week intra-treatment break 4 treatment interval surgery start RT 8weeks tested associations RT use metrics overall OS cause-specific survival CSS multivariate proportional hazards regression Median age 78years interquartile range IQR =74-83 Median follow-up 17months IQR=9-40 patients 69 received RT delivery metrics associated improved outcomes completion 20 fractions treatment duration 8weeks 1week intra-treatment break Patients achieved 3 metrics demonstrated better disease outcomes compared surgery OS hazard ratio HR death=0.62 95 confidence interval CI =0.46-0.82 P=0.001 CSS HR=0.58 95 CI=0.40-0.85 P=0.005 Patients achieving RT metrics demonstrated marginal improvements disease outcomes surgery OS HR=0.73 95 CI=0.55-0.99 P=0.04 CSS HR=0.76 95 CI=0.52-1.11 P=0.16 Notably 51 patients received RT achieved benchmarks cohort older women node-positive vulvar achieving metrics RT delivery important factor optimizing disease benefits treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1004, 249, 121, 36, 240, 119, 764, 1, 240, 989, 2, 38, 123, 4, 434, 7, 5, 289, 109, 12, 75, 1605, 1378, 1199, 74, 21, 108, 10325, 7, 70389, 5, 289, 109, 691, 31, 134, 187, 626, 196, 2, 73, 5, 86, 152, 59, 3372, 2, 1238, 21, 95, 2770, 6, 1004, 240, 119, 2, 3, 366, 989, 3589, 14, 1438, 1, 8076, 1550, 18, 24, 654, 29117, 27, 36244, 1, 2392, 24, 4338, 2, 39, 24, 268, 29, 152, 6, 2435, 1, 240, 29117, 21, 650, 685, 59, 240, 119, 2, 3589, 5, 63, 118, 2, 708, 112, 25, 2687, 75, 331, 831, 1017, 320, 52, 89, 10, 70390, 2899, 184, 2245, 794, 852, 52, 166, 126, 10, 70391, 2245, 83, 327, 169, 1128, 437, 7, 790, 103, 240, 169, 989, 3589, 11, 41, 5, 231, 123, 1438, 1, 8076, 1550, 24, 654, 29117, 2, 36244, 1, 2392, 24, 4338, 7, 54, 513, 46, 27, 3589, 264, 380, 34, 123, 72, 5, 152, 279, 118, 360, 197, 168, 9, 273, 13, 744, 48, 307, 268, 58, 13, 641, 13, 878, 19, 13, 144, 2687, 168, 13, 717, 48, 58, 13, 327, 13, 772, 19, 13, 1614, 7, 44, 1785, 240, 3589, 264, 3450, 1474, 4, 34, 123, 252, 152, 279, 118, 168, 13, 803, 48, 58, 13, 614, 13, 1058, 19, 13, 755, 2687, 168, 13, 846, 48, 58, 13, 653, 14, 175, 19, 13, 245, 2552, 158, 725, 1, 7, 54, 103, 240, 513, 62, 9945, 4, 26, 180, 1, 434, 117, 5, 289, 109, 12, 1785, 3589, 9, 240, 989, 10, 35, 305, 161, 9, 4336, 34, 1141, 29, 24]",1608.0,28506563,Challenges delivery effectiveness adjuvant radiation therapy elderly patients node-positive vulvar,2,0.03508771929824561
Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse.,Gynecologic oncology,Gynecol. Oncol.,2017-08-12,"To characterize risk for opioid misuse among gynecologic oncology patients. The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs. moderate or high). Chi-square tests were performed for categorical variables. A total of 118 women were screened. Most women were Caucasian (79%) with a median age of 57years. Ovarian cancer patients comprised 46% of the cohort with fewer endometrial (25%), cervical (23%), vulvar (4%), and vaginal (2%) cancer patients. The median ORT score was 1.0 (range, 0-10) out of a possible 26. Overall, 87% of patients were categorized as low-risk for opioid misuse, 7% as moderate-risk, and 6% as high-risk. Patients who were at moderate or high-risk of opioid misuse were significantly younger (47 vs. 58years, p=0.02), more likely to have cervical cancer (p=0.02), be smokers (p=0.01) and be uninsured or on Medicare (p=0.03). Most gynecologic oncology patients in our cohort were low-risk for opioid misuse (87%). Cervical cancer patients were more likely to be moderate to high-risk for misuse. Future screening efforts for opioid misuse may have the highest utility in this subset of patients.",Journal Article,892.0,5.0,characterize risk opioid misuse gynecologic oncology patients Opioid Risk Tool ORT validated screen opioid misuse risk administered convenience patients gynecologic receiving opioid prescriptions gynecologic oncology palliative care clinics January 2012-June 2016 Demographic clinical information abstracted chart review primary outcome ORT risk level low vs. moderate high Chi-square tests performed categorical variables total 118 women screened women Caucasian 79 median age 57years Ovarian patients comprised 46 cohort fewer endometrial 25 cervical 23 vulvar 4 vaginal 2 patients median ORT score 1.0 range 0-10 possible 26 Overall 87 patients categorized low-risk opioid misuse 7 moderate-risk 6 high-risk Patients moderate high-risk opioid misuse significantly younger 47 vs. 58years p=0.02 likely cervical p=0.02 smokers p=0.01 uninsured Medicare p=0.03 gynecologic oncology patients cohort low-risk opioid misuse 87 Cervical patients likely moderate high-risk misuse Future screening efforts opioid misuse highest utility subset patients,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1507, 43, 9, 2742, 13739, 107, 1512, 413, 7, 3, 2742, 43, 1515, 19957, 8, 938, 2413, 9, 2742, 13739, 43, 10, 468, 6, 8, 8184, 1000, 1, 7, 5, 1512, 12, 357, 2742, 7654, 4, 1512, 413, 15, 994, 165, 4736, 29, 1024, 1195, 1924, 1390, 1540, 2, 38, 487, 10, 4106, 23, 2937, 206, 3, 86, 228, 10, 19957, 43, 301, 154, 105, 1163, 15, 64, 3163, 3219, 895, 11, 173, 9, 5982, 682, 8, 181, 1, 4002, 117, 11, 2261, 96, 117, 11, 3229, 842, 5, 8, 52, 89, 1, 32414, 12, 7, 2603, 641, 1, 3, 180, 5, 1497, 243, 382, 39, 2, 18, 12, 7, 3, 52, 19957, 368, 10, 14, 13, 184, 13, 79, 1205, 1, 8, 899, 432, 63, 912, 1, 7, 11, 2320, 22, 154, 43, 9, 2742, 13739, 67, 22, 1163, 43, 2, 49, 22, 64, 43, 7, 54, 11, 28, 1163, 15, 64, 43, 1, 2742, 13739, 11, 97, 773, 662, 105, 71018, 19, 13, 588, 80, 322, 6, 47, 12, 19, 13, 588, 40, 1485, 19, 13, 355, 2, 40, 4955, 15, 23, 1378, 19, 13, 680, 96, 1512, 413, 7, 4, 114, 180, 11, 154, 43, 9, 2742, 13739, 912, 12, 7, 11, 80, 322, 6, 40, 1163, 6, 64, 43, 9, 13739, 508, 453, 1413, 9, 2742, 13739, 68, 47, 3, 1076, 1207, 4, 26, 697, 1, 7]",1319.0,28807366,Prospective screening validated Opioid Risk Tool demonstrates gynecologic oncology patients low risk opioid misuse,0,0.0
Long term outcome after resection of liver metastases from squamous cell carcinoma.,European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,Eur J Surg Oncol,2017-09-13,"Squamous cell carcinoma (SCC) liver metastases still remains a difficult challenge and the effectiveness of resection for SCC liver metastases is unclear. The aim of this study was to analyze long-term outcomes of surgically treated patients with SCC liver metastases. The clinicopathological characteristics, overall survival (OS), and recurrence free survival (RFS) of all patients with SCC liver metastases resected between 1998 and 2015, were analyzed. Among 28 patients who met inclusion criteria, there were 19 patients with anal cancer metastases (68%), 2 (7%) with cervix cancer metastases, 2 (7%) with tonsil cancer metastases, 2 (7%) with lung cancer metastases, 2 (7%) with primary unknown cancer metastases and 1 (4%) with vulvar cancer metastases. Four (14%) patients underwent major hepatectomy. There were no liver insufficiency cases or 90-day mortality. Cumulative 3- and 5-year OS rates were 52% and 47%. Cumulative 1- and 3-year RFS rates were 50% and 25%. Long-term outcomes after resection of SCC liver metastases compare favorably with those of colorectal or neuroendocrine liver metastases. Liver resection can be an effective treatment option for SCC liver metastases in appropriately selected patients after systemic therapy.",Journal Article,860.0,2.0,Squamous carcinoma SCC liver metastases remains difficult challenge effectiveness resection SCC liver metastases unclear aim long-term outcomes surgically treated patients SCC liver metastases clinicopathological characteristics overall survival OS recurrence free survival RFS patients SCC liver metastases resected 1998 2015 28 patients met inclusion criteria 19 patients anal metastases 68 2 7 cervix metastases 2 7 tonsil metastases 2 7 lung metastases 2 7 primary unknown metastases 1 4 vulvar metastases 14 patients underwent major hepatectomy liver insufficiency cases 90-day mortality Cumulative 3- 5-year OS rates 52 47 Cumulative 1- 3-year RFS rates 50 25 Long-term outcomes resection SCC liver metastases compare favorably colorectal neuroendocrine liver metastases Liver resection effective treatment option SCC liver metastases appropriately selected patients systemic therapy,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[691, 31, 134, 1791, 196, 1234, 469, 8, 1740, 1745, 2, 3, 1236, 1, 170, 9, 1791, 196, 16, 1200, 3, 1130, 1, 26, 45, 10, 6, 1992, 319, 337, 123, 1, 2350, 73, 7, 5, 1791, 196, 3, 2721, 374, 63, 25, 118, 2, 146, 115, 25, 1272, 1, 62, 7, 5, 1791, 196, 1133, 59, 1850, 2, 1483, 11, 311, 107, 339, 7, 54, 543, 1680, 371, 125, 11, 326, 7, 5, 12, 196, 806, 18, 67, 5, 3629, 12, 196, 18, 67, 5, 10226, 12, 196, 18, 67, 5, 12, 196, 18, 67, 5, 86, 860, 12, 196, 2, 14, 39, 5, 12, 196, 294, 213, 7, 208, 458, 2711, 125, 11, 77, 4360, 140, 15, 424, 218, 282, 967, 27, 2, 33, 111, 118, 151, 11, 653, 2, 662, 967, 14, 2, 27, 111, 1272, 151, 11, 212, 2, 243, 319, 337, 123, 50, 170, 1, 1791, 196, 932, 5001, 5, 135, 1, 15, 1542, 196, 170, 122, 40, 35, 323, 24, 1501, 9, 1791, 196, 4, 4544, 715, 7, 50, 403, 36]",1119.0,28958732,Long term outcome resection liver metastases squamous carcinoma,0,0.0
Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy.,Gynecologic oncology,Gynecol. Oncol.,2018-01-12,"To evaluate the effectiveness and long-term side effects of definitive groin radiotherapy for vulvar cancer with grossly involved inguinal lymph nodes. The records of 407 women with vulvar squamous cell carcinoma treated with radiotherapy at one institution during 1992-2014 were reviewed to identify patients who had radiographic or histologic evidence of grossly involved inguinal lymph nodes. Patients with lymphadenectomy before radiotherapy and patients treated for recurrent disease were excluded. Actuarial incidences of vulvar, inguinal, and distant recurrences, the relationship between vulvar recurrence and inguinal recurrence, and overall survival were analyzed using the Kaplan-Meier method. Thirty-three patients were identified. The median age at diagnosis was 64years. The median long-axis radiographic diameter of the largest inguinal lymph node or lymph node mass was 2.5cm (range, 1.4-8.7). Sixteen patients (48%) also had evidence of pelvic lymph node metastasis. The median radiation dose delivered to grossly involved nodes was 66.0Gy (range, 60.0-70.0). The 3-year actuarial incidences of vulvar, groin, and distant recurrences were 24.2%, 17.7%, and 30.3%, respectively. With a median follow-up time of 28months (range, 2-196), four patients (12%) had groin recurrence, of whom three also had vulvar recurrence. There were few major late adverse effects of regional radiotherapy. The 3-year overall survival rate was 51%. High-dose volume-directed radiotherapy achieves a high rate of local control with low risk of serious long-term toxic effects in patients with vulvar squamous cell carcinoma and grossly involved inguinal lymph nodes.",Journal Article,739.0,4.0,evaluate effectiveness long-term effects definitive groin radiotherapy vulvar grossly involved inguinal lymph nodes records 407 women vulvar squamous carcinoma treated radiotherapy institution 1992-2014 reviewed identify patients radiographic histologic evidence grossly involved inguinal lymph nodes Patients lymphadenectomy radiotherapy patients treated recurrent disease excluded Actuarial incidences vulvar inguinal distant recurrences relationship vulvar recurrence inguinal recurrence overall survival Kaplan-Meier Thirty-three patients identified median age diagnosis 64 years median long-axis radiographic diameter largest inguinal lymph node lymph node mass 2.5 cm range 1.4-8.7 Sixteen patients 48 evidence pelvic lymph node metastasis median radiation dose delivered grossly involved nodes 66.0 Gy range 60.0-70.0 3-year actuarial incidences vulvar groin distant recurrences 24.2 17.7 30.3 respectively median follow-up time 28 months range 2-196 patients 12 groin recurrence vulvar recurrence major late adverse effects regional radiotherapy 3-year overall survival rate 51 High-dose volume-directed radiotherapy achieves high rate local control low risk long-term toxic effects patients vulvar squamous carcinoma grossly involved inguinal lymph nodes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 1236, 2, 319, 337, 1152, 176, 1, 1057, 9264, 310, 9, 12, 5, 7185, 646, 4907, 263, 502, 3, 1064, 1, 11595, 117, 5, 691, 31, 134, 73, 5, 310, 28, 104, 731, 190, 2846, 1409, 11, 446, 6, 255, 7, 54, 42, 1580, 15, 884, 241, 1, 7185, 646, 4907, 263, 502, 7, 5, 2048, 348, 310, 2, 7, 73, 9, 387, 34, 11, 1800, 2361, 3981, 1, 4907, 2, 626, 1593, 3, 858, 59, 146, 2, 4907, 146, 2, 63, 25, 11, 311, 75, 3, 876, 882, 596, 977, 169, 7, 11, 108, 3, 52, 89, 28, 147, 10, 660, 60, 3, 52, 319, 2310, 1580, 2549, 1, 3, 2166, 4907, 263, 289, 15, 263, 289, 782, 10, 18, 33, 494, 184, 14, 39, 66, 67, 3228, 7, 576, 120, 42, 241, 1, 1110, 263, 289, 278, 3, 52, 121, 61, 1623, 6, 7185, 646, 502, 10, 700, 13, 381, 184, 335, 13, 431, 13, 3, 27, 111, 2361, 3981, 1, 9264, 2, 626, 1593, 11, 259, 18, 269, 67, 2, 201, 27, 106, 5, 8, 52, 166, 126, 98, 1, 339, 53, 184, 18, 6369, 294, 7, 133, 42, 9264, 146, 1, 953, 169, 120, 42, 146, 125, 11, 1021, 458, 807, 290, 176, 1, 951, 310, 3, 27, 111, 63, 25, 116, 10, 725, 64, 61, 433, 1166, 310, 6358, 8, 64, 116, 1, 293, 182, 5, 154, 43, 1, 1762, 319, 337, 1812, 176, 4, 7, 5, 691, 31, 134, 2, 7185, 646, 4907, 263, 502]",1573.0,29336837,Effectiveness definitive radiotherapy squamous carcinoma vulva gross inguinal lymphadenopathy,1,0.017543859649122806
Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies.,Gynecologic oncology,Gynecol. Oncol.,2018-04-01,"To examine temporal trends in treatment and survival among black, Asian, Hispanic, and white women diagnosed with endometrial, ovarian, cervical, and vulvar cancer. Using the National Cancer Database (2004-2014), we identified women diagnosed with endometrial, ovarian, cervical, and vulvar cancer. For each disease site, we analyzed race/ethnicity-specific trends in receipt of evidence-based practices. Professional societies' recommendations were used to define these practices. Using data from the Surveillance, Epidemiology, and End Results Program (2000-2009) we analyzed trends in 5-year survival. Throughout the study period black (64.8%) and Hispanic (68.3%) women were less likely to undergo lymphadenectomy for stage I ovarian cancer compared to Asian (79.5%) and white patients (74.6%). Black women were the least likely group to undergo lymphadenectomy in all periods. Among patients with stage II-IV ovarian cancer, 76.6% of white and Asian women received both surgery and chemotherapy, compared to 70.8% of black and 73.9% Hispanic women. Hispanic women with deeply invasive or high-grade stage I endometrial cancer underwent lymphadenectomy less frequently (74.5%) than all other groups (80.7%). Black women were less likely to have chemo-radiotherapy for stage IIB-IVA cervical cancer (75.6% versus 80.4% of all others). Black women were also less likely to have a surgical lymph node evaluation for vulvar cancer (58.8% versus 63.5% of all others). Among women diagnosed with ovarian, endometrial, and cervical cancer, black women had lower five-year survival than other groups. Significant racial disparities persist in the delivery of evidence-based care. Black women with ovarian, endometrial, and cervical cancer continue to experience higher cancer-specific mortality than other groups.",Journal Article,660.0,10.0,examine temporal trends treatment survival black Asian Hispanic white women diagnosed endometrial ovarian cervical vulvar National Database 2004-2014 identified women diagnosed endometrial ovarian cervical vulvar disease site race/ethnicity-specific trends receipt evidence-based practices Professional societies recommendations define practices Surveillance Epidemiology End Program 2000-2009 trends 5-year survival period black 64.8 Hispanic 68.3 women likely undergo lymphadenectomy stage ovarian compared Asian 79.5 white patients 74.6 Black women likely group undergo lymphadenectomy periods patients stage II-IV ovarian 76.6 white Asian women received surgery chemotherapy compared 70.8 black 73.9 Hispanic women Hispanic women deeply invasive high-grade stage endometrial underwent lymphadenectomy frequently 74.5 groups 80.7 Black women likely chemo-radiotherapy stage IIB-IVA cervical 75.6 versus 80.4 Black women likely surgical lymph node evaluation vulvar 58.8 versus 63.5 women diagnosed ovarian endometrial cervical black women lower five-year survival groups Significant racial disparities persist delivery evidence-based care Black women ovarian endometrial cervical continue experience higher cancer-specific mortality groups,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1004, 3264, 1963, 4, 24, 2, 25, 107, 1445, 2399, 1776, 2, 886, 117, 265, 5, 2, 12, 75, 3, 657, 12, 609, 1131, 1409, 21, 108, 117, 265, 5, 2, 12, 9, 296, 34, 606, 21, 311, 1047, 2091, 112, 1963, 4, 1699, 1, 241, 90, 2634, 5341, 10600, 883, 11, 95, 6, 1107, 46, 2634, 75, 74, 29, 3, 617, 1284, 2, 396, 99, 1243, 1081, 1238, 21, 311, 1963, 4, 33, 111, 25, 2432, 3, 45, 727, 1445, 660, 66, 2, 1776, 806, 27, 117, 11, 299, 322, 6, 1251, 2048, 9, 82, 70, 12, 72, 6, 2399, 842, 33, 2, 886, 7, 794, 49, 1445, 117, 11, 3, 506, 322, 87, 6, 1251, 2048, 4, 62, 3338, 107, 7, 5, 82, 215, 478, 12, 846, 49, 1, 886, 2, 2399, 117, 103, 110, 152, 2, 56, 72, 6, 431, 66, 1, 1445, 2, 803, 83, 1776, 117, 1776, 117, 5, 16394, 416, 15, 64, 88, 82, 70, 12, 208, 2048, 299, 746, 794, 33, 76, 62, 127, 271, 493, 67, 1445, 117, 11, 299, 322, 6, 47, 3341, 310, 9, 82, 3884, 5900, 12, 481, 49, 185, 493, 39, 1, 62, 1749, 1445, 117, 11, 120, 299, 322, 6, 47, 8, 221, 263, 289, 451, 9, 12, 717, 66, 185, 676, 33, 1, 62, 1749, 107, 117, 265, 5, 2, 12, 1445, 117, 42, 280, 365, 111, 25, 76, 127, 271, 93, 2257, 2227, 5589, 4, 3, 989, 1, 241, 90, 165, 1445, 117, 5, 2, 12, 1906, 6, 730, 142, 12, 112, 282, 76, 127, 271]",1567.0,29605048,Racial ethnic disparities time treatment mortality women gynecological malignancies,1,0.017543859649122806
Trends in Place of Death Among Patients With Gynecologic Cancer in the United States.,Obstetrics and gynecology,Obstet Gynecol,2018-06-01,"To describe the change over time in place of death (hospital, home, hospice) among all women in the United States who died of gynecologic malignancies and compare them with other leading causes of female cancer deaths. This is a retrospective cross-sectional study using national death certificate data from the Mortality Multiple Cause-of-Death Public Use Record Data. All women who died from gynecologic, breast, lung, and colorectal cancers were identified according to International Classification of Diseases, 10 Revision, cause of death from 2003 to 2015. Regression analyses with ordinary least-squares linear probability modeling were used to test for differences in location of death over time, and differences in trends by cancer type, while controlling for age, race, ethnicity, marital status, and education status. From 2003 to 2015, 2,133,056 women died from gynecologic, lung, breast, and colorectal malignancies in the United States. A total of 359,340 died from gynecologic malignancies, including ovarian cancer (n=188,366 [52.4%]), uterine cancer (n=106,454 [29.6%]), cervical cancer (n=52,320 [14.6%]), and vulvar cancer (n=12,200 [3.4%]). Overall, 49.2% (n=176,657) of gynecologic cancer deaths occurred at home or in hospice. The relative increase from 2003 to 2015 in the rate of deaths at home or in hospice was 47.2% for gynecologic cancer deaths (40.5% in 2003 to 59.5% in 2015). In adjusted analyses, the trend in the percentage of deaths at home or in hospice increased at a rate of 1.6 percentage points per year for gynecologic cancer deaths (95% CI 1.5-1.6) vs 1.5 (95% CI 1.4-1.5, P<.001), 1.4 (95% CI 1.4-1.5, P<.001), and 1.5 (95% CI 1.4-1.5, P=.09) percentage points per year for lung, breast, and colorectal cancer deaths, respectively. Between 2003 and 2015, there was a 47.2% increase (40.5-59.5%) in the rates of gynecologic cancer deaths occurring at home or in hospice. This trend may represent an increase in advance care planning and value-based treatment decisions.",Journal Article,599.0,2.0,"change time place death hospital home hospice women United States died gynecologic malignancies compare leading causes female deaths retrospective cross-sectional national death certificate Mortality Multiple Cause-of-Death Public Use Record women died gynecologic breast lung colorectal identified according International Classification Diseases 10 Revision cause death 2003 2015 Regression ordinary least-squares linear probability modeling test differences location death time differences trends type controlling age race ethnicity marital status education status 2003 2015 2,133,056 women died gynecologic lung breast colorectal malignancies United States total 359,340 died gynecologic malignancies including ovarian n=188,366 52.4 uterine n=106,454 29.6 cervical n=52,320 14.6 vulvar n=12,200 3.4 Overall 49.2 n=176,657 gynecologic deaths occurred home hospice relative increase 2003 2015 rate deaths home hospice 47.2 gynecologic deaths 40.5 2003 59.5 2015 adjusted trend percentage deaths home hospice increased rate 1.6 percentage points year gynecologic deaths 95 CI 1.5-1.6 vs 1.5 95 CI 1.4-1.5 P .001 1.4 95 CI 1.4-1.5 P .001 1.5 95 CI 1.4-1.5 P=.09 percentage points year lung breast colorectal deaths respectively 2003 2015 47.2 increase 40.5-59.5 rates gynecologic deaths occurring home hospice trend represent increase advance care planning value-based treatment decisions",1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 707, 252, 98, 4, 3536, 1, 273, 702, 3249, 2490, 107, 62, 117, 4, 3, 1088, 907, 54, 1016, 1, 1512, 441, 2, 932, 1370, 5, 127, 1049, 1626, 1, 1061, 12, 1043, 26, 16, 8, 459, 1383, 2832, 45, 75, 657, 273, 17216, 74, 29, 3, 282, 232, 708, 1, 273, 3067, 119, 3237, 74, 62, 117, 54, 1016, 29, 1512, 2, 163, 11, 108, 768, 6, 944, 947, 1, 1342, 79, 5646, 708, 1, 273, 29, 1522, 6, 1483, 320, 318, 5, 19493, 506, 11938, 1646, 1320, 2057, 11, 95, 6, 412, 9, 362, 4, 1147, 1, 273, 252, 98, 2, 362, 4, 1963, 20, 12, 267, 369, 1893, 9, 89, 1047, 2091, 5345, 156, 2, 1848, 156, 29, 1522, 6, 1483, 18, 5026, 9556, 117, 1016, 29, 1512, 2, 441, 4, 3, 1088, 907, 8, 181, 1, 10791, 7264, 1016, 29, 1512, 441, 141, 12, 78, 5664, 9797, 653, 39, 12, 78, 3251, 11026, 462, 49, 12, 78, 653, 5904, 213, 49, 2, 12, 78, 133, 1250, 27, 39, 63, 739, 18, 78, 5800, 13141, 1, 1512, 12, 1043, 489, 28, 3249, 15, 4, 2490, 3, 580, 344, 29, 1522, 6, 1483, 4, 3, 116, 1, 1043, 28, 3249, 15, 4, 2490, 10, 662, 18, 9, 1512, 12, 1043, 327, 33, 4, 1522, 6, 728, 33, 4, 1483, 4, 586, 318, 3, 853, 4, 3, 1150, 1, 1043, 28, 3249, 15, 4, 2490, 101, 28, 8, 116, 1, 14, 49, 1150, 862, 379, 111, 9, 1512, 12, 1043, 48, 58, 14, 33, 14, 49, 105, 14, 33, 48, 58, 14, 39, 14, 33, 19, 144, 14, 39, 48, 58, 14, 39, 14, 33, 19, 144, 2, 14, 33, 48, 58, 14, 39, 14, 33, 19, 1730, 1150, 862, 379, 111, 9, 2, 12, 1043, 106, 59, 1522, 2, 1483, 125, 10, 8, 662, 18, 344, 327, 33, 728, 33, 4, 3, 151, 1, 1512, 12, 1043, 1821, 28, 3249, 15, 4, 2490, 26, 853, 68, 1231, 35, 344, 4, 3148, 165, 1349, 2, 549, 90, 24, 1526]",1819.0,29742673,Trends Place Death Patients Gynecologic United States,0,0.0
The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.,Journal of gynecologic oncology,J Gynecol Oncol,2018-05-04,"To determine the effect of surgeon experience on intraoperative, postoperative and long-term outcomes among patients undergoing pelvic exenteration for gynecologic cancer. This was a retrospective analysis of all women who underwent exenteration for a gynecologic malignancy at MD Anderson Cancer Center, between January 1993 and June 2013. A logistic regression was used to model the relationship between surgeon experience (measured as the number of exenteration cases performed by the surgeon prior to a given exenteration) and operative outcomes and postoperative complications. Cox proportional hazards regression was used to model survival outcomes. A total of 167 exenterations were performed by 19 surgeons for cervix (78, 46.7%), vaginal (43, 25.8%), uterine (24, 14.4%), vulvar (14, 8.4%) and other cancer (8, 4.7%). The most common procedure was total pelvic exenteration (69.4%), incontinent urinary diversion (63.5%) and vertical rectus abdominis musculocutaneous reconstruction (42.5%). Surgical experience was associated with decreased estimated blood loss (p<0.001), intraoperative transfusion (p=0.009) and a shorter length of stay (p=0.03). No difference was noted in the postoperative complication rate (p=0.12-0.95). More surgeon experience was not associated with overall or disease specific survival: OS (hazard ratio [HR]=1.02; 95% confidence interval [CI]=0.97-1.06; p=0.46) and DSS (HR=1.01; 95% CI=0.97-1.04; p=0.66), respectively. Patients undergoing exenteration by more experienced surgeons had improvement in intraoperative factors such as estimated blood loss, transfusion rates and length of stay. No difference was seen in postoperative complication rates, overall or disease specific survival.",Journal Article,627.0,3.0,determine effect surgeon experience intraoperative postoperative long-term outcomes patients undergoing pelvic exenteration gynecologic retrospective women underwent exenteration gynecologic malignancy MD Anderson Center January 1993 June 2013 logistic regression model relationship surgeon experience measured number exenteration cases performed surgeon prior given exenteration operative outcomes postoperative complications Cox proportional hazards regression model survival outcomes total 167 exenterations performed 19 surgeons cervix 78 46.7 vaginal 43 25.8 uterine 24 14.4 vulvar 14 8.4 8 4.7 common procedure total pelvic exenteration 69.4 incontinent urinary diversion 63.5 vertical rectus abdominis musculocutaneous reconstruction 42.5 Surgical experience associated decreased estimated blood loss p 0.001 intraoperative transfusion p=0.009 shorter length stay p=0.03 difference noted postoperative complication rate p=0.12-0.95 surgeon experience associated overall disease specific survival OS hazard ratio HR =1.02 95 confidence interval CI =0.97-1.06 p=0.46 DSS HR=1.01 95 CI=0.97-1.04 p=0.66 respectively Patients undergoing exenteration experienced surgeons improvement intraoperative factors estimated blood loss transfusion rates length stay difference seen postoperative complication rates overall disease specific survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 223, 3, 254, 1, 1897, 730, 23, 1720, 573, 2, 319, 337, 123, 107, 7, 479, 1110, 5668, 9, 1512, 12, 26, 10, 8, 459, 65, 1, 62, 117, 54, 208, 5668, 9, 8, 1512, 710, 28, 2244, 1929, 12, 574, 59, 1024, 3343, 2, 1924, 1346, 8, 812, 320, 10, 95, 6, 202, 3, 858, 59, 1897, 730, 644, 22, 3, 207, 1, 5668, 140, 173, 20, 3, 1897, 324, 6, 8, 447, 5668, 2, 1208, 123, 2, 573, 521, 418, 831, 1017, 320, 10, 95, 6, 202, 25, 123, 8, 181, 1, 5431, 44747, 11, 173, 20, 326, 1613, 9, 3629, 833, 641, 67, 601, 243, 66, 259, 213, 39, 213, 66, 39, 2, 127, 12, 66, 39, 67, 3, 96, 186, 1299, 10, 181, 1110, 5668, 790, 39, 20445, 1660, 6067, 676, 33, 2, 11104, 15111, 18778, 33230, 1470, 595, 33, 221, 730, 10, 41, 5, 340, 661, 315, 407, 19, 13, 144, 1720, 2785, 19, 13, 2376, 2, 8, 985, 1318, 1, 2020, 19, 13, 680, 77, 523, 10, 1051, 4, 3, 573, 1447, 116, 19, 13, 133, 13, 48, 80, 1897, 730, 10, 44, 41, 5, 63, 15, 34, 112, 25, 118, 360, 197, 168, 14, 588, 48, 307, 268, 58, 13, 1015, 14, 1460, 19, 13, 641, 2, 1788, 168, 14, 355, 48, 58, 13, 1015, 14, 755, 19, 13, 700, 106, 7, 479, 5668, 20, 80, 592, 1613, 42, 767, 4, 1720, 130, 225, 22, 661, 315, 407, 2785, 151, 2, 1318, 1, 2020, 77, 523, 10, 527, 4, 573, 1447, 151, 63, 15, 34, 112, 25]",1631.0,30022632,influence surgeon volume outcomes pelvic exenteration gynecologic,0,0.0
Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs.,Journal of minimally invasive gynecology,J Minim Invasive Gynecol,2018-08-20,"We sought to estimate the impact of sentinel nodes in gynecologic oncology on fellowship training and discuss potential solutions. Retrospective multi-institution cohort (Canadian Task Force classification II-2). Three tertiary cancer referral cancer centers. Patients with endometrial and vulvar cancer undergoing lymph node evaluation. Patient history and fellow case volumes were evaluated retrospectively for type of lymph node assessment. Minimally invasive endometrial cancer and vulvar cancer fellow case volumes in 3 large institutions were reviewed and average annual volumes calculated for each clinical gynecologic oncology fellow. For vulvar cancer, probabilities of sentinel lymph node mapping and laterality of lesions were estimated from the literature. For endometrial cancer, estimates of lymphadenectomy rates were determined using probabilities calculated from our historic database and from review of the literature. Modeling the approaches to lymphadenectomy in endometrial cancer (full, selective, and sentinel), 100% versus 68% versus 24%, respectively, of patients would require complete pelvic lymphadenectomy and 100% versus 34% versus 12% would require para-aortic lymphadenectomy. In vulvar cancer, rates of inguinal femoral lymphadenectomy are expected to drop from 81% of unilateral groins to only 12% of groins. Sentinel lymph node biopsy for endometrial and vulvar cancer will play an increasing role in practice, and coincident with this will be a dramatic decrease in pelvic, para-aortic, and inguinal femoral lymphadenectomies. The declining numbers will require new strategies to maintain competency in our specialty. New approaches to surgical training and continued medical education will be necessary to ensure adequate training for fellows and young faculty across gynecologic surgery.",Journal Article,519.0,2.0,sought estimate impact sentinel nodes gynecologic oncology fellowship training discuss potential solutions Retrospective multi-institution cohort Canadian Task Force classification II-2 tertiary referral centers Patients endometrial vulvar undergoing lymph node evaluation Patient history fellow case volumes evaluated retrospectively type lymph node assessment Minimally invasive endometrial vulvar fellow case volumes 3 large institutions reviewed average annual volumes calculated clinical gynecologic oncology fellow vulvar probabilities sentinel lymph node mapping laterality lesions estimated literature endometrial estimates lymphadenectomy rates determined probabilities calculated historic database review literature Modeling approaches lymphadenectomy endometrial selective sentinel 100 versus 68 versus 24 respectively patients require complete pelvic lymphadenectomy 100 versus 34 versus 12 require para-aortic lymphadenectomy vulvar rates inguinal femoral lymphadenectomy expected drop 81 unilateral groins 12 groins Sentinel lymph node biopsy endometrial vulvar play increasing role practice coincident dramatic decrease pelvic para-aortic inguinal femoral lymphadenectomies declining numbers require new strategies maintain competency specialty New approaches surgical training continued medical education necessary ensure adequate training fellows young faculty gynecologic surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[21, 990, 6, 1191, 3, 345, 1, 1323, 502, 4, 1512, 413, 23, 9289, 1741, 2, 1139, 174, 6947, 459, 1414, 731, 180, 7170, 3488, 4380, 947, 215, 18, 169, 2557, 12, 2096, 12, 1168, 7, 5, 2, 12, 479, 263, 289, 451, 69, 532, 2, 10526, 473, 2225, 11, 194, 894, 9, 267, 1, 263, 289, 455, 2144, 416, 12, 2, 12, 10526, 473, 2225, 4, 27, 375, 1764, 11, 446, 2, 1011, 2114, 2225, 981, 9, 296, 38, 1512, 413, 10526, 9, 12, 3518, 1, 1323, 263, 289, 2568, 2, 9915, 1, 406, 11, 661, 29, 3, 789, 9, 12, 1423, 1, 2048, 151, 11, 509, 75, 3518, 981, 29, 114, 6875, 609, 2, 29, 206, 1, 3, 789, 2057, 3, 611, 6, 2048, 4, 12, 1647, 1094, 2, 1323, 394, 185, 806, 185, 259, 106, 1, 7, 688, 1353, 236, 1110, 2048, 2, 394, 185, 562, 185, 133, 688, 1353, 4615, 3938, 2048, 4, 12, 151, 1, 4907, 7649, 2048, 32, 1336, 6, 7215, 29, 865, 1, 3208, 26214, 6, 158, 133, 1, 26214, 1323, 263, 289, 411, 9, 2, 12, 303, 1343, 35, 602, 200, 4, 758, 2, 9955, 5, 26, 303, 40, 8, 3079, 775, 4, 1110, 4615, 3938, 2, 4907, 7649, 16322, 3, 6896, 1870, 303, 1353, 217, 422, 6, 3040, 17916, 4, 114, 5852, 217, 611, 6, 221, 1741, 2, 1351, 484, 1848, 303, 40, 1493, 6, 3478, 1658, 1741, 9, 7813, 2, 1169, 11137, 716, 1512, 152]",1694.0,30138740,Impact Sentinel Node Approach Gynecologic Training Needs,0,0.0
Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.,Gynecologic oncology,Gynecol. Oncol.,2018-11-03,"To evaluate the prevalence and associated prognostic indicators in patients with vulvar carcinoma with and without evidence of perineural invasion (PNI). A retrospective review identified 421 patients with invasive vulvar carcinoma evaluated at a single institution between 1993 and 2011. Medical records were reviewed for demographic data, pathologic information and presence or absence of PNI, treatment type, and recurrence/outcome information. Variables were compared between patients with PNI to those without PNI. Of the 421 patients included in the study, 32 (7.6%) had tumors with PNI. There were no significant differences in age, race/ethnicity, smoking history, histologic subtype, or grade between the group of patients with PNI and the group without PNI. The group with PNI was more likely to have lichen sclerosus (25.0% vs. 15.4%, p=0.024), stage III/IV disease (59.4% vs. 36.0%, p=0.007), lymph node involvement (50.0% vs. 21.6%, p=0.002), and lymphovascular space invasion (LVSI) (53.1% vs. 15.9%, p<0.001). A higher proportion of patients in the PNI group underwent primary or adjuvant radiation therapy (68.8% vs. 45.0%, p=0.016). The median follow-up was 67.1months (range<1.0 to 284.3). Patients with PNI had significantly shorter overall survival (OS), median 25.5 vs. 94.3months (p<0.001), and progression-free survival (PFS), median 17.5 vs. 29.0months (p=0.004). After adjusting for stage, patients with PNI had a greater risk for death and progression (OS: hazard ratio, 2.71; p<0.001; PFS: hazard ratio, 1.64; p-value=0.020). PNI should be considered an independent poor prognostic factor for patients with vulvar carcinoma, and should be included as part of the pathologic analysis.",Journal Article,444.0,4.0,evaluate prevalence associated prognostic indicators patients vulvar carcinoma evidence perineural invasion PNI retrospective review identified 421 patients invasive vulvar carcinoma evaluated single institution 1993 2011 Medical records reviewed demographic pathologic information presence absence PNI treatment type recurrence/outcome information Variables compared patients PNI PNI 421 patients included 32 7.6 PNI significant differences age race/ethnicity smoking history histologic subtype grade group patients PNI group PNI group PNI likely lichen sclerosus 25.0 vs. 15.4 p 0.024 stage III/IV disease 59.4 vs. 36.0 p 0.007 lymph node involvement 50.0 vs. 21.6 p 0.002 lymphovascular space invasion LVSI 53.1 vs. 15.9 p 0.001 higher proportion patients PNI group underwent primary adjuvant radiation therapy 68.8 vs. 45.0 p 0.016 median follow-up 67.1 months range 1.0 284.3 Patients PNI significantly shorter overall survival OS median 25.5 vs. 94.3 months p 0.001 progression-free survival PFS median 17.5 vs. 29.0 months p 0.004 adjusting stage patients PNI greater risk death progression OS hazard ratio 2.71 p 0.001 PFS hazard ratio 1.64 p-value 0.020 PNI considered independent poor prognostic factor patients vulvar carcinoma included pathologic,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 1078, 2, 41, 177, 3539, 4, 7, 5, 134, 5, 2, 187, 241, 1, 4917, 578, 5109, 8, 459, 206, 108, 9664, 7, 5, 416, 134, 194, 28, 8, 226, 731, 59, 3343, 2, 1132, 484, 1064, 11, 446, 9, 1540, 74, 510, 487, 2, 463, 15, 1127, 1, 5109, 24, 267, 2, 146, 228, 487, 682, 11, 72, 59, 7, 5, 5109, 6, 135, 187, 5109, 1, 3, 9664, 7, 159, 4, 3, 45, 531, 67, 49, 42, 57, 5, 5109, 125, 11, 77, 93, 362, 4, 89, 1047, 2091, 979, 532, 884, 875, 15, 88, 59, 3, 87, 1, 7, 5, 5109, 2, 3, 87, 187, 5109, 3, 87, 5, 5109, 10, 80, 322, 6, 47, 14899, 28318, 243, 13, 105, 167, 39, 19, 13, 4247, 82, 316, 478, 34, 728, 39, 105, 511, 13, 19, 13, 1999, 263, 289, 799, 212, 13, 105, 239, 49, 19, 13, 1111, 2, 2933, 3865, 578, 8004, 699, 14, 105, 167, 83, 19, 13, 144, 8, 142, 920, 1, 7, 4, 3, 5109, 87, 208, 86, 15, 249, 121, 36, 806, 66, 105, 512, 13, 19, 13, 3820, 3, 52, 166, 126, 10, 598, 14, 53, 184, 14, 13, 6, 8843, 27, 7, 5, 5109, 42, 97, 985, 63, 25, 118, 52, 243, 33, 105, 960, 27, 53, 19, 13, 144, 2, 91, 115, 25, 300, 52, 269, 33, 105, 462, 13, 53, 19, 13, 1520, 50, 1358, 9, 82, 7, 5, 5109, 42, 8, 378, 43, 9, 273, 2, 91, 118, 360, 197, 18, 792, 19, 13, 144, 300, 360, 197, 14, 660, 19, 549, 13, 5743, 5109, 257, 40, 515, 35, 306, 334, 177, 161, 9, 7, 5, 134, 2, 257, 40, 159, 22, 760, 1, 3, 510, 65]",1613.0,30396690,Perineural invasion PNI vulvar carcinoma review 421 cases,0,0.0
Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.,JAMA network open,JAMA Netw Open,2018-09-07,"In the last 4 decades, survival among patients with human papillomavirus (HPV)-associated cancers has improved, while the incidence of these cancers has increased among younger cohorts. Among survivors of HPV-associated cancers, persistent HPV infection may remain a risk factor for preventable HPV-associated second primary cancers (HPV-SPCs). To investigate the risk of HPV-SPCs among survivors of HPV-associated index cancers and to test the hypothesis that the HPV-SPC risk among these persons has increased over the last 4 decades. A retrospective cohort study of 9 cancer registries of the Surveillance, Epidemiology, and End Results (SEER) database was conducted to identify patients with HPV-associated (cervical, vaginal, vulvar, oropharyngeal, anal, and penile) cancers diagnosed from January 1, 1973, through December 31, 2014. The dates of analysis were July 1, 2017, to January 31, 2018. The HPV-SPC risk was quantified by calculating standard incidence ratios (SIRs) and excess absolute risks (EARs) per 10 000 person-years at risk (PYR). The HPV-SPC risk by time was estimated using Poisson regression. From 113 272 (73 085 female and 40 187 male) survivors of HPV-associated cancers, 1397 women and 1098 men developed HPV-SPCs. The SIRs for HPV-SPCs were 6.2 (95% CI, 5.9-6.6) among women and 15.8 (95% CI, 14.9-16.8) among men. The EARs were 18.2 per 10000 PYR for women and 53.5 per 10000 PYR for men. Among both women and men, those who had index oropharyngeal cancers had the highest HPV-SPC risk (SIR, 19.8 [95% CI, 18.4-21.4] and EAR, 80.6 per 10000 PYR among women; SIR, 18.0 [95% CI, 16.9-19.1] and EAR, 61.5 per 10000 PYR among men). Women who had index cervical cancers and men who had index anal cancers had the lowest HPV-SPC risk (SIR, 2.4 [95% CI, 2.2-2.7] and EAR, 4.5 per 10000 PYR among women; SIR, 6.5 [95% CI, 4.7-8.8] and EAR, 18.5 per 10000 PYR among men). Both women and men who had index HPV-associated cancers of any kind had a significantly higher risk of oropharyngeal HPV-SPCs. Over the last 4 decades, the risk of developing most types of HPV-SPCs after index cervical, vaginal, and vulvar cancers increased. According to this study, the HPV-SPC risk among survivors of HPV-associated cancers is significant, implying that persistent HPV infection at multiple sites may be associated with HPV-SPCs. These findings have the potential to inform surveillance recommendations for survivors of HPV-associated cancers.",Journal Article,501.0,4.0,4 decades survival patients human papillomavirus HPV -associated improved incidence increased younger cohorts survivors HPV-associated persistent HPV infection remain risk factor preventable HPV-associated second primary HPV-SPCs investigate risk HPV-SPCs survivors HPV-associated index test hypothesis HPV-SPC risk persons increased 4 decades retrospective cohort 9 registries Surveillance Epidemiology End SEER database conducted identify patients HPV-associated cervical vaginal vulvar oropharyngeal anal penile diagnosed January 1 1973 December 31 2014 dates July 1 2017 January 31 2018 HPV-SPC risk quantified calculating standard incidence ratios SIRs excess absolute risks EARs 10 000 person-years risk PYR HPV-SPC risk time estimated Poisson regression 113 272 73 085 female 40 187 male survivors HPV-associated 1397 women 1098 men developed HPV-SPCs SIRs HPV-SPCs 6.2 95 CI 5.9-6.6 women 15.8 95 CI 14.9-16.8 men EARs 18.2 10 000 PYR women 53.5 10 000 PYR men women men index oropharyngeal highest HPV-SPC risk SIR 19.8 95 CI 18.4-21.4 EAR 80.6 10 000 PYR women SIR 18.0 95 CI 16.9-19.1 EAR 61.5 10 000 PYR men Women index cervical men index anal lowest HPV-SPC risk SIR 2.4 95 CI 2.2-2.7 EAR 4.5 10 000 PYR women SIR 6.5 95 CI 4.7-8.8 EAR 18.5 10 000 PYR men women men index HPV-associated kind significantly higher risk oropharyngeal HPV-SPCs 4 decades risk developing types HPV-SPCs index cervical vaginal vulvar increased According HPV-SPC risk survivors HPV-associated significant implying persistent HPV infection multiple sites associated HPV-SPCs findings potential inform surveillance recommendations survivors HPV-associated,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 3, 1060, 39, 1968, 25, 107, 7, 5, 171, 3242, 933, 41, 163, 71, 231, 369, 3, 287, 1, 46, 163, 71, 101, 107, 773, 736, 107, 332, 1, 933, 41, 163, 1882, 933, 930, 68, 918, 8, 43, 161, 9, 7936, 933, 41, 419, 86, 163, 933, 25885, 6, 963, 3, 43, 1, 933, 25885, 107, 332, 1, 933, 41, 558, 163, 2, 6, 412, 3, 1492, 17, 3, 933, 13490, 43, 107, 46, 4327, 71, 101, 252, 3, 1060, 39, 1968, 8, 459, 180, 45, 1, 83, 12, 3768, 1, 3, 617, 1284, 2, 396, 99, 1605, 609, 10, 426, 6, 255, 7, 5, 933, 41, 2, 163, 265, 29, 1024, 14, 4756, 298, 1397, 456, 1409, 3, 9561, 1, 65, 11, 2066, 14, 1759, 6, 1024, 456, 2982, 3, 933, 13490, 43, 10, 2790, 20, 8408, 260, 287, 1137, 7120, 2, 2612, 1766, 1098, 19743, 379, 79, 984, 2719, 60, 28, 43, 17475, 3, 933, 13490, 43, 20, 98, 10, 661, 75, 7668, 320, 29, 4259, 6905, 803, 13639, 1061, 2, 327, 5568, 1045, 332, 1, 933, 41, 163, 30993, 117, 2, 39715, 325, 276, 933, 25885, 3, 7120, 9, 933, 25885, 11, 49, 18, 48, 58, 33, 83, 49, 49, 107, 117, 2, 167, 66, 48, 58, 213, 83, 245, 66, 107, 325, 3, 19743, 11, 203, 18, 379, 79, 984, 17475, 9, 117, 2, 699, 33, 379, 79, 984, 17475, 9, 325, 107, 110, 117, 2, 325, 135, 54, 42, 558, 163, 42, 3, 1076, 933, 13490, 43, 3636, 326, 66, 48, 58, 203, 39, 239, 39, 2, 7815, 493, 49, 379, 79, 984, 17475, 107, 117, 3636, 203, 13, 48, 58, 245, 83, 326, 14, 2, 7815, 713, 33, 379, 79, 984, 17475, 107, 325, 117, 54, 42, 558, 163, 2, 325, 54, 42, 558, 163, 42, 3, 2101, 933, 13490, 43, 3636, 18, 39, 48, 58, 18, 18, 18, 67, 2, 7815, 39, 33, 379, 79, 984, 17475, 107, 117, 3636, 49, 33, 48, 58, 39, 67, 66, 66, 2, 7815, 203, 33, 379, 79, 984, 17475, 107, 325, 110, 117, 2, 325, 54, 42, 558, 933, 41, 163, 1, 500, 11968, 42, 8, 97, 142, 43, 1, 933, 25885, 252, 3, 1060, 39, 1968, 3, 43, 1, 931, 96, 630, 1, 933, 25885, 50, 558, 2, 163, 101, 768, 6, 26, 45, 3, 933, 13490, 43, 107, 332, 1, 933, 41, 163, 16, 93, 7885, 17, 1882, 933, 930, 28, 232, 633, 68, 40, 41, 5, 933, 25885, 46, 272, 47, 3, 174, 6, 2295, 617, 883, 9, 332, 1, 933, 41, 163]",2254.0,30646145,Trends Risks Second Primary Associated Index Human Papillomavirus-Associated,0,0.0
Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study.,Gynecologic oncology,Gynecol. Oncol.,2019-03-01,"To estimate the prevalence of high-grade anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. In this cross-sectional study, participants underwent anal cytology, anal HPV testing with Cervista HPV16/18 and high-resolution anoscopy (HRA). Patients with HSIL (high-grade squamous cell intraepithelial lesion) or greater on anal cytology or anal biopsy were referred to a colorectal surgery specialist for further evaluation. Seventy-five women were enrolled in the study, including 47 with cervical (cervix group), 10 with vaginal (vagina group), 15 with vulvar (vulva group), 1 with cervical and vaginal, and 2 with vulvar and vaginal disease. The median age in the cervix group (40years (range 26-69)) was substantially younger than in the vagina (60years (38-69)) and the vulva (59years (36-75)) groups. Anal HSIL based on composite endpoints of the most severe cytology or histology result was diagnosed in 6 patients (8.0%). Anal cytology revealed HSIL in 2 (2.7%), atypical squamous cells of undetermined significance (ASCUS) in 12 (16.0%), low-grade squamous cell intraepithelial lesion (LSIL) in 2 (2.7%), and was normal in 59 (78.7%) patients. Anal HPV16/18 test was positive in 15 (20.0%), negative in 48 (64.0%) and insufficient in 12 (16.0%) patients. Of the 6 women with high-grade anal dysplasia, three (50%) had a positive anal HPV16/18 test. No case of anal cancer was observed. Our results suggest that the prevalence of anal HSIL is elevated among women with HPV-related lower genital tract dysplasia or cancer. To further support the inclusion of this high-risk group into screening guidelines for anal dysplasia, further studies are necessary to determine what screening strategy is suited to this population.",Journal Article,326.0,2.0,estimate prevalence high-grade anal dysplasia women high-grade dysplasia carcinoma cervix vagina vulva cross-sectional participants underwent anal cytology anal HPV testing Cervista HPV16/18 high-resolution anoscopy HRA Patients HSIL high-grade squamous intraepithelial lesion greater anal cytology anal biopsy referred colorectal surgery specialist evaluation Seventy-five women enrolled including 47 cervical cervix group 10 vaginal vagina group 15 vulvar vulva group 1 cervical vaginal 2 vulvar vaginal disease median age cervix group 40 years range 26-69 substantially younger vagina 60 years 38-69 vulva 59 years 36-75 groups Anal HSIL based composite endpoints severe cytology histology diagnosed 6 patients 8.0 Anal cytology revealed HSIL 2 2.7 atypical squamous undetermined significance ASCUS 12 16.0 low-grade squamous intraepithelial lesion LSIL 2 2.7 normal 59 78.7 patients Anal HPV16/18 test positive 15 20.0 negative 48 64.0 insufficient 12 16.0 patients 6 women high-grade anal dysplasia 50 positive anal HPV16/18 test case anal observed suggest prevalence anal HSIL elevated women HPV-related lower genital tract dysplasia support inclusion high-risk group screening guidelines anal dysplasia studies necessary determine screening strategy suited population,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1191, 3, 1078, 1, 64, 88, 2253, 4, 117, 5, 64, 88, 2253, 15, 134, 1, 3, 3629, 7553, 15, 9263, 4, 26, 1383, 2832, 45, 776, 208, 2045, 933, 471, 5, 74507, 4048, 203, 2, 64, 2125, 21979, 20959, 7, 5, 16067, 64, 88, 691, 31, 4153, 1180, 15, 378, 23, 2045, 15, 411, 11, 1995, 6, 8, 152, 6554, 9, 195, 451, 2073, 365, 117, 11, 346, 4, 3, 45, 141, 662, 5, 3629, 87, 79, 5, 7553, 87, 167, 5, 9263, 87, 14, 5, 2, 2, 18, 5, 2, 34, 3, 52, 89, 4, 3, 3629, 87, 327, 60, 184, 432, 790, 10, 2109, 773, 76, 4, 3, 7553, 335, 60, 519, 790, 2, 3, 9263, 728, 60, 511, 481, 271, 16067, 90, 23, 3308, 1387, 1, 3, 96, 905, 2045, 15, 784, 757, 10, 265, 4, 49, 7, 66, 13, 2045, 553, 16067, 4, 18, 18, 67, 1973, 691, 37, 1, 5206, 724, 21337, 4, 133, 245, 13, 154, 88, 691, 31, 4153, 1180, 17849, 4, 18, 18, 67, 2, 10, 295, 4, 728, 833, 67, 7, 4048, 203, 412, 10, 109, 4, 167, 179, 13, 199, 4, 576, 660, 13, 2, 3027, 4, 133, 245, 13, 7, 1, 3, 49, 117, 5, 64, 88, 2253, 169, 212, 42, 8, 109, 4048, 203, 412, 77, 473, 1, 12, 10, 164, 114, 99, 309, 17, 3, 1078, 1, 16067, 16, 804, 107, 117, 5, 933, 139, 280, 8226, 1696, 2253, 15, 12, 6, 195, 538, 3, 1680, 1, 26, 64, 43, 87, 237, 453, 677, 9, 2253, 195, 94, 32, 1493, 6, 223, 2067, 453, 692, 16, 7247, 6, 26, 266]",1562.0,30827725,Prevalence high-grade anal dysplasia women high-grade lower genital tract dysplasia pilot,0,0.0
"Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas.",Journal of lower genital tract disease,J Low Genit Tract Dis,2019-04-01,"To determine from the perspective of the State of Texas, the direct medical care costs associated with cervical, vaginal, and vulvar cancers in Texas Medicaid enrollees. We conducted a case-control study and searched Texas Medicaid databases between 2008 and 2012 for eligible cancer patients. A comparison group was selected for each cancer site using a 2-step 1:1 propensity score matching method. Patients were followed for 2 years after cancer diagnosis to estimate monthly and yearly direct medical costs. For each cancer site, the differential cost between patients and the matched comparison individuals was the estimated cost associated with cancer. The study included 583 cervical, 62 vaginal, and 137 vulvar cancer patients and equal numbers of cancer-free comparison individuals. Among the cases, 322 cervical cancer patients, 46 vaginal cancer patients, and 102 vulvar cancer patients were Medicaid-Medicare dual eligible enrollees. For Medicaid-only enrollees, the adjusted first- and second-year mean total differential costs were US $19,859 and $3,110 for cervical cancer, US $19,627 and $4,582 for vaginal cancer, and US $7,631 and $777 for vulvar cancer patients, respectively. For Medicaid-Medicare dual eligible enrollees, adjusted first- and second-year mean total differential costs incurred by Medicaid were US $2,565 and $792 for cervical cancer, US $1,293 and $181 for vaginal cancer, and US $1,774 and $1,049 for vulvar cancer patients, respectively. The direct medical costs associated with cervical, vaginal, and vulvar cancers in Texas Medicaid were substantial in the first 2 years after cancer diagnosis, but dual eligibility for Medicare coverage attenuated Medicaid costs.",Journal Article,295.0,0.0,"determine perspective State Texas direct medical care costs associated cervical vaginal vulvar Texas Medicaid enrollees conducted case-control searched Texas Medicaid databases 2008 2012 eligible patients comparison group selected site 2-step 1:1 propensity score matching Patients followed 2 years diagnosis estimate monthly yearly direct medical costs site differential cost patients matched comparison individuals estimated cost associated included 583 cervical 62 vaginal 137 vulvar patients equal numbers cancer-free comparison individuals cases 322 cervical patients 46 vaginal patients 102 vulvar patients Medicaid-Medicare dual eligible enrollees Medicaid-only enrollees adjusted first- second-year mean total differential costs 19,859 3,110 cervical 19,627 4,582 vaginal 7,631 777 vulvar patients respectively Medicaid-Medicare dual eligible enrollees adjusted first- second-year mean total differential costs incurred Medicaid 2,565 792 cervical 1,293 181 vaginal 1,774 1,049 vulvar patients respectively direct medical costs associated cervical vaginal vulvar Texas Medicaid substantial 2 years diagnosis dual eligibility Medicare coverage attenuated Medicaid costs",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 29, 3, 3727, 1, 3, 1309, 1, 2738, 3, 1196, 484, 165, 1201, 41, 5, 2, 163, 4, 2738, 2843, 9888, 21, 426, 8, 473, 182, 45, 2, 3080, 2738, 2843, 2348, 59, 1375, 2, 1195, 9, 625, 12, 7, 8, 1155, 87, 10, 715, 9, 296, 12, 606, 75, 8, 18, 2458, 14, 14, 1925, 368, 2616, 596, 7, 11, 370, 9, 18, 60, 50, 12, 147, 6, 1191, 3889, 2, 9460, 1196, 484, 1201, 9, 296, 12, 606, 3, 1777, 835, 59, 7, 2, 3, 655, 1155, 869, 10, 3, 661, 835, 41, 5, 12, 3, 45, 159, 12876, 744, 2, 4352, 12, 7, 2, 2997, 1870, 1, 12, 115, 1155, 869, 107, 3, 140, 8024, 12, 7, 641, 12, 7, 2, 2867, 12, 7, 11, 2843, 1378, 1828, 625, 9888, 9, 2843, 158, 9888, 3, 586, 157, 2, 419, 111, 313, 181, 1777, 1201, 11, 843, 326, 20149, 2, 27, 3129, 9, 12, 843, 326, 13598, 2, 39, 13909, 9, 12, 2, 843, 67, 14576, 2, 12021, 9, 12, 7, 106, 9, 2843, 1378, 1828, 625, 9888, 586, 157, 2, 419, 111, 313, 181, 1777, 1201, 11172, 20, 2843, 11, 843, 18, 10852, 2, 13760, 9, 12, 843, 14, 7541, 2, 5540, 9, 12, 2, 843, 14, 11927, 2, 14, 5121, 9, 12, 7, 106, 3, 1196, 484, 1201, 41, 5, 2, 163, 4, 2738, 2843, 11, 1281, 4, 3, 157, 18, 60, 50, 12, 147, 84, 1828, 2317, 9, 1378, 2139, 2656, 2843, 1201]",1518.0,30907776,Cervical Vaginal Vulvar Costs Incurred Medicaid Program Publicly Insured Patients Texas,0,0.0
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.,Gynecologic oncology,Gynecol. Oncol.,2019-04-13,"Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially aromatase inhibitors (AIs). The purpose of this study was to evaluate the frequency and clinical relevance of ESR1 genomic alterations in gynecologic malignancies. DNA from FFPE tumor tissue obtained during routine clinical care for 9645 gynecologic malignancies (ovary, fallopian tube, uterus, cervix, vagina, vulvar, and placenta) was analyzed for all classes of genomic alterations (base substitutions (muts), insertions, deletions, rearrangements, and amplifications) in ESR1 by hybrid capture next generation sequencing. A subset of alterations was characterized in laboratory-based transcription assays for response to endocrine therapies. A total of 295 ESR1 genomic alterations were identified in 285 (3.0%) cases. mutESR1 were present in 86 (0.9%) cases and were more common in uterine compared to other cancers (2.0% vs <1%, respectively p<0.001). mutESR1 were enriched in carcinomas with endometrioid versus serous histology (4.4% vs 0.2% respectively, p<0.0001 in uterine and 3.5% vs 0.3% respectively, p=0.0004 in ovarian carcinomas). In three of four patients with serial sampling, mutESR1 emerged under the selective pressure of AI therapy. Despite decreased potency of estrogen receptor (ER) antagonists in transcriptional assays, clinical benefit was observed following treatment with selective ER-targeted therapy, in one case lasting >48months. While the prevalence of ESR1 mutations in gynecologic malignancies is low, there are significant clinical implications useful in guiding therapeutic approaches for these cancers.",Journal Article,283.0,1.0,Endocrine therapy considered treatment hormone-responsive gynecologic malignancies breast activating estrogen receptor mutESR1 contribute therapeutic resistance endocrine therapy especially aromatase inhibitors AIs purpose evaluate frequency clinical relevance ESR1 genomic alterations gynecologic malignancies DNA FFPE tissue obtained routine clinical care 9645 gynecologic malignancies ovary fallopian tube uterus cervix vagina vulvar placenta classes genomic alterations base substitutions muts insertions deletions rearrangements amplifications ESR1 hybrid capture generation sequencing subset alterations characterized laboratory-based transcription response endocrine therapies total 295 ESR1 genomic alterations identified 285 3.0 cases mutESR1 present 86 0.9 cases common uterine compared 2.0 vs 1 respectively p 0.001 mutESR1 enriched carcinomas endometrioid versus serous histology 4.4 vs 0.2 respectively p 0.0001 uterine 3.5 vs 0.3 respectively p 0.0004 ovarian carcinomas patients serial sampling mutESR1 emerged selective pressure AI therapy Despite decreased potency estrogen receptor ER antagonists transcriptional clinical benefit observed following treatment selective ER-targeted therapy case lasting 48 months prevalence ESR1 gynecologic malignancies low significant clinical implications useful guiding therapeutic approaches,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[1293, 36, 16, 629, 515, 22, 8, 24, 9, 785, 2443, 1512, 441, 4, 12, 1616, 138, 4, 3, 808, 153, 36746, 1248, 6, 189, 251, 6, 1293, 36, 1093, 2106, 222, 3826, 3, 743, 1, 26, 45, 10, 6, 376, 3, 675, 2, 38, 2088, 1, 4518, 572, 593, 4, 1512, 441, 261, 29, 4412, 30, 246, 683, 190, 1311, 38, 165, 9, 49324, 1512, 441, 3631, 2330, 3629, 7553, 2, 19600, 10, 311, 9, 62, 3211, 1, 572, 593, 1782, 7646, 19173, 6315, 2439, 2072, 2, 4877, 4, 4518, 20, 4542, 2891, 1305, 914, 615, 8, 697, 1, 593, 10, 765, 4, 1624, 90, 866, 1013, 9, 51, 6, 1293, 235, 8, 181, 1, 7051, 4518, 572, 593, 11, 108, 4, 8121, 27, 13, 140, 36746, 11, 364, 4, 868, 13, 83, 140, 2, 11, 80, 186, 4, 72, 6, 127, 163, 18, 13, 105, 14, 106, 19, 13, 144, 36746, 11, 2220, 4, 826, 5, 3151, 185, 1744, 784, 39, 39, 105, 13, 18, 106, 19, 13, 488, 4, 2, 27, 33, 105, 13, 27, 106, 19, 13, 5295, 4, 826, 4, 169, 1, 294, 7, 5, 2108, 2874, 36746, 2054, 669, 3, 1094, 3738, 1, 2247, 36, 550, 340, 3593, 1, 808, 153, 516, 4444, 4, 1431, 1013, 38, 247, 10, 164, 366, 24, 5, 1094, 516, 238, 36, 4, 104, 473, 3443, 576, 53, 369, 3, 1078, 1, 4518, 138, 4, 1512, 441, 16, 154, 125, 32, 93, 38, 1268, 999, 4, 5972, 189, 611, 9, 46, 163]",1674.0,30987772,Constitutively active ESR1 gynecologic malignancies clinical response estrogen-receptor directed therapies,0,0.0
GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE).,Gynecologic oncology,Gynecol. Oncol.,2019-10-31,"To explore whether patient-reported lymphedema-related symptoms, as measured by the Gynecologic Cancer Lymphedema Questionnaire (GCLQ), are associated with a patient-reported diagnosis of lymphedema of the lower extremity (LLE) and limb volume change (LVC) in patients who have undergone radical surgery, including lymphadenectomy, for endometrial, cervical, or vulvar cancer on Gynecologic Oncology Group (GOG) study 244. Patients completed the baseline and at least one post-surgery GCLQ and LVC assessment. The 20-item GCLQ measures seven symptom clusters-aching, heaviness, infection-related, numbness, physical functioning, general swelling, and limb swelling. LLE was defined as a patient self-reported LLE diagnosis on the GCLQ. LVC was measured by volume calculations based on circumferential measurements. A linear mixed model was fitted for change in symptom cluster scores and GCLQ total score and adjusted for disease sites and assessment time. Of 987 eligible patients, 894 were evaluable (endometrial, 719; cervical, 136; vulvar, 39). Of these, 14% reported an LLE diagnosis (endometrial, 11%; cervical, 18%; vulvar, 38%). Significantly more patients diagnosed versus not diagnosed with LLE reported 4-point increase from baseline on the GCLQ total score (p<0.001). Changes from baseline were significantly larger on all GCLQ symptom cluster scores in patients with LLE compared to those without LLE. An LVC increment of >10% was significantly associated with reported general swelling (p<0.001), heaviness (p=0.005), infection-related symptoms (p=0.002), and physical function (p=0.006). Patient-reported symptoms, as measured by the GCLQ, discerned those with and without a patient-reported LLE diagnosis and demonstrated predictive value. The GCLQ combined with LVC may enhance our ability to identify LLE.",Journal Article,82.0,0.0,explore patient-reported lymphedema-related symptoms measured Gynecologic Lymphedema Questionnaire GCLQ associated patient-reported diagnosis lymphedema lower extremity LLE limb volume change LVC patients undergone radical surgery including lymphadenectomy endometrial cervical vulvar Gynecologic Oncology Group GOG 244 Patients completed baseline post-surgery GCLQ LVC assessment 20-item GCLQ measures seven symptom clusters-aching heaviness infection-related numbness physical functioning general swelling limb swelling LLE defined patient self-reported LLE diagnosis GCLQ LVC measured volume calculations based circumferential measurements linear mixed model fitted change symptom cluster scores GCLQ total score adjusted disease sites assessment time 987 eligible patients 894 evaluable endometrial 719 cervical 136 vulvar 39 14 reported LLE diagnosis endometrial 11 cervical 18 vulvar 38 Significantly patients diagnosed versus diagnosed LLE reported 4-point increase baseline GCLQ total score p 0.001 Changes baseline significantly larger GCLQ symptom cluster scores patients LLE compared LLE LVC increment 10 significantly associated reported general swelling p 0.001 heaviness p 0.005 infection-related symptoms p 0.002 physical function p 0.006 Patient-reported symptoms measured GCLQ discerned patient-reported LLE diagnosis demonstrated predictive value GCLQ combined LVC enhance ability identify LLE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1645, 317, 69, 210, 3063, 139, 507, 22, 644, 20, 3, 1512, 12, 3063, 1770, 24352, 32, 41, 5, 8, 69, 210, 147, 1, 3063, 1, 3, 280, 2678, 24353, 2, 3930, 433, 707, 15022, 4, 7, 54, 47, 1989, 711, 152, 141, 2048, 9, 15, 12, 23, 1512, 413, 87, 4760, 45, 6567, 7, 781, 3, 330, 2, 28, 506, 104, 539, 152, 24352, 2, 15022, 455, 3, 179, 3471, 24352, 1018, 648, 934, 3780, 36769, 22328, 930, 139, 8655, 900, 2702, 1083, 6967, 2, 3930, 6967, 24353, 10, 395, 22, 8, 69, 1074, 210, 24353, 147, 23, 3, 24352, 15022, 10, 644, 20, 433, 8229, 90, 23, 7937, 1685, 8, 1646, 1739, 202, 10, 7315, 9, 707, 4, 934, 3132, 703, 2, 24352, 181, 368, 2, 586, 9, 34, 633, 2, 455, 98, 1, 16906, 625, 7, 13341, 11, 859, 16012, 4829, 587, 1, 46, 213, 210, 35, 24353, 147, 175, 203, 519, 97, 80, 7, 265, 185, 44, 265, 5, 24353, 210, 5915, 741, 344, 29, 330, 23, 3, 24352, 181, 368, 19, 13, 144, 400, 29, 330, 11, 97, 1077, 23, 62, 24352, 934, 3132, 703, 4, 7, 5, 24353, 72, 6, 135, 187, 24353, 35, 15022, 9705, 1, 79, 10, 97, 41, 5, 210, 1083, 6967, 19, 13, 144, 22328, 19, 13, 1614, 930, 139, 507, 19, 13, 1111, 2, 900, 343, 19, 13, 1861, 69, 210, 507, 22, 644, 20, 3, 24352, 19767, 135, 5, 2, 187, 8, 69, 210, 24353, 147, 2, 264, 464, 549, 3, 24352, 397, 5, 15022, 68, 1304, 114, 801, 6, 255, 24353]",1670.0,31679787,GOG 244 LymphEdema Gynecologic LEG association gynecologic lymphedema questionnaire GCLQ lymphedema lower extremity LLE,0,0.0
